SURFACE EXPRESSION LIBRARIES OF HETEROMERIC RECEPTORS

Patent Number: WO9206204 Publication date: 1992-04-16

Inventor(s):

HUSE WILLIAM D (US)

Applicant(s)::

IXSYS INC (US)

Requested

Patent:

T WO9206204

Application

Number:

WO1991US07149 19910927

Priority Number

(s):

US19900590219 19900928

IPC

Classification:

C12N15/64; C12N15/70

EC

C07K16/00, C12N15/64, C12N15/65, C12N15/70, C07K14/01, C07K14/705, C07K16/44,

Classification:

C12N15/10C1

Equivalents:

AU667291, AU8731891, CA2092802, DE69132700D, DE69132700T, F EP0550645

(WO9206204), A4, B1, IE63054, IE913425, JP6505145T, NZ239988

Abstract

A composition of matter comprising a plurality of procaryotic cells containing diverse combinations of first and second DNA sequences encoding first and second polypeptides which form a heteromeric receptor exhibiting binding activity toward a preselected molecule, said heteromeric receptors being expressed on the surface of filamentous bacteriophage.

Data supplied from theesp@cenettest database - I2

SURFACE EXPRESSION LIBRARIES OF HETEROMERIC RECEPTORS

BACKGROUND OF THE INVENTION

This invention relates generally to recombinant expression of heteromeric receptors and, more particularly, to expression of such receptors on the surface of filamentous bacteriophage.

vertebrates organism's immune system which bind to an antigen. The molecules are composed of two heavy and two light chains disulfide bonded together. Antibodies have the appearance of a "Y" - shaped structure and the antigen binding portion being located at the end of both short arms of the Y. The region on the heavy and light chain polypeptides which corresponds to the antigen binding portion is known as variable region. The differences between antibodies within this region are primarily responsible for the variation in binding specificities between antibody molecules. The binding specificities are a composite of the antigen interactions with both heavy and light chain polypeptides.

The immune system has the capability of generating an almost infinite number of different antibodies. Such a large diversity is generated primarily through recombination to form the variable regions of each chain and through differential pairing of heavy and light chains. The ability to mimic the natural immune system and generate antibodies that bind to any desired molecule is valuable because such antibodies can be used for diagnostic and therapeutic purposes.

Until recently, generation of antibodies against a

2

desired molecule was accomplished only through manipulation of natural immune responses. Methods included classical immunization techniques of laboratory animals and monoclonal antibody production. Generation of monoclonal antibodies is laborious and time consuming. It involves a series of different techniques and is only performed on animal cells. Animal cells have relatively long generation times and require extra precautions to be taken compared to procaryotic cells to ensure viability of the cultures.

A method for the generation of a large repertoire of 10 diverse antibody molecules in bacteria has been described, Huse et al., Science, 246, 1275-1281 (1989), which is herein incorporated by reference. The method uses the bacteriophage lambda as the vector. The lambda vector is 15 a long, linear double-stranded DNA molecule. Production of antibodies using this vector involves the cloning of heavy and light chain populations of DNA sequences into separate vectors. The vectors are subsequently combined randomly to form a single vector which directs the coexpression of 20 heavy and light chains to form antibody fragments. disadvantage to this method is that undesired combinations of vector portions are brought together when generating the coexpression vector. Although these undesired combinations do not produce viable phage, they do however, result in a 25 significant loss of sequences from the population and, therefore, a loss in diversity of the number of different combinations which can be obtained between heavy and light chains. Additionally, the size of the lambda phage gene is large compared to the genes that encode the antibody This makes the lambda system inherently more difficult to manipulate as compared to other available vector systems.

There thus exists a need for a method to generate diverse populations of heteromeric receptors which mimics the natural immune system, which is fast and efficient and

PCT/US91/07149 WO 92/06204

3

results in only desired combinations without loss of diversity. The present invention satisfies these needs and provides related advantages as well.

SUMMARY OF THE INVENTION

5

The invention relates to a plurality of cells containing diverse combinations of first and second DNA sequences encoding first and second polypeptides which form a heteromeric receptor, said heteromeric receptors being expressed on the surface of a cell, preferably one which 10 produces filamentous bacteriophage, such as M13. Vectors, cloning systems and methods of making and screening the heteromeric receptors are also provided.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic diagram of the two vectors 15 used for surface expression library construction from heavy M13IX30 (Figure 1A) is the and light chain libraries. vector used to clone the heavy chain sequences (open box). The single-headed arrow represents the Lac p/o expression sequences and the double-headed arrow represents the 20 portion of M13IX30 which is to be combined with M13IX11. The amber stop codon and relevant restriction sites are M13IX11 (Figure 1B) is the vector used to also shown. clone the light chain sequences (hatched box). Thick lines gVIII) and wild type represent the pseudo-wild type (The double-headed arrow 25 (gVIII) gene VIII sequences. represents the portion of M13IX11 which is to be combined with M13IX30. Relevant restriction sites are also shown. Figure 1C shows the joining of vector population from heavy and light chain libraries to form the functional surface 30 expression vector M13IXHL. Figure 1D shows the generation of a surface expression library in a non-suppressor strain and the production of phage. The phage are used to infect a suppressor strain (Figure 1E) for surface expression and

4

screening of the library.

Figure 2 is the nucleotide sequence of M13IX30 (SEQ ID NO: 1).

Figure 3 is the nucleotide sequence of M13IX11 (SEQ ID 5 NO:2).

Figure 4 is the nucleotide sequence of M13IX34 (SEQ ID NO: 3) .

Figure 5 is the nucleotide sequence of M13IX13 (SEQ ID NO: 4).

Figure 6 is the nucleotide sequence of M13IX60 (SEQ ID NO: 5).

DETAILED DESCRIPTION OF THE INVENTION

This invention is directed to simple and efficient methods to generate a large repertoire of diverse 15 combinations of heteromeric receptors. The method is advantageous in that only proper combinations of vector portions are randomly brought together for the coexpression of different DNA sequences without loss of population size The receptors can be expressed on the or diversity. 20 surface of cells, such as those producing filamentous bacteriophage, which can be screened in large numbers. nucleic acid sequences encoding the receptors be readily characterized because the filamentous bacteriophage produce single strand DNA for efficient sequencing and mutagenesis 25 methods. The heteromeric receptors so produced are useful in an unlimited number of diagnostic and therapeutic procedures.

In one embodiment, two populations of diverse heavy (Hc) and light (Lc) chain sequences are synthesized by

5

These populations are polymerase chain reaction (PCR). cloned into separate M13-based vector containing elements necessary for expression. The heavy chain vector contains a gene VIII (gVIII) coat protein sequence so that 5 translation of the Hc sequences produces gVIII-Hc fusion The populations of two vectors are randomly proteins. combined such that only the vector portions containing the Hc and Lc sequences are joined into a single circular The combined vector directs the coexpression of vector. 10 both Hc and Lc sequences for assembly of the two polypeptides and surface expression on M13. A mechanism also exists to control the expression of gVIII-Hc fusion proteins during library construction and screening.

As used herein, the term "heteromeric receptors"

refers to proteins composed of two or more subunits which together exhibit binding activity toward particular molecule. It is understood that the term includes the subunit fragments so long as assembly of the polypeptides and function of the assembled complex is retained.

Heteromeric subunits include, for example, antibodies and fragments thereof such as Fab and (Fab)₂ portions, T cell receptors, integrins, hormone receptors and transmitter receptors.

As used herein, the term "preselected molecule" refers
to a mclecule which is chosen from a number of choices.
The molecule can be, for example, a protein or peptide, or
an organic molecule such as a drug. Benzodiazapam is a
specific example of a preselected molecule.

As used herein, the term "coexpression" refers to the expression of two or more nucleic acid sequences usually expressed as separate polypeptides. For heteromeric receptors, the coexpressed polypeptides assemble to form the heteromer. Therefore, "expression elements" as used herein, refers to sequences necessary for the

6

transcription, translation, regulation and sorting of the expressed polypeptides which make up the heteromeric receptors. The term also includes the expression of two subunit polypeptides which are linked but are able to assemble into a heteromeric receptor. A specific example of coexpression of linked polypeptides is where Hc and Lc polypeptides are expressed with a flexible peptide or polypeptide linker joining the two subunits into a single chain. The linker is flexible enough to allow association of Hc and Lc portions into a functional Fab fragment.

The invention provides for a composition of matter comprising a plurality of procaryotic cells containing diverse combinations of first and second DNA sequences encoding first and second polypeptides which form a heteromeric receptor exhibiting binding activity toward a preselected molecule, said heteromeric receptors being expressed on the surface of filamentous bacteriophage.

15

DNA sequences encoding the polypeptides heteromeric receptors are obtained by methods known to one skilled in the art. Such methods include, for example, cDNA synthesis and polymerase chain reaction (PCR). need will determine which method or combinations of methods is to be used to obtain the desired populations sequences. Expression can be performed in any compatible vector/host system. Such systems include, for example, plasmids or phagemids in procaryotes such as E. coli, yeast systems and other eucaryotic systems such as mammalian cells, but will be described herein in context with its presently preferred embodiment, i.e. expression on the surface of filamentous bacteriophage. 30 Filamentous bacteriophage include, for example, M13, fl and fd. Additionally, the heteromeric receptors can also expressed in soluble or secreted form depending on the need and the vector/host system employed.

PCT/US91/07149 WO 92/06204

7

Expression of heteromeric receptors such as antibodies or functional fragments thereof on the surface of M13 can be accomplished, for example, using the vector system shown in Figure 1. Construction of the vectors enabling one of ordinary skill to make them are explicitly set out in Example I. The complete nucleotide sequences are given in Figures 2 and 3 (SEQ ID NOS: 1 and 2). produces randomly combined populations of heavy (Hc) and light (Lc) chain antibody fragments functionally linked to 10 expression elements. The Hc polypeptide is produced as a fusion protein with the M13 coat protein encoded by gene The gVIII-Hc fusion protein therefore anchors the assembled Hc and Lc polypeptides on the surface of M13. The diversity of Hc and Lc combinations obtained by this system can be 5×10^7 or greater. Diversity of less than 5 \times 10⁷ can also be obtained and will be determined by the need and type of heteromeric receptor to be expressed.

Populations of Hc and Lc encoding sequences to be combined into a vector for coexpression are each cloned into separate vectors. For the vectors shown in Figure 1, diverse populations of sequences encoding Hc polypeptides are cloned into M13IX30 (SEQ ID NO: 1). Sequences encoding Lc polypeptides are cloned into M13IX11 (SEQ ID NO: 2). The populations are inserted between the Xho I-Spe I or Stu I restriction enzyme sites in M13IX30 and between the Sac 25 I-Xba I or Eco RV sites in M13IX11 (Figures 1A and B, respectively).

20

The populations of Hc and Lc sequences inserted into the vectors can be synthesized with appropriate restriction recognition sequences flanking opposite ends of the encoding sequences but this is not necessary. allow annealing and ligation in-frame with expression elements of these sequences into a double-stranded vector restricted with the appropriate restriction enzyme. 35 Alternatively, and a preferred embodiment, the Hc and Lc

8

sequences can be inserted into the vector without restriction of the DNA. This method of cloning is beneficial because naturally encoded restriction enzyme sites may be present within the sequences, thus, causing 5 destruction of the sequence when treated with a restriction enzyme. For cloning without restriction, the sequences are treated briefly with a 3' to 5' exonuclease such as T4 DNA polymerase or exonuclease III. A 5' to 3' exonuclease will also accomplish the same function. The protruding 5' 10 termini which remains should be complementary to singlestranded overhangs within the vector which remain after restriction at the cloning site and treatment with exonuclease. The exonuclease treated inserts are annealed with the restricted vector by methods known to one skilled The exonuclease method decreases background 15 in the art. and is easier to perform.

2

£

The vector used for Hc populations, M13IX30 (Figure 1A; SEQ ID NO: 1) contains, in addition to expression elements, a sequence encoding the pseudo-wild type gVIII 20 product downstream and in frame with the cloning sites. This gene encodes the wild type M13 gVIII amino acid sequence but has been changed at the nucleotide level to reduce homologous recombination with the wild type gVIII contained on the same vector. The wild type gVIII is 25 present to ensure that at least some functional, non-fusion coat protein will be produced. The inclusion of a wild type gVIII therefore reduces the possibility of non-viable phage production and biological selection against certain peptide fusion proteins. Differential regulation of the 30 two genes can also be used to control the relative ratio of the pseudo and wild type proteins.

Also contained downstream and in frame with the cloning sites is an amber stop codon. The stop codon is located between the inserted Hc sequences and the gVIII sequence and is in frame. As was the function of the wild

9

type gVIII, the amber stop codon also reduces biological selection when combining vector portions to produce This vectors. is expression functional surface accomplished by using a non-suppressor (sup 0) host strain non-suppressor strains will the expression after the Hc sequences but before the pseudo Therefore, the pseudo gVIII will qVIII sequences. essentially never be expressed on the phage surface under these circumstances. Instead, only soluble Hc polypeptides Expression in a non-suppressor host 10 will be produced. strain can be advantageously utilized when one wishes to produce large populations of antibody fragments. codons other than amber, such as opal and ochre, or molecular switches, such as inducible repressor elements, 15 can also be used to unlink peptide expression from surface expression.

The vector used for Lc populations, M13IX11 (SEQ ID NO: 2), contains necessary expression elements and cloning sites for the Lc sequences, Figure 1B. As with M13IX30, upstream and in frame with the cloning sites is a leader sequence for sorting to the phage surface. Additionally, a ribosome binding site and Lac Z promoter/operator elements are also present for transcription and translation of the DNA sequences.

Both vectors contain two pairs of Mlu I-Hind III restriction enzyme sites (Figures 1A and B) for joining together the Hc and Lc encoding sequences and their associated vector sequences. Mlu I and Hind III are non-compatible restriction sites. The two pairs are symmetrically orientated about the cloning site so that only the vector portions containing the sequences to be expressed are exactly combined into a single vector. The two pairs of sites are oriented identically with respect to one another on both vectors and the DNA between the two sites must be homologous enough between both vectors to

10

allow annealing. This orientation allows cleavage of each circular vector into two portions and combination of essential components within each vector into a single circular vector where the encoded polypeptides can be coexpressed (Figure 1C).

Any two pairs of restriction enzyme sites can be used so long as they are symmetrically orientated about the cloning site and identically orientated on both vectors. The sites within each pair, however, should be nonidentical or able to be made differentially recognized as a cleavage substrate. For example, the two pairs of restriction sites contained within the vectors shown in Figure 1 are Mlu I and Hind III. The sites are differentially cleavable by Mlu I and One skilled in the art knows how to 15 respectively. substitute alternative pairs of restriction enzyme sites for the Mlu I-Hind III pairs described above. instead of two Hind III and two Mlu I sites, a Hind III and Not I site can be paired with a Mlu I and a Sal I site, for 20 example.

The combining step randomly brings together different HC and LC encoding sequences within the two diverse populations into a single vector (Figure 1C; M13IXHL). The vector sequences donated from each independent vector, M13IX30 and M13IX11, are necessary for production of viable phage. Also, since the pseudo gVIII sequences are contained in M13IX30, coexpression of functional antibody fragments as LC associated gVIII-HC fusion proteins cannot be accomplished on the phage surface until the vector sequences are linked as shown in M13IXHL.

The combining step is performed by restricting each population of Hc and Lc containing vectors with Mlu I and Hind III, respectively. The 3' termini of each restricted vector population is digested with a 3' to 5' exonuclease

Ė

PCT/US91/07149 WO 92/06204

11

as described above for inserting sequences into the cloning sites. The vector populations are mixed, allowed to anneal and introduced into an appropriate host. A non-suppressor is preferably used during initial (Figure 1D) 5 construction of the library to ensure that sequences are not selected against due to expression as fusion proteins. Phage isolated from the library constructed in a nonsuppressor strain can be used to infect a suppressor strain for surface expression of antibody fragments.

10

for selecting a heteromeric receptor A method exhibiting binding activity toward a preselected molecule from a population of diverse heteromeric receptors, comprising: (a) operationally linking to a first vector a first population of diverse DNA sequences encoding a 15 diverse population of first polypeptides, said first vector having two pairs of restriction sites symmetrically oriented about a cloning site; (b) operationally linking to a second vector a second population of diverse DNA encoding a diverse population of 20 polypeptides, said second vector having two pairs of restriction sites symmetrically oriented about a cloning site in an identical orientation to that of the first vector; (c) combining the vector products of step (a) and (b) under conditions which allow only the operational 25 combination of vector sequences containing said first and second DNA sequences; (d) introducing said population of combined vectors into a compatible host under conditions sufficient for expressing said population of first and second DNA sequences; and (e) determining the heteromeric 30 receptors which bind to said preselected molecule. invention also provides for determining the nucleic acid sequences encoding such polypeptides as well.

Surface expression of the antibody performed in an amber suppressor strain. As described 35 above, the amber stop codon between the Hc sequence and the

12

gVIII sequence unlinks the two components in a nonsuppressor strain. Isolating the phage produced from the non-suppressor strain and infecting a suppressor strain will link the Hc sequences to the gVIII sequence during 5 expression (Figure 1E). Culturing the suppressor strain after infection allows the coexpression on the surface of M13 of all antibody species within the library as gVIII (gVIII-Fab fusion proteins fusion proteins). Alternatively, the DNA can be isolated from the non-10 suppressor strain and then introduced into a suppressor strain to accomplish the same effect.

The level of expression of gVIII-Fab fusion proteins can additionally be controlled at the transcriptional Both polypeptides of the gVIII-Fab fusion proteins under the inducible control of the promoter/operator system. Other inducible promoters can work as well and are known by one skilled in the art. For high levels of surface expression, the suppressor library is cultured in an inducer of the Lac Z promoter such as 20 isopropylthio-6-galactoside (IPTG). Inducible control is beneficial because biological selection against nonfunctional gVIII-Fab fusion proteins can be minimized by culturing the library under non-expressing conditions. Expression can then be induced only at the time of 25 screening to ensure that the entire population of antibodies within the library are accurately represented on the phage surface. Also, this can be used to control the valency of the antibody on the phage surface.

15

The surface expression library is screened 30 specific Fab fragments which bind preselected molecules by standard affinity isolation procedures. include, for example, panning, affinity chromatography and solid phase blotting procedures. Panning as described by Parmley and Smith, Gene 73:305-318 (1988), which is 35 incorporated herein by reference, is preferred because high

13

titers of phage can be screened easily, quickly and in small volumes. Furthermore, this procedure can select minor Fab fragments species within the population, which otherwise would have been undetectable, and amplified to substantially homogenous populations. The selected Fab fragments can be characterized by sequencing the nucleic acids encoding the polypeptides after amplification of the phage population.

The following examples are intended to illustrate but not limit the invention.

EXAMPLE I

Construction. Expression and Screening of Antibody Fragments on the Surface of M13

population of heavy (Hc) and light (Lc) chain antibody fragments and their expression on the surface of M13 as gene VIII-Fab fusion proteins. The expressed antibodies derive from the random mixing and coexpression of a Hc and Lc pair. Also demonstrated is the isolation and characterization of the expressed Fab fragments which bind benzodiazapam (BDP) and their corresponding nucleotide sequence.

<u>Isolation of mRNA and PCR Amplification of Antibody</u> Fragments

The surface expression library is constructed from mRNA isolated from a mouse that had been immunized with KLH-coupled benzodiazapam (BDP). BDP was coupled to keyhole limpet hemocyanin (KLH) using the techniques described in Antibodies: A Laboratory Manual, Harlow and Lane, eds., Cold Spring Harbor, New York (1988), which is incorporated herein by reference. Briefly, 10.0 milligrams (mg) of keyhole limpet hemocyanin and 0.5 mg of BDP with a

14

glutaryl spacer arm N-hydroxysuccinimide linker appendages.
Coupling was performed as in Jonda et al., <u>Science</u>,
241:1188 (1988), which is incorporated herein by reference.
The KLH-BDP conjugate was removed by gel filtration
5 chromatography through Sephadex G-25.

The KLH-BDP conjugate was prepared for injection into mice by adding 100 μ g of the conjugate to 250 μ l of phosphate buffered saline (PBS). An equal volume of complete Freund's adjuvant was added and emulsified the 10 entire solution for 5 minutes. Mice were injected with 300 μ l of the emulsion. Injections were given subcutaneously at several sites using a 21 gauge needle. A second immunization with BDP was given two weeks later. injection was prepared as follows: 50 μ g of BDP was 15 diluted in 250 μ l of PBS and an equal volume of alum was mixed with the solution. The mice were intraperitoneally with 500 μ l of the solution using a 23 gauge needle. One month later the mice were given a final injection of 50 μ g of the conjugate diluted to 200 μ l in 20 PBS. This injection was given intravenously in the lateral tail vein using a 30 gauge needle. Five days after this final injection the mice were sacrificed and total cellular RNA was isolated from their spleens.

Total RNA was isolated from the spleen of a single mouse immunized as described above by the method of Chomczynski and Sacchi, Anal. Biochem., 162:156-159 (1987), which is incorporated herein by reference. Briefly, immediately after removing the spleen from the immunized mouse, the tissue was homogenized in 10 ml of a denaturing solution containing 4.0 M guanine isothiocyanate, 0.25 M sodium citrate at pH 7.0, and 0.1 M 2-mercaptoethanol using a glass homogenizer. One ml of sodium acetate at a concentration of 2 M at pH 4.0 was mixed with the homogenized spleen. One ml of saturated phenol was also mixed with the denaturing solution containing the

ķ

15

homogenized spleen. Two ml of a chloroform: isoamyl alcohol (24:1 v/v) mixture was added to this homogenate. homogenate was mixed vigorously for ten seconds and maintained on ice for 15 minutes. The homogenate was then polypropylene 5 transferred to a thick-walled 50 ml centrifuge tube (Fisher Scientific Company, Pittsburgh, The solution was centrifuged at 10,000 x g for 20 minutes at 4°C. The upper RNA-containing aqueous layer was transferred to a fresh 50 ml polypropylene centrifuge tube 10 and mixed with an equal volume of isopropyl alcohol. This solution was maintained at -20°C for at least one hour to The solution containing the precipitate the RNA. precipitated RNA was centrifuged at 10,000 x g for twenty The pelleted total cellular RNA was minutes at 4°C. 15 collected and dissolved in 3 ml of the denaturing solution described above. Three mls of isopropyl alcohol was added to the resuspended total cellular RNA and vigorously mixed. This solution was maintained at -20°C for at least 1 hour to precipitate the RNA. The solution containing the precipitated RNA was centrifuged at 10,000 x g for ten minutes at 4°C. The pelleted RNA was washed once with a solution containing 75% ethanol. The pelleted F. . was dried under vacuum for 15 minutes and then resuspended in dimethyl pyrocarbonate (DEPC) treated (DEPC-H2O) H2O.

Poly A RNA for use in first strand cDNA synthesis was prepared from the above isolated total RNA using a spin-column kit (Pharmacia, Piscataway, NJ) as recommended by the manufacturer. The basic methodology has been described by Aviv and Leder, Proc. Natl. Acad. Sci., USA, 69:1408-1412 (1972), which is incorporated herein by reference. Briefly, one half of the total RNA isolated from a single immunized mouse spleen prepared as described above was resuspended in one ml of DEPC-treated dH₂O and maintained at 65°C for five minutes. One ml of 2x high salt loading buffer (100 mm Tris-HCL at pH 7.5, 1 M sodium chloride, 2.0 mM disodium ethylene diamine tetraacetic acid (EDTA) at pH

16

ě

8.0, and 0.2% sodium dodecyl sulfate (SDS)) was added to the resuspended RNA and the mixture was allowed to cool to room temperature. The mixture was then applied to an oligo-dT (Collaborative Research Type 2 or Type 3 Bedford, 5 MA) column that was previously prepared by washing the oligo-dT with a solution containing 0.1 M sodium hydroxide and 5 mM EDTA and then equilibrating the column with DEPCtreated dH,O. The eluate was collected in a sterile polypropylene tube and reapplied to the same column after 10 heating the eluate for 5 minutes at 65°C. The oligo dT column was then washed with 2 ml of high salt loading buffer consisting of 50 mM Tris-HCL at pH 7.5, 500 mM sodium chloride, 1 mM EDTA at pH 8.0 and 0.1% SDS. oligo dT column was then washed with 2 ml of 1 X medium 15 salt buffer (50 mM Tris-HCL at pH 7.5, 100 mM sodium chloride, 1 mM EDTA at pH 8.0 and 0.1% SDS). The mRNA was eluted with 1 ml of buffer consisting of 10 mM Tris-HCL at pH 7.5, 1 mM EDTA at pH 8.0 and 0.05% SDS. The messenger RNA was purified by extracting this solution with phenol/chloroform followed by a single extraction with 100% chloroform, ethanol precipitated and resuspended in DEPC treated dH20.

In preparation for PCR amplification, mRNA was used as a template for cDNA synthesis. In a typical 250 µl reverse transcription reaction mixture, 5-10 µg of spleen mRNA in water was first annealed with 500 ng (0.5 pmol) of either the 3' V_H primer (primer 12, Table I) or the 3' V_L primer (primer 9, Table II) at 65°C for 5 minutes. Subsequently, the mixture was adjusted to contain 0.8 mM dATP, 0.8 mM dCTP, 0.8 mM dGTP, 0.8 mM dTTP, 100 mM Tris-HCL (pH 8.6), 10 mM MgCl₂, 40 mM KCl, and 20 mM 2-ME. Moloney-Murine Leukemia Virus (Bethesda Research Laboratories (BRL), Gaithersburg, MD) Reverse transcriptase, 26 units, was added and the solution was incubated for 1 hour at 40°C.

The resultant first strand cDNA was phenol extracted, ethanol precipitated and then used in the polymerase chain

17

reaction (PCR) procedures described below for amplification of heavy and light chain sequences.

Primers used for amplification of heavy chain Fd fragments for construction of the M13IX30 library is shown 5 in Table I. Amplification was performed in eight separate reactions, as described by Saiki et al., Science, 239:487-491 (1988), which is incorporated herein by reference, each reaction containing one of the 5' primers (primers 2 to 9; SEQ ID NOS: 7 through 14, respectively) and one of the 3' 10 primers (primer 12; SEQ ID NO: 17) listed in Table I. remaining 5' primers, used for amplification in a single reaction, are either a degenerate primer (primer 1; SEQ ID NO: 6) or a primer that incorporates inosine at four degenerate positions (primer 10; SEQ ID NO: 15). 15 remaining 3' primer (primer 11; SEQ ID NO: 16) was used to construct Fv fragments. The underlined portion of the 5' primers incorporates an Xho I site and that of the 3' primer an Spe I restriction site for cloning the amplified fragments into the M13IX30 vector in a predetermined 20 reading frame for expression.

TABLE I HEAVY CHAIN PRIMERS

5'- AGGT A CT CTCGAGTC GG - 3' 1) 25 5' - AGGTCCAGCTGCTCGAGTCTGG - 3' 2) 5' - AGGTCCAGCTGCTCGAGTCAGG - 3' 3) 5' - AGGTCCAGCTTCTCGAGTCTGG - 3' 4) 5' - AGGTCCAGCTTCTCGAGTCAGG - 3' 5) 5' - AGGTCCAACTGCTCGAGTCTGG - 3' 30 6) 5' - AGGTCCAACTGCTCGAGTCAGG - 3' 7) 5' - AGGTCCAACTTCTCGAGTCTGG - 3' 8)

18

- 9) 5' AGGTCCAACTTCTCGAGTCAGG 3'
- 10) 5' AGGTIIAICTI<u>CTCGAG</u>TC GG 3'
- 5 11) 5' CTATTA<u>ACTAGT</u>AACGGTAACAGT GGTGCCTTGCCCA 3'
 - 12) 5' AGGCTT<u>ACTAGT</u>ACAATCCCTGG GCACAAT 3'

Primers used for amplification of mouse kappa light 10 chain sequences for construction of the M13IX11 library are shown in Table II. These primers were chosen to contain restriction sites which were compatible with vector and not present in the conserved sequences of the mouse light chain Amplification was performed as described above in 15 five separate reactions, each containing one of the 5' primers (primers 3 to 7; SEQ ID NOS: 20 through 24, respectively) and one of the 3' primers (primer 9; SEQ ID NO: 26) listed in Table II. The remaining 3' primer (primer 8; SEQ ID NO: 25) was used to construct Fv The underlined portion of the 5' primers depicts a Sac I restriction site and that of the 3' primers an Xba I restriction site for cloning of the amplified fragments into the M13IX11 vector in a predetermined reading frame for expression.

25 <u>TABLE II</u> LIGHT CHAIN PRIMERS

- 1) 5' CCAGTTCCGAGCTCGTTGTGACTCAGGAATCT 3'
- 2) 5' CCAGTTCCGAGCTCGTGTTGACGCAGCCGCCC 3'
- 3) 5' CCAGTTCCGAGCTCGTGCTCACCCAGTCTCCA 3'
- 30 4) 5' CCAGTTCCGAGCTCCAGATGACCCAGTCTCCA 3'
 - 5) 5' CCAGATGTGAGCTCGTGATGACCCAGACTCCA 3'
 - 6) 5' CCAGATGTGAGCTCGTCATGACCCAGTCTCCA 3'
 - 7) 5' CCAGTTCCGAGCTCGTGATGACACAGTCTCCA 3'

٤

- 8) 5' GCAGCAT<u>TCTAGAGTTTCAGCTCCAGCTTGCC 3'</u>
- 35 9) 5' GCGCCGTCTAGAATTAACACTCATTCCTGTTGAA 3'

19

PCR amplification for heavy and light chain fragments was performed in a 100 μ l reaction mixture containing the above described products of the reverse transcription reaction (\approx 5 μ g of the cDNA-RNA hybrid), 300 nmol of 3 $^{\circ}$ V_{H} 5 primer (primer 12, Table I; SEQ ID NO: 17), and one of the 5' V_{H} primers (primers 2-9, Table I; SEQ ID NOS: 7 through 14, respectively) for heavy chain amplification, or, 300 nmol of 3' V_i primer (primer 9, Table II; SEQ ID NO: 26), and one of the 5' V_L primers (primers 3-7, Table II; SEQ ID NOS: 20 through 24, respectively) for each light chain amplification, a mixture of dNTPs at 200 mM, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 15 mM MgCl2, 0.1% gelatin, and 2 units of Thermus aquaticus DNA polymerase. The reaction mixture was overlaid with mineral oil and subjected to 40 cycles of amplification cycle Each amplification. 15 denaturation at 92°C for 1 minute, annealing at 52°C for 2 minutes, and elongation at 72°C for 1.5 minutes. amplified samples were extracted twice with phenol/CHCl3 and once with CHCl3, ethanol-precipitated, and stored at -70°C 20 in 10 mM Tris-HCl, pH 7.5 1 mM EDTA. The resultant products were used in constructing the M13IX30 and M13IX11 libraries (see below).

Vector Construction

Two M13-based vectors, M13IX30 (SEQ ID NO: 1) and M13IX11 (SEQ ID NO: 2), were constructed for the cloning and propagation of Hc and Lc populations of antibody fragments, respectively. The vectors were constructed to facilitate the random joining and subsequent surface expression of antibody fragment populations.

M13IX30 (SEQ ID NO: 1), or the Hc vector, was constructed to harbor diverse populations of Hc antibody fragments. M13mp19 (Pharmacia, Piscataway, NJ) was the starting vector. This vector was modified to contain, in addition to the encoded wild type M13 gene VIII: (1) a

20

pseudo-wild type gene VIII sequence with an amber stop codon between it and the restriction sites for cloning oligonucleotides; (2) Stu I restriction site for insertion of sequences by hybridization and, Spe I and Xho I restriction sites in-frame with the pseudo-wild type gene VIII for cloning Hc sequences; (3) sequences necessary for expression, such as a promoter, signal sequence and translation initiation signals; (4) two pairs of Hind III-Mlu I sites for random joining of Hc and Lc vector portions, and (5) various other mutations to remove redundant restriction sites and the amino terminal portion of Lac Z.

٤

Construction of M13IX30 was performed in four steps. In the first step, an M13-based vector containing the pseudo gVIII and various other mutations was constructed, M13IX01F. The second step involved the construction of a small cloning site in a separate M13mp18 vector to yield M13IX03. This vector was then expanded to contain expression sequences and restriction sites for Hc sequences to form M13IX04B. The fourth and final step involved the incorporation of the newly constructed sequences in M13IX04B into M13IX01F to yield M13IX30.

Construction of M13IX01F first involved the generation of a pseudo wild-type gVIII sequence for surface expression of antibody fragments. The pseudo-wild type gene encodes the identical amino acid sequence as that of the wild type gene; however, the nucleotide sequence has been altered so that only 63% identity exists between this gene and the encoded wild type gene VIII. Modification of the gene VIII nucleotide sequence used for surface expression reduces the possibility of homologous recombination with the wild type gene VIII contained on the same vector. Additionally, the wild type M13 gene VIII was retained in the vector system to ensure that at least some functional, non-fusion coat protein would be produced. The inclusion of wild type gene

21

VIII facilitates the growth of phage under conditions where there is surface expression of the polypeptides and therefore reduces the possibility of non-viable phage production from the fusion genes.

The pseudo-wild type gene VIII was constructed by chemically synthesizing a series of oligonucleotides which encode both strands of the gene. The oligonucleotides are presented in Table III.

22

TABLE III

Pseudo-Wild Type Gene VIII Oligonucleotide Series

	Top Strand <u>Oligonucleotides</u>	Sequence (5' to 3')
5	VIII 03	GATCC TAG GCT GAA GGC
		GAT GAC CCT GCT AAG GCT
		GC .
	VIII 04	A TTC AAT AGT TTA CAG
		GCA AGT GCT ACT GAG TAC
10		A
	VIII 05	TT GGC TAC GCT TGG GCT
		ATG GTA GTA GTT ATA GTT
	VIII 06	GGT GCT ACC ATA GGG ATT
		AAA TTA TTC AAA AAG TT
15	VIII 07	T ACG AGC AAG GCT TCT
		TA
	Bottom Strand Oligonucleotides	
	VIII 08	AGC TTA AGA AGC CTT GCT
20		CGT AAA CTT TTT GAA TAA
	·	TTT
	VIII 09	AAT CCC TAT GGT AGC ACC
		AAC TAT AAC TAC TAC CAT
	VIII 10	AGC CCA AGC GTA GCC AAT
25		GTA CTC AGT AGC ACT TG
	VIII 11	C CTG TAA ACT ATT GAA
		TGC AGC CTT AGC AGG GTC
	VIII 12	ATC GCC TTC AGC CTA G

Except for the terminal oligonucleotides VIII 03 (SEQ 30 ID NO: 27) and VIII 08 (SEQ ID NO: 32), the above oligonucleotides (oligonucleotides VIII 04-07 (SEQ ID NOS: 28 through 31, respectively) and VIII 09-12 (SEQ ID NOS: 33

23

through 36, respectively)) were mixed at 200 ng each in 10 μ l final volume, phosphorylated with T4 polynucleotide Kinase (Pharmacia) and 1 mM ATP at 37°C for 1 hour, heated to 70°C for 5 minutes, and annealed into double-stranded 5 form by heating to 65°C for 3 minutes, followed by cooling to room temperature over a period of 30 minutes. reactions were treated with 1.0 U of T4 DNA ligase (BRL) and 1 mM ATP at room temperature for 1 hour, followed by heating to 70°C for 5 minutes. Terminal oligonucleotides 10 were then annealed to the ligated oligonucleotides. annealed and ligated oligonucleotides yielded a doublestranded DNA flanked by a Bam HI site at its 5' end and by a Hind III site at its 3' end. A translational stop codon (amber) immediately follows the Bam HI site. The gene VIII 15 sequence begins with the codon GAA (Glu) two codons 3' to the stop codon. The double-stranded insert was cloned in frame with the Eco RI and Sac I sites within the M13 To do so, M13mp19 was digested with Bam HI (New England Biolabs, Beverley, MA) and Hind III (New 20 England Biolabs) and combined at a molar ratio of 1:10 with the double-stranded insert. The ligations were performed at room temperature overnight in 1% ligase buffer (50 mM Tris-HCl, pH 7.8, 10 mM MgCl,, 20 mM DTT, 1 mM ATP, 50 μ g/ml BSA) containing 1.0 U of T4 DNA ligase (New England 25 Biolabs). The ligation mixture was transformed into a host and screened for positive clones using standard procedures in the art.

Several mutations were generated within the construct to yield functional M13IX01F. The mutations were generated using the method of Kunkel et al., Meth. Enzymol. 154:367-382 (1987), which is incorporated herein by reference, for site-directed mutagenesis. The reagents, strains and protocols were obtained from a Bio Rad Mutagenesis kit (Bio Rad, Richmond, CA) and mutagenesis was performed as recommended by the manufacturer.

24

š

Two Fok I sites were removed from the vector as well as the Hind III site at the end of the pseudo gene VIII using oligonucleotides sequence the mutant CATTTTTGCAGATGGCTTAGA-3 ' (SEQ NO: ID 37) and 5 TAGCATTAACGTCCAATA-3' (SEQ ID NO: 38). New Hind III and Mlu I sites were also introduced at position 3919 and 3951 M13IX01F. The oligonucleotides used mutagenesis had the sequences ATATATTTTAGTAAGCTTCATCTTCT-3 ' (SEQ ID NO: 39) and 5'-10 GACAAAGAACGCGTGAAAACTTT-3' (SEQ ID NO: 40), respectively. The amino terminal portion of Lac Z was deleted by oligonucleotide-directed mutagenesis using the mutant oligonucleotide 5'-GCGGGCCTCTTCGCTATTGCTTAAGAAGCCTTGCT-3' (SEQ ID NO: 41). In constructing the above mutations, all 15 changes made in a M13 coding region were performed such that the amino acid sequence remained unaltered. resultant vector, M13IX01F, was used in the final step to construct M13IX30 (see below).

In the second step, M13mp18 was mutated to remove the 5' end of Lac Z up to the Lac i binding site and including the Lac Z ribosome binding site and start codon. Additionally, the polylinker was removed and a Mlu I site was introduced in the coding region of Lac Z. A single oligonucleotide was used for these mutagenesis and had the sequence 5'-AAACGACGGCCAGTGCCAAGTGACGCGTGTGAAATTGTTATCC-3' (SEQ ID NO: 42). Restriction enzyme sites for Hind III and Eco RI were introduced downstream of the Mlu I site using the oligonucleotide 5'-GGCGAAAGGGAATTCTGCAAGGCGATTAAGCTTGGG TAACGCC-3' (SEQ ID NO. 43). These modifications of M13mp18 yielded the precursor vector M13IX03.

The expression sequences and cloning sites were introduced into M13IX03 by chemically synthesizing a series of oligonucleotides which encode both strands of the desired sequence. The oligonucleotides are presented in Table IV.

25

TABLE IV M13IX30 Oligonucleotide Series

	Top Strand <u>Oligonucleotides</u>	Sequence (5' to 3')
5	084	GGCGTTACCCAAGCTTTGTACATGGAGAAAATAAAG
	027	TGAAACAAAGCACTATTGCACTGGCACTCTTACCGT TACCGT
	028	TACTGTTTACCCCTGTGACAAAAGCCGCCCAGGTCC AGCTGC
10	029	TCGAGTCAGGCCTATTGTGCCCAGGGATTGTACTAG TGGATCCG
	Dettem	•
	Bottom Oligonucleotides	Sequence (5' to 3')
		Sequence (5' to 3') TGGCGAAAGGGAATTCGGATCCACTAGTACAATCCCTG
15	Oligonucleotides	
15	Oligonucleotides 085	TGGCGAAAGGGAATTCGGATCCACTAGTACAATCCCTG GGCACAATAGGCCTGACTCGAGCAGCTGGACCAGGGCG

The above oligonucleotides of Table IV, except for the terminal oligonucleotides 084 (SEQ ID NO: 44) and 085 (SEQ ID NO: 48), were mixed, phosphorylated, annealed and ligated to form a double-stranded insert as described in Example I. However, instead of cloning directly into the intermediate vector the insert was first amplified by PCR. The terminal oligonucleotides were used as primers for PCR. Oligonucleotide 084 (SEQ ID NO: 44) contains a Hind III site, 10 nucleotides internal to its 5' end and oligonucleotide 085 (SEQ ID NO: 48) has an Eco RI site at its 5' end. Following amplification, the products were restricted with Hind III and Eco RI and ligated, as described in Example I, into the polylinker of M13mp18 digested with the same two enzymes. The resultant double

26

stranded insert contained a ribosome binding site, a translation initiation codon followed by a leader sequence and three restriction enzyme sites for cloning random oligonucleotides (Xho I, Stu I, Spe I). The intermediate vector was named M13IX04.

Ŧ,

During cloning of the double-stranded insert, it was found that one of the GCC codons in oligonucleotides 028 and its complement in 031 was deleted. Since this deletion did not affect function, the final construct is missing one of the two GCC codons. Additionally, oligonucleotide 032 (SEQ ID NO: 50) contained a GTG codon where a GAG codon was needed. Mutagenesis was performed using the oligonucleotide 5'-TAACGGTAAGAGTGCCAGTGC-3' (SEQ ID NO: 52) to convert the codon to the desired sequence. The resultant vector is named M13IX04B.

The third step in constructing M13IX30 involved inserting the expression and cloning sequences from M13IX04B upstream of the pseudo wild-type gVIII M13IX01F. This was accomplished by digesting M13IX04B with 20 Dra III and Bam HI and gel isolating the 700 base pair insert containing the sequences of interest. M13IX01F was likewise digested with Dra III and Bam HI. The insert was combined with the double digested vector at a molar ratio of 1:1 and ligated as described in Example I. The sequence 25 of the final construct M13IX30, is shown in Figure 2 (SEQ ID NO: 1). Figure 1A also shows M13IX30 where each of the elements necessary for surface expression of Hc fragments is marked. It should be noted during modification of the vectors, certain sequences differed from the published 30 sequence of M13mp18. The new sequences are incorporated into the sequences recorded herein.

M13IX11 (SEQ ID NO: 2), or the Lc vector, was constructed to harbor diverse populations of Lc antibody fragments. This vector was also constructed from M13mp19

and contains: (1) sequences necessary for expression, such as a promoter, signal sequence and translation initiation signals; (2) Eco RV restriction site for insertion of sequences by hybridization and Sac I and Xba I restriction sites for cloning of Lc sequences; (3) two pairs of Hind III-Mlu I sites for random joining of Hc and Lc vector portions, and (4) various other mutation to remove redundant restriction sites.

The expression, translation initiation signals, cloning sites, and one of the Mlu I sites were constructed by annealing of overlapping oligonucleotides as described above to produce a double-stranded insert containing a 5' Eco RI site and a 3' Hind III site. The overlapping oligonucleotides are shown in Table V and were ligated as a cuble-stranded insert between the Eco RI and Hind III sites of M13mp18 as described for the expression sequences inserted into M13IX03. The ribosome binding site (AGGAGAC) is located in oligonucleotide 015 and the translation initiation codon (ATG) is the first three nucleotides of oligonucleotide 016 (SEQ ID NO: 55).

TABLE V

Oligonucleotide Series for Construction of
Translation Signals in M13IX11

	<u>Oligonucleotide</u>	Sequence (5' to 3')
5	082	CACC TTCATG AATTC GGC AAG GAGACA GTCAT
	015	AATT C GCC AAG GAG ACA GTC AT
	016	AATG AAA TAC CTA TTG CCT ACG
		GCA GCC GCT GGA TTG TT
10	017	ATTA CTC GCT GCC CAA CCA GCC
		ATG GCC GAG CTC GTG AT
•	018	GACC CAG ACT CCA GATATC CAA
		CAG GAA TGA GTG TTA AT
	019	TCT AGA ACG CGT C
15	. 083	TTCAGGTTGAAGC TTA CGC GTT
	•	CTA GAA TTA ACA CTC ATT
		CCTGT
	021	TG GAT ATC TGG AGT CTG GGT
		CAT CAC GAG CTC GGC CAT G
20	022	GC TGG TTG GGC AGC GAG TAA
		TAA CAA TCC AGC GGC TGC C
	023	GT AGG CAA TAG GTA TTT CAT
		TAT GAC TGT CCT TGG CG

Oligonucleotide 017 (SEQ ID NO: 56) contained a Sac I restriction site 67 nucleotides downstream from the ATG codon. The naturally occurring Eco RI site was removed and new Eco RI and Hind III sites were introduced downstream from the Sac I. Oligonucleotides 5'-TGACTGTCTCCTTGGCGTGTGAAATTGTTA-3' (SEQ ID NO: 63) and 5'-TAACACTCATTCCGGATGGAATTCTGGAGTCTGGGT-3' (SEQ ID NO: 64) were used to generate each of the mutations, respectively. The Lac Z ribosome binding site was removed when the

original Eco RI site in M13mp19 was mutated. Additionally, when the new Eco RI and Hind III sites were generated, a spontaneous 100 bp deletion was found just 3' to these sites. Since the deletion does not affect the function, it was retained in the final vector.

In addition to the above mutations, a variety of other modifications were made to incorporate or remove certain sequences. The Hind III site used to ligate the double-stranded insert was removed with the oligonucleotide 5'-GCCAGTGCCAAGTGACGCGTTCTA-3' (SEQ ID NO: 65). Second Hind III and Mlu I sites were introduced at positions 3922 and 3952, respectively, using the oligonucleotides 5'-ATATATTTTAGTAAGCTTCATCTTCT-3' (SEQ ID NO: 66) for the Hind III mutagenesis and 5'-GACAAAGAACGCGTGAAAACTTT-3' (SEQ ID NO: 67) for the Mlu I mutagenesis. Again, mutations within the coding region did not alter the amino acid sequence.

The sequence of the resultant vector, M13IX11, is shown in Figure 3 (SEQ ID NO: 2). Figure 1B also shows M13IX11 where each of the elements necessary for producing a surface expression library between Lc fragments is marked.

Library Construction

Each population of Hc and Lc sequences synthesized by PCR above are separately cloned into M13IX30 and M13IX11, respectively, to create Hc and Lc libraries.

The Hc and Lc products (5 µg) are mixed, ethanol precipitated and resuspended in 20 µl of NaOAc buffer (33 mM Tris acetate, pH 7.9, 10 mM Mg-acetate, 66 mM K-acetate, 0.5 mM DTT). Five units of T4 DNA polymerase is added and the reactions incubated at 30°C for 5 minutes to remove 3' termini by exonuclease digestion. Reactions are stopped by heating at 70°C for 5 minutes. M13IX30 is digested with

30

Stu I and M13IX11 is digested with Eco RV. Both vectors are treated with T4 DNA polymerase as described above and combined with the appropriate PCR products at a 1:1 molar ratio at 10 ng/ μ l to anneal in the above buffer at room temperature overnight. DNA from each annealing is electroporated into MK30-3 (Boehringer, Indianapolis, IN), as described below, to generate the Hc and Lc libraries.

ř

E. coli MK30-3 is electroporated as described by Smith et al., Focus 12:38-40 (1990) which is incorporated herein 10 by reference. The cells are prepared by inoculating a fresh colony of MK30-3 into 5 mls of SOB without magnesium (20 g bacto-tryptone, 5 g bacto-yeast extract, 0.584 g NaCl, 0.186 g KCl, dH₂O to 1,000 mls) and grown with vigorous aeration overnight at 37°C. SOB without magnesium 15 (500 ml) is inoculated at 1:1000 with the overnight culture and grown with vigorous aeration at 37°C until the OD₅₅₀ is 0.8 (about 2 to 3 h). The cells are harvested by centrifugation at 5,000 rpm (2,600 x g) in a GS3 rotor (Sorvall, Newtown, CT) at 4°C for 10 minutes, resuspended 20 in 500 ml of ice-cold 10% (v/v) sterile glycerol, centrifuged and resuspended a second time in the same After a third centrifugation, the cells are resuspended in 10% sterile glycerol at a final volume of about 2 ml, such that the OD_{550} of the suspension was 200 to 25 300. Usually, resuspension is achieved in the 10% glycerol that remained in the bottle after pouring off the Cells are frozen in 40 μ l aliquots in supernate. microcentrifuge tubes using a dry ice-ethanol bath and stored frozen at -70°C.

30 Frozen cells are electroporated by thawing slowly on ice before use and mixing with about 10 pg to 500 ng of vector per 40 μ l of cell suspension. A 40 μ l aliquot is placed in an 0.1 cm electroporation chamber (Bio-Rad, Richmond, CA) and pulsed once at 0°C using 4 k Ω parallel resistor 25 μ F, 1.88 KV, which gives a pulse length (τ) of

31

 74 ms. A 10 μ l aliquot of the pulsed cells are diluted into 1 ml SOC (98 mls SOB plus 1 ml of 2 M MgCl₂ and 1 ml of 2 M glucose) in a 12- x 75-mm culture tube, and the culture is shaken at 37°C for 1 hour prior to culturing in selective media, (see below).

Each of the libraries are cultured using methods known to one skilled in the art. Such methods can be found in Sanbrook et al., Molecular Cloning: A Laboratory Manuel, Cold Spring Harbor Laboratory, Cold Spring Harbor, 1989, and in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, New York, 1989, both of which are incorporated herein by reference. Briefly, the above 1 ml library cultures are grown up by diluting 50-fold into 2XYT media (16 g tryptone, 10 g yeast extract, 5 g NaCl) and culturing at 37°C for 5-8 hours. The bacteria are pelleted by centrifugation at 10,000 x g. The supernatant containing phage is transferred to a sterile tube and stored at 4°C.

Double strand vector DNA containing Hc and Lc antibody 20 fragments are isolated from the cell pellet of each library. Briefly, the pellet is washed in TE (10 mM Tris, pH 8.0, 1 mM EDTA) and recollected by centrifugation at 7,000 rpm for 5' in a Sorval centrifuge (Newtown, CT). Pellets are resuspended in 6 mls of 10% Sucrose, 50 mM Tris, pH 8.0. 3.0 ml of 10 mg/ μ l lysozyne is added and incubated on ice for 20 minutes. 12 mls of 0.2 M NaOH, 1% SDS is added followed by 10 minutes on ice. suspensions are then incubated on ice for 20 minutes after addition of 7.5 mls of 3 M NaOAc, pH 4.6. The samples are 30 centrifuged at 15,000 rpm for 15 minutes at 4°C, RNased and extracted with phenol/chloroform, followed by ethanol precipitation. The pellets are resuspended, weighed and an equal weight of CsCl2 is dissolved into each tube until a density of 1.60 g/ml is achieved. EtBr is added to 600 35 μ g/ml and the double-stranded DNA isolated by is

32

equilibrium centrifugation in a TV-1665 rotor (Sorval) at 50,000 rpm for 6 hours. These DNAs from each right and left half sublibrary are used to generate forty libraries in which the right and left halves of the randomized oligonucleotides have been randomly joined together.

The surface expression library is formed by the random joining of the Hc containing portion of M13IX30 with the Lc containing portion of M13IX11. The DNAs isolated from each library was digested separately with an excess amount of restriction enzyme. The Lc population (5 μ g) is digested with Hind III. The Hc (5 μ g) population is digested with Mlu I. The reactions are stopped by phenol/chloroform extraction followed by ethanol precipitation. The pellets are washed in 70% ethanol and resuspended in 20 μ l of NaOAc Five units of T4 DNA polymerase (Pharmacia) is added and the reactions incubated at 30°C for 5 minutes. Reactions are stopped by heating at 70°C for 5 minutes. The Hc and Lc DNAs are mixed to a final concentration of 10 ng each vector/ μ l and allowed to anneal at room temperature 20 overnight. The mixture is electroporated into MK30-3 cells as described above.

Screening of Surface Expression Libraries

Purified phage are prepared from 50 ml liquid cultures of XL1 BlueTM cells (Stratagene, La Jolla, CA) which had been infected at a m.o.i. of 10 from the phage stocks stored at 4°C. The cultures are induced with 2 mM IPTG. Supernatants are cleared by two centrifugations, and the phage are precipitated by adding 1/7.5 volumes of PEG solution (25% PEG-8000, 2.5 M NaCl), followed by incubation at 4°C overnight. The precipitate is recovered by centrifugation for 90 minutes at 10,000 x g. Phage pellets are resuspended in 25 ml of 0.01 M Tris-HCl, pH 7.6, 1.0 mM EDTA, and 0.1% Sarkosyl and then shaken slowly at room temperature for 30 minutes. The solutions are adjusted to

0.5 M NaCl and to a final concentration of 5% polyethylene glycol. After 2 hours at 4°C, the precipitates containing the phage are recovered by centrifugation for 1 hour at 15,000 X g. The precipitates are resuspended in 10 ml of 5 NET buffer (0.1 M NaCl, 1.0 mM EDTA, and 0.01 M Tris-HCl, mixed well, and the phage repelleted by pH 7.6), centrifugation at 170,000 X g for 3 hours. The phage pellets are resuspended overnight in 2 ml of NET buffer and subjected to cesium chloride centrifugation for 18 hours at 110,000 X g (3.86 g of cesium chloride in 10 ml of buffer). Phage bands are collected, diluted 7-hold with NET buffer, recentrifuged at 170,000 X g for 3 hours, resuspended, and stored at 4°C in 0.3 ml of NET buffer containing 0.1 mM sodium azide.

The BDP used for panning on streptavidin coated dishes 15 is first biotinylated and then absorbed against UVinactivated blocking phage (see below). The biotinylating reagents are dissolved in dimethylformamide at a ratio of (sulfosuccinimidyl NHS-SS-Biotin solid (biotinamido) ethyl-1,3'-dithiopropionate; Pierce, Rockford, IL) to 1 ml solvent and used as recommended by the Small-scale reactions are accomplished by manufacturer. mixing 1 μ l dissolved reagent with 43 μ l of 1 mg/ml BDP diluted in sterile bicarbonate buffer (0.1 M NaHCO3, pH After 2 hours at 25°C, residual biotinylating 25 reagent is reacted with 500 μ l 1 M ethanolamine (pH adjusted to 9 with HCl) for an additional 2 hours. entire sample is diluted with 1 ml TBS containing 1 mg/ml BSA, concentrated to about 50 μ l on a Centricon 30 ultra-30 filter (Amicon), and washed on the same filter three times with 2 ml TBS and once with 1 ml TBS containing 0.02% NaNz and 7 x 10 12 UV-inactivated blocking phage (see below); the final retentate (60-80 μ l) is stored at 4 °C. biotinylated with the NHS-SS-Biotin reagent is linked to 35 biotin via a disulfide-containing chain.

34

UV-irradiated M13 phage are used for blocking any biotinylated BDP which fortuitously binds filamentous phage in general. M13mp8 (Messing and Vieira, Gene 19: 262-276 (1982), which is incorporated herein by reference) is chosen because it carries two amber mutations, which ensure that the few phage surviving irradiation will not grow in the sup O strains used to titer the surface expression library. A 5 ml sample containing 5 x 10¹³ M13mp8 phage, purified as described above, is placed in a small petri plate and irradiated with a germicidal lamp at a distance of two feet for 7 minutes (flux 150 μW/cm²). NaN₃ is added to 0.02% and phage particles concentrated to 10¹⁴ particles/ml on a Centricon 30-kDa ultrafilter (Amicon).

For panning, polystyrene petri plates (60 x 15 mm) are incubated with 1 ml of 1 mg/ml of streptavidin (BRL) in 0.1 M NaHCO₃ pH 8.6-0.02% NaN₃ in a small, air-tight plastic box overnight in a cold room. The next day streptavidin is removed and replaced with at least 10 ml blocking solution (29 mg/ml of BSA; 3 μ g/ml of streptavidin; 0.1 M NaHCO₃ pH 8.6-0.02% NaN₃) and incubated at least 1 hour at room temperature. The blocking solution is removed and plates are washed rapidly three times with Tris buffered saline containing 0.5% Tween 20 (TBS-0.5% Tween 20).

Selection of phage expressing antibody fragments which bind BDP is performed with 5 μl (2.7 μg BDP) of blocked biotinylated BDP reacted with a 50 μl portion of the library. Each mixture is incubated overnight at 4°C, diluted with 1 ml TBS-0.5% Tween 20, and transferred to a streptavidin-coated petri plate prepared as described above. After rocking 10 minutes at room temperature, unbound phage are removed and plates washed ten times with TBS-0.5% Tween 20 over a period of 30-90 minutes. Bound phage are eluted from plates with 800 μl sterile elution buffer (1 mg/ml BSA, 0.1 M HCl, pH adjusted to 2.2 with glycerol) for 15 minutes and eluates neutralized with 48 μl

35

2 M Tris (pH unadjusted). A 20 μ l portion of each eluate is titered on MK30-3 concentrated cells with dilutions of input phage.

A second round of panning is performed by treating 750 5 μ l of first eluate from the library with 5 mM DTT for 10 minutes to break disulfide bonds linking biotin groups to residual biotinylated binding proteins. The treated eluate is concentrated on a Centricon 30 ultrafilter (Amicon), washed three times with TBS-0.5% Tween 20, and concentrated 10 to a final volume of about 50 μ l. Final retentate is transferred to a tube containing 5.0 μ l (2.7 μ g BDP) blocked biotinylated BDP and incubated overnight. solution is diluted with 1 ml TBS-0.5% Tween 20, panned, and eluted as described above on fresh streptavidin-coated The entire second eluate (800 μ l) is 15 petri plates. neutralized with 48 μ l 2 M Tris, and 20 μ l is titered simultaneously with the first eluate and dilutions of the If necessary, further rounds of panning can input phage. be performed to obtain homogeneous populations of phage. 20 Additionally, phage can be plaque purified if reagents are available for detection.

Template Preparation and Sequencing

Templates are prepared for sequencing by inoculating a 1 ml culture of 2XYT containing a 1:100 dilution of an overnight culture of XL1 with an individual plaque from the purified population. The plaques are picked using a sterile toothpick. The culture is incubated at 37°C for 5-6 hours with shaking and then transferred to a 1.5 ml microfuge tube. 200 μ l of PEG solution is added, followed by vortexing and placed on ice for 10 minutes. The phage precipitate is recovered by centrifugation in a microfuge at 12,000 x g for 5 minutes. The supernatant is discarded and the pellet is resuspended in 230 μ l of TE (10 mM TrisHCl, pH 7.5, 1 mM EDTA) by gently pipeting with a yellow

WO 92/06204 PCT/US91/07149

36

pipet tip. Phenol (200 μl) is added, followed by a brief vortex and microfuged to separate the phases. The aqueous phase is transferred to a separate tube and extracted with 200 μl of phenol/chloroform (1:1) as described above for the phenol extraction. A 0.1 volume of 3 M NaOAc is added, followed by addition of 2.5 volumes of ethanol and precipated at -20°C for 20 minutes. The precipated templates are recovered by centrifugation in a microfuge at 12,000 x g for 8 minutes. The pellet is washed in 70% ethanol, dried and resuspended in 25 μl TE. Sequencing was performed using a SequenaseTM sequencing kit following the protocol supplied by the manufacturer (U.S. Biochemical, Cleveland, OH).

EXAMPLE II

Cloning of Heavy and Light Chain Sequences Without Restriction Enzyme Digestion

15

This example shows the simultaneous incorporation of antibody heavy and light chain fragment encoding sequences into a M13IXHL-type vector with the use of restriction 20 endonucleases.

For the simultaneous incorporation of heavy and light chain encoding sequences into a single coexpression vector, a M13IXHL vector was produced that contained heavy and light chain encoding sequences for a mouse monoclonal antibody (DAN-18H4; Biosite, San Diego, CA). The inserted antibody fragment sequences are used as complementary sequences for the hybridization and incorporation of Hc and Lc sequences by site-directed mutagenesis. The genes encoding the heavy and light chain polypeptides were inserted into M13IX30 (SEQ ID NO: 1) and M13IX11 (SEQ ID NO: 2), respectively, and combined into a single surface expression vector as described in Example I. The resultant M13IXHL-type vector is termed M13IX50.

The combinations were performed under conditions that facilitate the formation of one Hc and one Lc vector half into a single circularized vector. Briefly, the overhangs generated between the pairs of restriction sites after 5 restriction with Mlu I or Hind III and exonuclease digestion are unequal (i.e., 64 nucleotides compared to 32 nucleotides). These unequal lengths result in differential hybridization temperatures for specific annealing of the complementary ends from each vector. The specific 10 hybridization of each end of each vector half was accomplished by first annealing at 65°C in a small volume (about 100 μ g/ μ l) to form a dimer of one Hc vector half and The dimers were circularized by one Lc vector half. diluting the mixture (to about 20 $\mu g/\mu l$) and lowering the 15 temperature to about 25-37°C to allow annealing. T4 ligase was present to covalently close the circular vectors.

M13IX50 was modified such that it did not produce a functional polypeptide for the DAN monoclonal antibody. To do this, about eight amino acids were changed within the 20 variable region of each chain by mutagenesis. variable region was mutagenized using the oligonucleotide 5'-CTGAACCTGTCTGGGACCACAGTTGATGCTATAGGATCAGATCTAGAATTCATT TAGAGACTGGCCTGCCTTCTGC-3' (SEQ ID NO: 68). The Hc sequence the oligonucleotide mutagenized with TCGACCGTTGGTAGGAATAATGCAATTAATG GAGTAGCTCTAAATTCAGAATTCATCTACACCCAGTGCATCCAGTAGCT-3' (SEQ An additional mutation was also introduced ID NO: 69). into M13IX50 to yield the final form of the vector. During construction of an intermediate to M13IX50 (M13IX04 30 described in Example I), a six nucleotide sequence was duplicated in oligonucleotide 027 and its complement 032. This sequence, 5'TTACCG-3' was deleted by mutagenesis using the oligonucleotide 5'-GGTAAACAGTAACGGTAAGAGTGCCAG-3' (SEQ ID NO: 70). The resultant vector was designated M13IX53.

WO 92/06204 PCT/US91/07149

38

contains all the functional elements of the previously described M13IXHL vector except that it does not express functional antibody heteromers. The single-stranded vector can be hybridized to populations of single-stranded Hc and Lc encoding sequences for their incorporation into the vector by mutagenesis. Populations of single-stranded Hc and Lc encoding sequences can be produced by one skilled in the art from the PCR products described in Example I or by other methods known to one skilled in the art using the primers and teachings described therein. The resultant vectors with Hc and Lc encoding sequences randomly incorporated are propagated and screened for desired binding specificities as described in Example I.

Other vectors similar to M13IX53 and the vectors it's

derived from, M13IX11 and M13IX30, have also been produced
for the incorporation of Hc and Lc encoding sequences
without restriction. In contrast to M13IX53, these vectors
contain human antibody sequences for the efficient
hybridization and incorporation of populations of human Hc

and Lc sequences. These vectors are briefly described
below. The starting vectors were either the Hc vector
(M13IX30) or the Lc vector (M13IX11) previously described.

M13IX32 was generated from M13IX30 by removing the six nucleotide redundant sequence 5'-TTACCG-3' described above 25 and mutation of the leader sequence to increase secretion of the product. The oligonucleotide used to remove the redundant sequence is the same as that given above. The mutation in the leader sequence was generated using the oligonucleotide 5'GGGCTTTTGCCACAGGGGT-3'. This mutagenesis resulted in the A residue at position 6353 of M13IX30 being changed to a G residue.

A decapeptide tag for affinity purification of antibody fragments was incorporated in the proper reading frame at the carboxy-terminal end of the Hc expression site in M13IX32. The oligonucleotide used for this mutagenesis was 5'-CGCCTT CAGCCTAAGAAGCGTAGTCCGGAACGTCGTACGGGTAGGATCCA CTAG-3' (SEQ ID NO: 71). The resultant vector was designated M13IX33. Modifications to this or other vectors are envisioned which include various features known to one skilled in the art. For example, a peptidase cleavage site can be incorporated following the decapeptide tag which allows the antibody to be cleaved from the gene VIII portion of the fusion protein.

cloning in the gene encoding a human IgGl heavy chain. The reading frame of the variable region was changed and a stop codon was introduced to ensure that a functional polypeptide would not be produced. The oligonucleotide used for the mutagenesis of the variable region was 5'-CACCGGTTCGGGGAATTAGTCTTGACCAGGCAGCCCAGGGC-3' (SEQ ID NO: 72). The complete nucleotide sequence of this vector is shown in Figure 4 (SEQ ID NO: 3).

Several vectors of the M13IX11 series were also 20 generated to contain similar modifications as that described for the vectors M13IX53 and M13IX34. The promoter region in M13IX11 was mutated to conform to the 35 M13IX12. generate to sequence consensus oligonucleotide used for this mutagenesis was 5'-ATTCCACAC 25 ATTATACGAGCCGGAAGCATAAAGTGTCAAGCCTGGGGTGCC-3' (SEQ ID NO: A human kappa light chain sequence was cloned into M13IX12 and the variable region subsequently deleted to generate M13IX13 (SEQ ID NO: 4). The complete nucleotide sequence of this vector is shown in Figure 5 (SEQ ID NO: A similar vector, designated M13IX14, was also 30 4). generated in which the human lambda light chain was inserted into M13IX12 followed by deletion of the variable region. The oligonucleotides used for the variable region M13IX14 were M13IX13 and of deletion 35 CTCATCAGATGGCGGGAAGAGCTCGGCCATGGCTGGTTG-3' (SEQ ID NO: 74)

WO 92/06204 PCT/US91/07149

40

and 5'-GAACAGAGT GACCGAGGGGGGGGGGCCATGGCTGGTTG-3' (SEQ ID NO: 75), respectively.

The Hc and Lc vectors or modified forms thereof can be combined using the methods described in Example I to produce a single vector similar to M13IX53 that allows the efficient incorporation of human Hc and Lc encoding sequences by mutagenesis. An example of such a vector is the combination of M13IX13 with M13IX34. The complete nucleotide sequence of this vector, M13IX60, is shown in Figure 6 (SEQ ID NO: 5).

Additional modifications to any of the previously described vectors can also be performed to generate vectors which allow the efficient incorporation and surface expression of Hc and Lc sequences. For example, 15 alleviate the use of uracil selection against wild-type template during mutagenesis procedures, the variable region locations within the vectors can be substituted by a set of palindromic restriction enzyme sites (i.e., two similar sites in opposite orientation). The palindromic sites will 20 loop out and hybridize together during the mutagenesis and thus form a double-stranded substrate for restriction endonuclease digestion. Cleavage of the site results in the destruction of the wild-type template. The variable region of the inserted Hc or Lc sequences will not be 25 affected since they will be in single stranded form.

Following the methods of Example I, single-stranded Hc or Lc populations can be produced by a variety of methods known to one skilled in the art. For example, the PCR primers described in Example I can be used in asymmetric PCR to generate such populations. Gelfand et al., "PCR Protocols: A Guide to Methods and Applications", Ed by M.A. Innis (1990), which is incorporated herein by reference. Asymmetric PCR is a PCR method that differentially amplifies only a single strand of the double

WO 92/06204 PCT/US91/07149

41

Such differential amplification is stranded template. accomplished by decreasing the primer amount for the undesirable strand about 10-fold compared to that for the single-stranded Alternatively, strand. desirable 5 populations can be produced from double-stranded PCR products generated as described in Example I except that the primer(s) used to generate the undesirable strand of the double-stranded products is first phosphorylated at its 5' end with a kinase. The resultant products can then be 10 treated with a 5' to 3' exonuclease, such as lambda exonuclease (BRL, Bethesda, MD) to digest away the unwanted strand.

single-stranded Hc and Lc populations generated by the methods described above or by others known to one skilled in the art are hybridized to complementary sequences encoded in the previously described vectors. The population of the sequences are subsequently incorporated into a double-stranded form of the vector by polymerase extension of the hybridized templates. Propagation and surface expression of the randomly combined Hc and Lc sequences are performed as described in Example I.

Although the invention has been described with reference to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the claims.

WO 92/06204 PCT/US91/07149

42

SEQUENCE LISTING

(1) GENERAL	INFORMATION:
-------------	--------------

- (i) APPLICANT: HUSE, WILLIAM D.
- (ii) TITLE OF INVENTION: SURFACE EXPRESSION LIBRARIES OF HETEROMERIC RECEPTORS
- (iii) NUMBER OF SEQUENCES: 75
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK
 (B) STREET: 444 SO. FLOWER STREET, SUITE 200
 (C) CITY: LOS ANGELES
 (D) STATE: CALIFORNIA
 (E) COUNTRY: UNITED STATES
 (F) ZIP: 90071
- (v) COMPUTER READABLE FORM:

 - (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: (B) FILING DATE:

 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 (A) NAME: CAMPBELL, CATHRYN A.
 (B) REGISTRATION NUMBER: 31,815
 (C) REFERENCE/DOCKET NUMBER: P31 8882
 - (ix) TELECOMMUNICATION INFORMATION:
 (A) TELEPHONE: 619-535-9001
 (B) TELEFAX: 619-535-8949
- (2) INFORMATION FOR SEQ ID NO:1:
 - (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 7445 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: both

 - (D) TOPOLOGY: circular
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTTCAG	CTCGCGCCCC	AAATGAAAAT	60
ATAGCTAAAC	AGGTTATTGA	CCATTTGCGA	AATGTATCTA	ATGGTCAAAC	TAAATCTACT	120
CGTTCGCAGA	ATTGGGAATC	AACTGTTACA	TGGAATGAAA	CTTCCAGACA	CCGTACTTTA	180
GTTGCATATT	TAAAACATGT	TGAGCTACAG	CACCAGATTC	AGCAATTAAG	CTCTAAGCCA	240
TCTGCAAAAA	TGACCTCTTA	TCAAAAGGAG	CAATTAAAGG	TACTCTCTAA	TCCTGACCTG	300
TTGGAGTTTG	CTTCCGGTCT	GGTTCGCTTT	GAAGCTCGAA	TTAAAACGCG	ATATTTGAAG	360
TCTTTCGGGC	TTCCTCTTAA	TCTTTTTGAT	GCAATCCGCT	TTGCTTCTGA	CTATAATAGT	420

CAGGGTAAAG	ACCTGATTTT	TGATTTATGG	TCATTCTCGT	TTTCTGAACT	GTTTAAAGCA	480
TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCCGCAG	TATTGGACGC	TATCCAGTCT	540
AAACATTTTA	CTATTACCCC	CTCTGGCAAA	ACTTCTTTTG	CAAAAGCCTC	TCGCTATTTT	600
GGTTTTTATC	GTCGTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCTCGT	660
AATTCCTTTT	GGCGTTATGT	ATCTGCATTA	GTTGAATGTG	GTATTCCTAA	ATCTCAACTG	720
ATGAATCTTT	CTACCTGTAA	TAATGTTGTT	CCGTTAGTTC	GTTTTATTAA	CGTAGATTTT	780
TCTTCCCAAC	GTCCTGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA	AGGTAATTCA	840
CAATGATTAA	AGTTGAAATT	AAACGATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGTTT	900
CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTTG	TTACGTTGAT	TTGGGTAATG	960
AATATCCGGT	TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC	1020
TGTACACCGT	TCATCTGTCC	TCTTTCAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC	1080
GTCTGCGCCT	CGTTCCGGCT	AAGTAACATG	GAGCAGGTCG	CGGATTTCGA	CACAATTTAT	1140
CAGGCGATGA	TACAAATCTC	CGTTGTACTT	TGTTTCGCGC	TTGGTATAAT	CGCTGGGGGT	1200
CAAAGATGAG	TGTTTTAGTG	TATTCTTTCG	CCTCTTTCGT	TTTAGGTTGG	TGCCTTCGTA	1260
GTGGCATTAC	GTATTTTACC	CGTTTAATGG	AAACTTCCTC	ATGAAAAAGT	CTTTAGTCCT	1320
CAAAGCCTCT	GTAGCCGTTG	CTACCCTCGT	TCCGATGCTG	TCTTTCGCTG	CTGAGGGTGA	1380
CGATCCCGCA	AAAGCGGCCT	TTAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA	1440
TGCGTGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAGAA	1500
ATTCACCIUG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT	1560
TTTTTGGAGA	TTTTCAACGT	GAAAAAATTA	TTATTCGCAA	TTCCTTTAGT	TGTTCCTTTC	1620
TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTCA	1680
TTTACTAACG	TCTGGAAAGA	CGACAAAACT	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT	1740
CTGTGGAATG	CTACAGGCGT	TGTAGTTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA	1800
TGGGTTCCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	1860
TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
ATTCCGGGCT	ATACTTATAT	CAACCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA	1980
AACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	2040
CAGAATAATA	GGTTCCGAAA	TAGGCAGGGG	GCATTAACTG	TTTATACGGG	CACTGTTACT	2100
CAAGGCACTG	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG	2160
TATGACGCTT	ACTGGAACGG	TAAATTCAGA	GACTGCGCTT	TCCATTCTGG	CTTTAATGAA	2220
GATCCATTCG	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCTCAACC	TCCTGTCAAT	2280
GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340
GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT	2400
GATTTTGATT	ATGAAAAGAT	GGCAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT	2460

GAAAACGCGC TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT	2520
GCTGCTATCG ATGGTTTCA	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	2580
GGTGATTTTG CTGGCTCTA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTCACCT	2640
TTAATGAATA ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	2700
TTTGTCTTTA GCGCTGGTA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	2760
TTCCGTGGTG TCTTTGCGT	TCTTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG	2820
TTTGCTAACA TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTTG	GGTATTCCGT	2880
TATTATTGCG TTTCCTCGG	TTCCTTCTGG	TAACTTTGTT	CGGCTATCTG	CTTACTTTTC	2940
TTAAAAAGGG CTTCGGTAAG	ATAGCTATTG	CTATTTCATT	GTTTCTTGCT	CTTATTATTG	3000
GGCTTAACTC AATTCTTGTC	GGTTATCTCT	CTGATATTAG	CGCTCAATTA	CCCTCTGACT	3060
TTGTTCAGGG TGTTCAGTTA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTTT	TATGTTATTC	3120
TCTCTGTAAA GGCTGCTAT	TTCATTTTTG	ACGTTAAACA	AAAAATCGTT	TCTTATTTGG	3180
ATTGGGATAA ATAATATGG	TGTTTATTTT	GTAACTGGCA	AATTAGGCTC	TGGAAAGACG	3240
CTCGTTAGCG TTGGTAAGA	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT	3300
CTTGATTTAA GGCTTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAAC	GCCTCGCGTT	3360
CTTAGAATAC CGGATAAGC	TTCTATATCT	GATTTGCTTG	CTATTGGGCG	CGGTAATGAT	3420
TCCTACGATG AAAATAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCGGTAC	TTGGTTTAAT	3480
ACCCGTTCTT GGAATGATA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT	3540
AAATTAGGAT GGGATATTA	TTTTCTTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG	3600
CGTTCTGCAT TAGCTGAACA	A TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT	3660
TTTGTCGGTA CTTTATATT	C TCTTATTACT	GGCTCGAAAA	TGCCTCTGCC	TAAATTACAT	3720
GTTGGCGTTG TTAAATATG	G CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT	3780
ACTGGTAAGA ATTTGTATA	A CGCATATGAT	ACTAAACAGG	CTTTTTCTAG	TAATTATGAT	3840
TCCGGTGTTT ATTCTTATT	C AACGCCTTAT	TTATCACACG	GTCGGTATTT	CAAACCATTA	3900
AATTTAGGTC AGAAGATGA	A GCTTACTAAA	ATATATTTGA	AAAAGTTTTC	ACGCGTTCTT	3960
TGTCTTGCGA TTGGATTTG	C ATCAGCATTT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
GAGGTTAAAA AGGTAGTCT	C TCAGACCTAT	GATTTTGATA	AATTCACTAT	TGACTCTTCT	4080
CAGCGTCTTA ATCTAAGCT	A TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	TAATTAATTA	4140
AGCGACGATT TACAGAAGC	A AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTTCC	4200
ATTAAAAAAG GTAATTCAA	A TGAAATTGTT	AAATGTAATT	AATTTTGTTT	TCTTGATGTT	4260
TGTTTCATCA TCTTCTTTT	G CTCAGGTAAT	TGAAATGAAT	AATTCGCCTC	TGCGCGATTT	4320
TGTAACTTGG TATTCAAAG	C AATCAGGCGA	ATCCGTTATT	GTTTCTCCCG	ATGTAAAAGG	4380
TACTGTTACT GTATATTCA	I CTGACGTTAA	ACCTGAAAAT	CTACGCAATT	TCTTTATTTC	4440
TGTTTTACGT GCTAATAAT	r ttgatatggt	TGGTTCAATT	CCTTCCATAA	TTCAGAAGTA	4500

TAATCCAAAC	AATCAGGATT	ATATTGATGA	ATTGCCATCA	TCTGATAATC	AGGAATATGA	4560
TGATAATTCC	GCTCCTTCTG	GTGGTTTCTT	TGTTCCGCAA	AATGATAATG	TTACTCAAAC	4620
TTTAAAATT	AATAACGTTC	GGGCAAAGGA	TTTAATACGA	GTTGTCGAAT	TGTTTGTAAA	4680
GTCTAATACT	TCTAAATCCT	CAAATGTATT	ATCTATTGAC	GGCTCTAATC	TATTAGTTGT	4740
TAGTGCACCT	AAAGATATTT	TAGATAACCT	TCCTCAATTC	CTTTCTACTG	TTGATTTGCC	4800
AACTGACCAG	ATATTGATTG	AGGGTTTGAT	ATTTGAGGTT	CAGCAAGGTG	ATGCTTTAGA	4860
TTTTTCATTT	GCTGCTGGCT	CTCAGCGTGG	CACTGTTGCA	GGCGGTGTTA	ATACTGACCG	4920
CCTCACCTCT	GTTTTATCTT	CTGCTGGTGG	TTCGTTCGGT	ATTTTTAATG	GCGATGTTTT	4980
AGGGCTATCA	GTTCGCGCAT	TAAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	5040
TATTCTTACG	CTTTCAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAATG	TCCCTTTTAT	5100
TACTGGTCGT	GTGACTGGTG	AATCTGCCAA	TGTAAATAAT	CCATTTCAGA	CGATTGAGCG	5160
TCAAAATGTA	GGTATTTCCA	TGAGCGTTTT	TCCTGTTGCA	ATGGCTGGCG	GTAATATTGT	5220
TCTGGATATT	ACCAGCAAGG	CCGATAGTTT	GAGTTCTTCT	ACTCAGGCAA	GTGATGTTAT	5280
TACTAATCAA	AGAAGTATTG	CTACAACGGT	TAATTTGCGT	GATGGACAGA	CTCTTTTACT	5340
CGGTGGCCTC	ACTGATTATA	AAAACACTTC	TCAAGATTCT	GGCGTACCGT	TCCTGTCTAA	5400
AATCCCTTTA	ATCGGCCTCC	TGTTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCACGTT	5460
ATACGTGCTC	GTCAAAGCAA	CCATAGTACG	CGCCCTGTAG	CGGCGCATTA	AGCGCGGCGG	5520
GTGTGGTGGT	TACGCGCAGC	GTGACCGCTA	CACTTGCCAG	CGCCCTAGCG	CCCGCTCCTT	5580
TCGCTTTCTT	CCCTTCCTTT	CTCGCCACGT	TCGCCGGCTT	TCCCCGTCAA	GCTCTAAATC	5640
GGGGGCTCCC	TTTAGGGTTC	CGATTTAGTG	CTTTACGGCA	CCTCGACCCC	AAAAAACTTG	5700
ATTTGGGTGA	TGGTTCACGT	AGTGGGCCAT	CGCCCTGATA	GACGGTTTTT	CGCCCTTTGA	5760
CGTTGGAGTC	CACGTTCTTT	AATAGTGGAC	TCTTGTTCCA	AACTGGAACA	ACACTCAACC	5820
CTATCTCGGG	CTATTCTTTT	GATTTATAAG	GGATTTTGCC	GATTTCGGAA	CCACCATCAA	5880
ACAGGATTTT	CGCCTGCTGG	GGCAAACCAG	CGTGGACCGC	TTGCTGCAAC	TCTCTCAGGG	5940
CCAGGCGGTG	AAGGGCAATC	AGCTGTTGCC	CGTCTCGCTG	GTGAAAAGAA	AAACCACCCT	6000
GGCGCCCAAT	ACGCAAACCG	CCTCTCCCCG	CGCGTTGGCC	GATTCATTAA	TGCAGCTGGC	6060
ACGACAGGTT	TCCCGACTGG	AAAGCGGGCA	GTGAGCGCAA	CGCAATTAAT	GTGAGTTAGC	6120
TCACTCATTA	GGCACCCCAG	GCTTTACACT	TTATGCTTCC	GGCTCGTATG	TTGTGTGGAA	6180
TTGTGAGCGG	ATAACAATTT	CACACGCGTC	ACTTGGCACT	GGCCGTCGTT	TTACAACGTC	6240
GTGACTGGGA	AAACCCTGGC	GTTACCCAAG	CTTTGTACAT	GGAGAAAATA	AAGTGAAACA	6300
AAGCACTATT	GCACTGGCAC	TCTTACCGTT	ACCGTTACTG	TTTACCCCTG	TGACAAAAGC	6360
CGCCCAGGTC	CAGCTGCTCG	AGTCAGGCCT	ATTGTGCCCA	GGGGATTGTA	CTAGTGGATC	6420
CTAGGCTGAA	GGCGATGACC	CTGCTAAGGC	TGCATTCAAT	AGTTTACAGG	CAAGTGCTAC	6480
TGAGTACATT	GGCTACGCTT	GGGCTATGGT	AGTAGTTATA	GTTGGTGCTA	CCATAGGGAT	6540

PCT/US91/07149 WO 92/06204

46

TAAATTATTC	AAAAGTTTA	CGAGCAAGGC	TTCTTAAGCA	ATAGCGAAGA	GGCCCGCACC	6600
GATCGCCCTT	CCCAACAGTT	GCGCAGCCTG	AATGGCGAAT	GGCGCTTTGC	CTGGTTTCCG	6660
GCACCAGAAG	CGGTGCCGGA	AAGCTGGCTG	GAGTGCGATC	TTCCTGAGGC	CGATACGGTC	6720
GTCGTCCCCT	CAAACTGGCA	GATGCACGGT	TACGATGCGC	CCATCTACAC	CAACGTAACC	6780
TATCCCATTA	CGGTCAATCC	GCCGTTTGTT	CCCACGGAGA	ATCCGACGGG	TTGTTACTCG	6840
CTCACATTTA	ATGTTGATGA	AAGCTGGCTA	CAGGAAGGCC	AGACGCGAAT	TATTTTTGAT	6900
GGCGTTCCTA	TTGGTTAAAA	AATGAGCTGA	TTTAACAAAA	ATTTAACGCG	AATTTTAACA	6960
AAATATTAAC	GTTTACAATT	TAAATATTTG	CTTATACAAT	CTTCCTGTTT	TTGGGGCTTT	7020
TCTGATTATC	AACCGGGGTA	CATATGATTG	ACATGCTAGT	TTTACGATTA	CCGTTCATCG	7080
ATTCTCTTGT	TTGCTCCAGA	CTCTCAGGCA	ATGACCTGAT	AGCCTTTGTA	GATCTCTCAA	7140
AAATAGCTAC	CCTCTCCGGC	ATTAATTTAT	CAGCTAGAAC	GGTTGAATAT	CATATTGATG	7200
GTGATTTGAC	TGTCTCCGGC	CTTTCTCACC	CTTTTGAATC	TTTACCTACA	CATTACTCAG	7260
GCATTGCATT	TAAAATATAT	GAGGGTTCTA	AAAATTTTTA	TCCTTGCGTT	GAAATAAAGG	7320
CTTCTCCCGC	AAAAGTATTA	CAGGGTCATA	ATGTTTTTGG	TACAACCGAT	TTAGCTTTAT	7380
GCTCTGAGGC	TTTATTGCTT	AATTTTGCTA	ATTCTTTGCC	TTGCCTGTAT	GATTTATTGG	7440
ACGTT						7445

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:

 (A) LENGTH: 7317 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: both
 (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTTCAG	CTCGCGCCCC	AAATGAAAAT	60
ATAGCTAAAC	AGGTTATTGA	CCATTTGCGA	AATGTATCTA	ATGGTCAAAC	TAAATCTACT	120
CGTTCGCAGA	ATTGGGAATC	AACTGTTACA	TGGAATGAAA	CTTCCAGACA	CCGTACTTTA	180
GTTGCATATT	TAAAACATGT	TGAGCTACAG	CACCAGATTC	AGCAATTAAG	CTCTAAGCCA	240
TCCGCAAAAA	TGACCTCTTA	TCAAAAGGAG	CAATTAAAGG	TACTCTCTAA	TCCTGACCTG	300
TTGGAGTTTG	CTTCCGGTCT	GGTTCGCTTT	GAAGCTCGAA	TTAAAACGCG	ATATTTGAAG	360
TCTTTCGGGC	TTCCTCTTAA	TCTTTTTGAT	GCAATCCGCT	TTGCTTCTGA	CTATAATAGT	420
CAGGGTAAAG	ACCTGATTTT	TGATTTATGG	TCATTCTCGT	TTTCTGAACT	GTTTAAAGCA	480
TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCCGCAG	TATTGGACGC	TATCCAGTCT	540
AAACATTTTA	CTATTACCCC	CTCTGGCAAA	ACTTCTTTTG	CAAAAGCCTC	TCGCTATTTT	600
GGTTTTTATC	GTCGTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCTCGT	660
AATTCCTTTT	GGCGTTATGT	ATCTGCATTA	GTTGAATGTG	GTATTCCTAA	ATCTCAACTG	720

ATGAATCTTT	CTACCTGTAA	TAATGTTGTT	CCGTTAGTTC	GTTTTATTAA	CGTAGATTTT	780
TCTTCCCAAC	GTCCTGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA	AGGTAATTCA	840
CAATGATTAA	AGTTGAAATT	AAACCATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGTTT	900
CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTTG	TTACGTTGAT	TTGGGTAATG	960
AATATCCGGT	TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC	1020
TGTACACCGT	TCATCTGTCC	TCTTTCAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC	1080
GTCTGCGCCT	CGTTCCGGCT	AAGTAACATG	GAGCAGGTCG	CGGATTTCGA	CACAATTTAT	1140
CAGGCGATGA	TACAAATCTC	CGTTGTACTT	TGTTTCGCGC	TTGGTATAAT	CGCTGGGGGT	1200
CAAAGATGAG	TGTTTTAGTG	TATTCTTTCG	CCTCTTTCGT	TTTAGGTTGG	TGCCTTCGTA	1260
GTGGCATTAC	GTATTTTACC	CGTTTAATGG	AAACTTCCTC	ATGAAAAAGT	CTTTAGTCCT	1320
CAAAGCCTCT	GTAGCCGTTG	CTACCCTCGT	TCCGATGCTG	TCTTTCGCTG	CTGAGGGTGA	1380
CGATCCCGCA	AAAGCGGCCT	TTAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA	1440
TGCGTGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAGAA	1500
ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT	1560
TTTTTGGAGA	TTTTCAACGT	GAAAAAATTA	TTATTCGCAA	TTCCTTTAGT	TGTTCCTTTC	1620
TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTCA	1680
TTTACTAACG	TCTGGAAAGA	CGACAAAACT	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT	1740
CTGTGGAATG	CTACAGGCGT	TGTAGTTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA	1800
TGGGTTCCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	1860
TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
ATTCCGGGCT	ATACTTATAT	CAACCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA	1980
AACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	2040
CAGAATAATA	GGTTCCGAAA	TAGGCAGGGG	GCATTAACTG	TTTATACGGG	CACTGTTACT	2100
CAAGGCACTG	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG	2160
TATGACGCTT	ACTGGAACGG	TAAATTCAGA	GACTGCGCTT	TCCATTCTGG	CTTTAATGAA	2220
GATCCATTCG	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCTCAACC	TCCTGTCAAT	2280
GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340
GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT	2400
GATTTTGATT	ATGAAAAGAT	GGCAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT	2460
	TACAGTCTGA					2520
GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	2580
GGTGATTTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTCACCT	2640
TTAATGAATA	ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	2700
TTTGTCTTTA	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	2760

TTCCGTGGTG	TCTTTGCGTT	TCTTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG	2820
TTTGCTAACA	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTTG	GGTATTCCGT	2880
TATTATTGCG	TTTCCTCGGT	TTCCTTCTGG	TAACTTTGTT	CGGCTATCTG	CTTACTTTTC	2940
TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CTATTTCATT	GTTTCTTGCT	CTTATTATTG	3000
GGCTTAACTC	AATTCTTGTG	GGTTATCTCT	CTGATATTAG	CGCTCAATTA	CCCTCTGACT	3060
TTGTTCAGGG	TGTTCAGTTA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTTT	TATGTTATTC	3120
TCTCTGTAAA	GGCTGCTATT	TTCATTTTTG	ACGTTAAACA	AAAAATCGTT	TCTTATTTGG	3180
ATTGGGATAA	ATAATATGGC	TGTTTATTTT	GTAACTGGCA	AATTAGGCTC	TGGAAAGACG	3240
CTCGTTAGCG	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT	3300
CTTGATTTAA	GGCTTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAAC	GCCTCGCGTT	3360
CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGGCG	CGGTAATGAT	3420
TCCTACGATG	AAAATAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCGGTAC	TTGGTTTAAT	3480
ACCCGTTCTT	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT	3540
AAATTAGGAT	GGGATATTAT	TTTTCTTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG	3600
CGTTCTGCAT	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT	3660
TTTGTCGGTA	CTTTATATTC	TCTTATTACT	GGCTCGAAAA	TGCCTCTGCC	TAAATTACAT	3720
GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT	3780
ACTGGTAAGA	ATTTGTAȚAA	CGCATATGAT	ACTAAACAGG	CTTTTTCTAG	TAATTATGAT	3840
TCCGGTGTTT	ATTCTTATTT	AACGCCTTAT	TTATCACACG	GTCGGTATTT	CAAACCATTA	3900
AATTTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTTGA	AAAAGTTTTC	ACGCGTTCTT	3960
TGTCTTGCGA	TTGGATTTGC	ATCAGCATTT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
GAGGTTAAAA	AGGTAGTCTC	TCAGACCTAT	GATTTTGATA	AATTCACTAT	TGACTCTTCT	4080
CAGCGTCTTA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
AGCGACGATT	TACAGAAGCA	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTTCC	4200
ATTAAAAAAG	GTAATTCAAA	TGAAATTGTT	AAATGTAATT	AATTTTGTTT	TCTTGATGTT	4260
TGTTTCATCA	TCTTCTTTTG	CTCAGGTAAT	TGAAATGAAT	AATTCGCCTC	TGCGCGATTT	4320
TGTAACTTGG	TATTCAAAGC	AATCAGGCGA	ATCCGTTATT	GTTTCTCCCG	ATGTAAAAGG	4380
TACTGTTACT	GTATATTCAT	CTGACGTTAA	ACCTGAAAAT	CTACGCAATT	TCTTTATTTC	4440
TGTTTTACGT	GCTAATAATT	TTGATATGGT	TGGTTCAATT	CCTTCCATAA	TTCAGAAGTA	4500
TAATCCAAAC	AATCAGGATT	ATATTGATGA	ATTGCCATCA	TCTGATAATC	AGGAATATGA	4560
TGATAATTCC	GCTCCTTCTG	GTGGTTTCTT	TGTTCCGCAA	AATGATAATG	TTACTCAAAC	4620
TTTTAAAATT	AATAACGTTC	GGGCAAAGGA	TTTAATACGA	GTTGTCGAAT	TGTTTGTAAA	4680
GTCTAATACT	TCTAAATCCT	CAAATGTATT	ATCTATTGAC	GGCTCTAATC	TATTAGTTGT	4740
TAGTGCACCT	AAAGATATTT	TAGATAACCT	TCCTCAATTC	CTTTCTACTG	TTGATTTGCC	4800

AACTGACCAG	ATATTGATTG	AGGGTTTGAT	ATTTGAGGTT	CAGCAAGGTG	ATGCTTTAGA	4860
TTTTTCATTT	GCTGCTGGCT	CTCAGCGTGG	CACTGTTGCA	GGCGGTGTTA	ATACTGACCG	4920
CCTCACCTCT	GTTTTATCTT	CTGCTGGTGG	TTCGTTCGGT	ATTTTTAATG	GCGATGTTTT	4980
AGGGCTATCA	GTTCGCGCAT	TAAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	5040
TATTCTTACG	CTTTCAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAATG	TCCCTTTTAT	5100
TACTGGTCGT	GTGACTGGTG	AATCTGCCAA	TGTAAATAAT	CCATTTCAGA	CGATTGAGCG	5160
	GGTATTTCCA					5220
TCTGGATATT	ACCAGCAAGG	CCGATAGTTT	GAGTTCTTCT	ACTCAGGCAA	GTGATGTTAT	5280
TACTAATCAA	AGAAGTATTG	CTACAACGGT	TAATTTGCGT	GATGGACAGA	CTCTTTTACT	5340
CGGTGGCCTC	ACTGATTATA	AAAACACTTC	TCAAGATTCT	GGCGTACCGT	TCCTGTCTAA	5400
AATCCCTTTA	ATCGGCCTCC	TGTTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCACGTT	5460
ATACGTGCTC	GTCAAAGCAA	CCATAGTACG	CGCCCTGTAG	CGGCGCATTA	AGCGCGGCGG	5520
GTGTGGTGGT	TACGCGCAGC	GTGACCGCTA	CACTTGCCAG	CGCCCTAGCG	CCCGCTCCTT	5580
TCGCTTTCTT	CCCTTCCTTT	CTCGCCACGT	TCGCCGGCTT	TCCCCGTCAA	GCTCTAAATC	5640
GGGGGCTGCC	TTTAGGGTTC	CGATTTAGTG	CTTTACGGCA	CCTCGACCCC	AAAAAACTTG	5700
ATTTGGGTGA	TGGTTCACGT	AGTGGGCCAT	CGCCCTGATA	GACGGTTTTT	CGCCCTTTGA	5760
CGTTGGAGTC	CACGTTCTTT	AATAGTGGAC	TCTTGTTCCA	AACTGGAACA	ACACTCAACC	5820
CTATCTCGGG	CTATTCTTTT	GATTTATAAG	GGATTTTGCC	GATTTCGGAA	CCACCATCAA	5880
ACAGGATTTT	CGCCTGCTGG	GGCAAACCAG	CGTGGACCGC	TTGCTGCAAC	TCTCTCAGGG	5940
CCAGGCGGTG	AAGGGCAATC	AGCTGTTGCC	CGTCTCGCTG	GTGAAAAGAA	AAAGCACCCT	6000
GGCGCCCAAT	ACGCAAACCG	CCTCTCCCCG	CGCGTTGGCC	GATTCATTAA	TGCAGCTGGC	6060
ACGACAGGTT	TCCCGACTGG	AAAGCGGGCA	GTGAGCGCAA	CGCAATTAAT	GTGAGTTAGC	6120
	GGCACCCCAG					6180
	ATAACAATTT					6240
	GCTGGATTGT					6300
					TCACTTGGCA	6360
					AGCTTAATCG	6420
	TTCCCTTTCG					6480
					CGGCACCAGA	6540
	GAAAGCTGGC					6600
	CAGATGCACG					6660
					CGCTCACATT	6720
	GAAAGCTGGC					6780
TATTGGTTAA	AAAATGAGCT	GATTTAACAA	AAATTTAACG	CGAATTTTAA	CAAAATATTA	6840

WO 92/06204 PCT/US91/07149

50

ACGTTTACAA	TTTAAATATT	TGCTTATACA	ATCTTCCTGT	TTTTGGGGCT	TTTCTGATTA	6900
TCAACCGGGG	TACATATGAT	TGACATGCTA	GTTTTACGAT	TACCGTTCAT	CGATTCTCTT	6960
GTTTGCTCCA	GACTCTCAGG	CAATGACCTG	ATAGCCTTTG	TAGATCTCTC	AAAAATAGCT	7020
ACCCTCTCCG	GCATTAATTT	ATCAGCTAGA	ACGGTTGAAT	ATCATATTGA	TGGTGATTTG	7080
ACTGTCTCCG	GCCTTTCTCA	CCCTTTTGAA	TCTTTACCTA	CACATTACTC	AGGCATTGCA	7140
TTTAAAATAT	ATGAGGGTTC	TAAAAATTT	TATCCTTGCG	TTGAAATAAA	GGCTTCTCCC	7200
GCAAAAGTAT	TACAGGGTCA	TAATGTTTTT	GGTACAACCG	ATTTAGCTTT	ATGCTCTGAG	7260
GCTTTATTGC	TTAATTTTGC	TAATTCTTTG	CCTTGCCTGT	ATGATTTATT	GGATGTT	7317
(2) THEODING	ים פחיד מחדים	יניסא חד סי				

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7729 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: circular

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AATGCTACTA CTATTAGTAG AATTGATGCC ACCTTTTCAG CTCGCGCCCC AAATGAAAAT	60
ATAGCTAAAC AGGTTATTGA CCATTTGCGA AATGTATCTA ATGGTCAAAC TAAATCTACT	120
CGTTCGCAGA ATTGGGAATC AACTGTTACA TGGAATGAAA CTTCCAGACA CCGTACTTTA	180
GTTGCATATT TAAAACATGT TGAGCTACAG CACCAGATTC AGCAATTAAG CTCTAAGCCA	240
TCTGCAAAAA TGACCTCTTA TCAAAAGGAG CAATTAAAGG TACTCTCTAA TCCTGACCTG	300
TTGGAGTTTG CTTCCGGTCT GGTTCGCTTT GAAGCTCGAA TTAAAACGCG ATATTTGAAG	360
TCTTTCGGGC TTCCTCTTAA TCTTTTTGAT GCAATCCGCT TTGCTTCTGA CTATAATAGT	420
CAGGGTAAAG ACCTGATTTT TGATTTATGG TCATTCTCGT TTTCTGAACT GTTTAAAGCA	480
TTTGAGGGGG ATTCAATGAA TATTTATGAC GATTCCGCAG TATTGGACGC TATCCAGTCT	540
AAACATTTTA CTATTACCCC CTCTGGCAAA ACTTCTTTTG CAAAAGCCTC TCGCTATTTT	600
GGTTTTTATC GTCGTCTGGT AAACGAGGGT TATGATAGTG TTGCTCTTAC TATGCCTCGT	660
AATTCCTTTT GGCGTTATGT ATCTGCATTA GTTGAATGTG GTATTCCTAA ATCTCAACTG	720
ATGAATCTTT CTACCTGTAA TAATGTTGTT CCGTTAGTTC GTTTTATTAA CGTAGATTTT	780
TCTTCCCAAC GTCCTGACTG GTATAATGAG CCAGTTCTTA AAATCGCATA AGGTAATTCA	840
CAATGATTAA AGTTGAAATT AAACCATCTC AAGCCCAATT TACTACTCGT TCTGGTGTTT	900
CTCGTCAGGG CAAGCCTTAT TCACTGAATG AGCAGCTTTG TTACGTTGAT TTGGGTAATG	960
AATATCCGGT TCTTGTCAAG ATTACTCTTG ATGAAGGTCA GCCAGCCTAT GCGCCTGGTC	1020
TGTACACCGT TCATCTGTCC TCTTTCAAAG TTGGTCAGTT CGGTTCCCTT ATGATTGACC	1080
GTCTGCGCCT CGTTCCGGCT AAGTAACATG GAGCAGGTCG CGGATTTCGA CACAATTTAT	1140
CAGGCGATGA TACAAATCTC CGTTGTACTT TGTTTCGCGC TTGGTATAAT CGCTGGGGGT	1200

CAAAGATGAG	TGTTTTAGTG	TATTCTTTCG	CCTCTTTCGT	TTTAGGTTGG	TGCCTTCGTA	1260
GTGGCATTAC	GTATTTTACC	CGTTTAATGG	AAACTTCCTC	ATGAAAAAGT	CTTTAGTCCT	1320
CAAAGCCTCT	GTAGCCGTTG	CTACCCTCGT	TCCLATGCTG	TCTTTCGCTG	CTGAGGGTGA	1380
CGATCCCGCA	AAAGCGGCCT	TTAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA	1440
TGCGTGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAGAA	1500
ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT	1560
TTTTTGGAGA	TTTTCAACGT	GAAAAAATTA	TTATTCGCAA	TTCCTTTAGT	TGTTCCTTTC	1620
TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTCA	1680
TTTACTAACG	TCTGGAAAGA	CGACAAAACT	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT	1740
CTGTGGAATG	CTACAGGCGT	TGTAGTTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA	1800
TGGGTTCCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	1860
TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
ATTCCGGGCT	ATACTTATAT	CAACCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA	1980
AACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	2040
CAGAATAATA	GGTTCCGAAA	TAGGCAGGGG	GCATTAACTG	TTTATACGGG	CACTGTTACT	2100
CAAGGCACTG	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG	2160
TATGACGCTT	ACTGGAACGG	TAAATTCAGA	GACTGCGCTT	TCCATTCTGG	CTTTAATGAA	2220
GATCCATTCG	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCTCAACC	TCCTGTCAAT	2280
GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340
GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT	2400
GATTTTGATT	ATGAAAAGAT	GGCAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT	2460
GAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT	2520
GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	2580
GGTGATTTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTCACCT	2640
TTAATGAATA	ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	2700
TTTGTCTTTA	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	2760
TTCCGTGGTG	TCTTTGCGTT	TCTTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG	2820
TTTGCTAACA	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTTG	GGTATTCCGT	2880
TATTATTGCG	TTTCCTCGGT	TTCCTTCTGG	TAACTTTGTT	CGGCTATCTG	CTTACTTTTC	2940
TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CTATTTCATT	GTTTCTTGCT	CTTATTATTG	3000
GGCTTAACTC	AATTCTTGTG	GGTTATCTCT	CTGATATTAG	CGCTCAATTA	CCCTCTGACT	3060
TTGTTCAGGG	TGTTCAGTTA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTTT	TATGTTATTC	3120
TCTCTGTAAA	GGCTGCTATT	TTCATTTTTG	ACGTTAAACA	AAAAATCGTT	TCTTATTTGG	3180
ATTGGGATAA	ATAATATGGC	TGTTTATTTT	GTAACTGGCA	AATTAGGCTC	TGGAAAGACG	3240

CTCGTTAGCG	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT	3300
CTTGATTTAA	GGCTTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAAC	GCCTCGCGTT	3360
CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGGCG	CGGTAATGAT	3420
TCCTACGATG	AAAATAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCGGTAC	TTGGTTTAAT	3480
ACCCGTTCTT	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT	3540
AAATTAGGAT	GGGATATTAT	TTTTCTTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG	3600
CGTTCTGCAT	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT	3660
TTTGTCGGTA	CTTTATATTC	TCTTATTACT	GGCTCGAAAA	TGCCTCTGCC	TAAATTACAT	3720
GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT	3780
ACTGGTAAGA	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTTCTAG	TAATTATGAT	3840
TCCGGTGTTT	ATTCTTATTT	AACGCCTTAT	TTATCACACG	GTCGGTATTT	CAAACCATTA	3900
AATTTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTTGA	AAAAGTTTTC	ACGCGTTCTT	3960
TGTCTTGCGA	TTGGATTTGC	ATCAGCATTT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
GAGGTTAAAA	AGGTAGTCTC	TCAGACCTAT	GATTTTGATA	AATTCACTAT	TGACTCTTCT	4080
CAGCGTCTTA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
AGCGACGATT	TACAGAAGCA	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTTCC	4200
ATTAAAAAAG	GTAATTCAAA	TGAAATTGTT	AAATGTAATT	AATTTTGTTT	TCTTGATGTT	4260
TGTTTCATCA	TCTTCTTTTG	CTCAGGTAAT	TGAAATGAAT	AATTCGCCTC	TGCGCGATTT	4320
TGTAACTTGG	TATTCAAAGC	AATCAGGCGA	ATCCGTTATT	GTTTCTCCCG	ATGTAAAAGG	4380
TACTGTTACT	GTATATTCAT	CTGACGTTAA	ACCTGAAAAT	CTACGCAATT	TCTTTATTTC	4440
TGTTTTACGT	GCTAATAATT	TTGATATGGT	TGGTTCAATT	CCTTCCATAA	TTCAGAAGTA	4500
TAATCCAAAC	AATCAGGATT	ATATTGATGA	ATTGCCATCA	TCTGATAATC	AGGAATATGA	4560
TGATAATTCC	GCTCCTTCTG	GTGGTTTCTT	TGTTCCGCAA	AATGATAATG	TTACTCAAAC	4620
TTTTAAAATT	AATAACGTTC	GGGCAAAGGA	TTTAATACGA	GTTGTCGAAT	TGTTTGTAAA	4680
GTCTAATACT	TCTAAATCCT	CAAATGTATT	ATCTATTGAC	GGCTCTAATC	TATTAGTTGT	4740
TAGTGCACCT	AAAGATATTT	TAGATAACCT	TCCTCAATTC	CTTTCTACTG	TTGATTTGCC	4800
AACTGACCAG	ATATTGATTG	AGGGTTTGAT	ATTTGAGGTT	CAGCAAGGTG	ATGCTTTAGA	4860
TTTTTCATTT	GCTGCTGGCT	CTCAGCGTGG	CACTGTTGCA	GGCGGTGTTA	ATACTGACCG	4920
CCTCACCTCT	GTTTTATCTT	CTGCTGGTGG	TTCGTTCGGT	ATTTTTAATG	GCGATGTTTT	4980
AGGGCTATCA	GTTCGCGCAT	TAAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	5040
TATTCTTACG	CTTTCAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAATG	TCCCTTTTAT	5100
TACTGGTCGT	GTGACTGGTG	AATCTGCCAA	TGTAAATAAT	CCATTTCAGA	CGATTGAGCG	5160
TCAAAATGTA	GGTATTTCCA	TGAGCGTTTT	TCCTGTTGCA	ATGGCTGGCG	GTAATATTGT	5220
TCTGGATATT	ACCAGCAAGG	CCGATAGTTT	GAGTTCTTCT	ACTCAGGCAA	GTGATGTTAT	5280

TACTAATCAA	AGAAGTATTG	CTACAACGGT	TAATTTGCGT	GATGGACAGA	CTCTTTTACT	5340
CGGTGGCCTC	ACTGATTATA	AAAACACTTC	TCAAGATTCT	GGCGTACCGT	TCCTGTCTAA	5400
AATCCCTTTA	ATCGGCCTCC	TGTTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCACGTT	5460
ATACGTGCTC	GTCAAAGCAA	CCATAGTACG	CGCCCTGTAG	CGGCGCATTA	AGCGCGGCGG	5520
GTGTGGTGGT	TACGCGCAGC	GTGACCGCTA	CACTTGCCAG	CGCCCTAGCG	CCCGCTCCTT	5580
TCGCTTTCTT	CCCTTCCTTT	CTCGCCACGT	TCGCCGGCTT	TCCCCGTCAA	GCTCTAAATC	5640
GGGGGCTCCC	TTTAGGGTTC	CGATTTAGTG	CTTTACGGCA	CCTCGACCCC	AAAAAACTTG	5700
ATTTGGGTGA	TGGTTCACGT	AGTGGGCCAT	CGCCCTGATA	GACGGTTTTT	CGCCCTTTGA	5760
CGTTGGAGTC	CACGTTCTTT	AATAGTGGAC	TCTTGTTCCA	AACTGGAACA	ACACTCAACC	5820
CTATCTCGGG	CTATTCTTTT	GATTTATAAG	GGATTTTGCC	GATTTCGGAA	CCACCATCAA	5880
ACAGGATTTT	CGCCTGCTGG	GGCAAACCAG	CGTGGACCGC	TTGCTGCAAC	TCTCTCAGGG	5940
CCAGGCGGTG	AAGGGCAATC	AGCTGTTGCC	CGTCTCGCTG	GTGAAAAGAA	AAACCACCCT	6000
GGCGCCCAAT	ACGCAAACCG	CCTCTCCCCG	CGCGTTGGCC	GATTCATTAA	TGCAGCTGGC	6060
ACGACAGGTT	TCCCGACTGG	AAAGCGGGCA	GTGAGCGCAA	CGCAATTAAT	GTGAGTTAGC	6120
TCACTCATTA	GGCACCCCAG	GCTTTACACT	TTATGCTTCC	GGCTCGTATG	TTGTGTGGAA	6180
TTGTGAGCGG	ATAACAATTT	CACACGCGTC	ACTTGGCACT	GGCCGTCGTT	TTACAACGTC	6240
GTGACTGGGA	AAACCCTGGC	GTTACCCAAG	CTTTGTACAT	GGAGAAAATA	AAGTGAAACA	6300
AAGCACTATT	GCACTGGCAC	TCTTACCGTT	ACTGTTTACC	CCTGTGGCAA	AAGCCCAGGT	6360
CCAGCTGCTC	GAGTCGGTCT	TCCCCCTGGC	ACCCTCCTCC	AAGAGCACCT	CTGGGGGCAC	6420
AGCGGCCCTG	GGCTGCCTGG	TCAAGACTAA	TTCCCCGAAC	CGGTGACGGT	GTCGTGGAAC	6480
TCAGGCGCCC	TGACCAGCGG	CGTGCACACC	TTCCCGGCTG	TCCTACAGTC	CTCAGGACTC	6540
TACTCCCTCA	GCAGCGTGGT	GACCGTGCCC	TCCAGCAGCT	TGGGCACCCA	GACCTACATC	6600
TGCAACGTGA	ATCACAAGCC	CAGCAACACC	AAGGTGGACA	AGAAAGCAGA	GCCCAAATCT	6660
TGTACTAGTG	GATCCTACCC	GTACGACGTT	CC. ACTACG	CTTCTTAGGC	TGAAGGCGAT	6720
GACCCTGCTA	AGGCTGCATT	CAATAGTTTA	CAGGCAAGTG	CTACTGAGTA	CATTGGCTAC	6780
					ATTCAAAAAG	6840
TTTACGAGCA	AGGCTTCTTA	AGCAATAGCG	AAGAGGCCCG	CACCGATCGC	CCTTCCCAAC	6900
	CCTGAATGGC					6960
					CCCTCAAACT	7020
	CGGTTACGAT					7080
	TGTTCCCACG					7140
	GCTACAGGAA					7200
					TAACGTTTAC	7260
					TATCAACCGG	7320

WO 92/06204 PCT/US91/07149

54

GGTACATATG	ATTGACATGC	TAGTTTTACG	ATTACCGTTC	ATCGATTCTC	TTGTTTGCTC	7380
CAGACTCTCA	GGCAATGACC	TGATAGCCTT	TGTAGATCTC	TCAAAAATAG	CTACCCTCTC	7440
CGGCATTAAT	TTATCAGCTA	GAACGGTTGA	ATATCATATT	GATGGTGATT	TGACTGTCTC	7500
CGGCCTTTCT	CACCCTTTTG	AATCTTTACC	TACACATTAC	TCAGGCATTG	CATTTAAAAT	7560
ATATGAGGGT	TCTAAAAATT	TTTATCCTTG	CGTTGAAATA	AAGGCTTCTC	CCGCAAAAGT	7620
ATTACAGGGT	CATAATGTTT	TTGGTACAAC	CGATTTAGCT	TTATGCTCTG	AGGCTTTATT	7680
GCTTAATTTT	GCTAATTCTT	TGCCTTGCCT	GTATGATTTA	TTGGACGTT		7729

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:

 (A) LENGTH: 7557 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: both
 (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AATGCTACTA CTATTAGTAG AATTGATGCC ACCTTTTCAG CTCGCGCCCC AAATGAAAAT	60
ATAGCTAAAC AGGTTATTGA CCATTTGCGA AATGTATCTA ATGGTCAAAC TAAATCTACT	120
CGTTCGCAGA ATTGGGAATC AACTGTTACA TGGAATGAAA CTTCCAGACA CCGTACTTTA	180
GTTGCATATT TAAAACATGT TGAGCTACAG CACCAGATTC AGCAATTAAG CTCTAAGCCA	240
TCCGCAAAAA TGACCTCTTA TCAAAAGGAG CAATTAAAGG TACTCTCTAA TCCTGACCTG	300
TTGGAGTTTG CTTCCGGTCT GGTTCGCTTT GAAGCTCGAA TTAAAACGCG ATATTTGAAG	360
TCTTTCGGGC TTCCTCTTAA TCTTTTTGAT GCAATCCGCT TTGCTTCTGA CTATAATAGT	420
CAGGGTAAAG ACCTGATTTT TGATTTATGG TCATTCTCGT TTTCTGAACT GTTTAAAGCA	480
TTTGAGGGGG ATTCAATGAA TATTTATGAC GATTCCGCAG TATTGGACGC TATCCAGTCT	540
AAACATTTTA CTATTACCCC CTCTGGCAAA ACTTCTTTTG CAAAAGCCTC TCGCTATTTT	600
GGTTTTTATC GTCGTCTGGT AAACGAGGGT TATGATAGTG TTGCTCTTAC TATGCCTCGT	660
AATTCCTTTT GGCGTTATGT ATCTGCATTA GTTGAATGTG GTATTCCTAA ATCTCAACTG	720
ATGAATCTTT CTACCTGTAA TAATGTTGTT CCGTTAGTTC GTTTTATTAA CGTAGATTTT	780
TCTTCCCAAC GTCCTGACTG GTATAATGAG CCAGTTCTTA AAATCGCATA AGGTAATTCA	840
CAATGATTAA AGTTGAAATT AAAGGATCTC AAGCCCAATT TACTACTCGT TCTGGTGTTT	900
CTCGTCAGGG CAAGCCTTAT TCACTGAATG AGCAGCTTTG TTACGTTGAT TTGGGTAATG	960
AATATCCGGT TCTTGTCAAG ATTACTCTTG ATGAAGGTCA GCCAGCCTAT GCGCCTGGTC	1020
TGTACACCGT TCATCTGTCC TCTTTCAAAG TTGGTCAGTT CGGTTCCCTT ATGATTGACC	1080
GTCTGCGCCT CGTTCCGGCT AAGTAACATG GAGCAGGTCG CGGATTTCGA CACAATTTAT	1140
CAGGCGATGA TACAAATCTC CGTTGTACTT TGTTTCGCGC TTGGTATAAT CGCTGGGGGT	1200
CAAAGATGAG TGTTTTAGTG TATTCTTTCG CCTCTTTCGT TTTAGGTTGG TGCCTTCGTA	1260

GTGGCATTAC	GTATTTTACC	CGTTTAATGG	AAACTTCCTC	ATGAAAAAGT	CTTTAGTCCT	1320
CAAAGCCTCT	GTAGCCGTTG	CTACCCTCGT	TCCGATGCTG	TCTTTCGCTG	CTGAGGGTGA	1380
CGATCCCGCA	AAAGCGGCCT	TTAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA	1440
TGCGTGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAGAA	1500
ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT	1560
TTTTTGGAGA	TTTTCAACGT	GAAAAAATTA	TTATTCGCAA	TTCCTTTAGT	TGTTCCTTTC	1620
TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTCA	1680
TTTACTAACG	TCTGGAAAGA	CGACAAAACT	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT	1740
CTGTGGAATG	CTACAGGCGT	TGTAGTTTGT	ACTCCTGACG	AAACTCAGTG	TTACGGTACA	1800
TGGGTTCCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	1860
TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
ATTCCGGGCT	ATACTTATAT	CAACCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA	1980
AACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	2040
CAGAATAATA	GGTTCCGAAA	TAGGCAGGGG	GCATTAACTG	TTTATACGGG	CACTGTTACT	2100
CAAGGCACTG	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG	2160
TATGACGCTT	ACTGGAACGG	TAAATTCAGA	GACTGCGCTT	TCCATTCTGG	CTTTAATGAA	2220
GATCCATTCG	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCTCAACC	TCCTGTCAAT	2280
GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340
GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT	2400
GATTTTGATT	ATGAAAAGAT	GGCAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT	2460
GAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT	2520
GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	2580
GGTGATTTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTCACCT	2640
TTAATGAATA	ATTTCCGTCA	ATATTTACCT	TCCCTCCCTG	AATCGGTTGA	ATGTCGCCCT	2700
TTTGTCTTTA	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	2760
TTCCGTGGTG	TCTTTGCGTT	TCTTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG	2820
TTTGCTAACA	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTTG	GGTATTCCGT	2880
TATTATTGCG	TTTCCTCGGT	TTCCTTCTGG	TAACTTTGTT	CGGCTATCTG	CTTACTTTTC	2940
TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CCTGTTTCTT	GCTCTTATTA	TTGGGCTTAA	3000
CTCAATTCTT	GTGGGTTATC	TCTCTGATAT	TAGCGCTCAA	TTACCCTCTG	ACTTTGTTCA	3060
GGGTGTTCAG	TTAATTCTCC	CGTCTAATGC	GCTTCCCTGT	TTTTATGTTA	TTCTCTCTGT	3120
AAAGGCTGCT	ATTTTCATTT	TTGACGTTAA	ACAAAAAATC	GTTTCTTATT	TGGATTGGGA	3180
TAAATAATAT	GGCTGTTTAT	TTTGTAACTG	GCAAATTAGG	CTCTGGAAAG	ACGCTCGTTA	3240
GCGTTGGTAA	GATTCAGGAT	AAAATTGTAG	CTGGGTGCAA	AATAGCAACT	AATCTTGATT	3300

TAAGGCTTCA	AAACCTCCCG	CAAGTCGGGA	GGTTCGCTAA	AACGCCTCGC	GTTCTTAGAA	3360
TACCGGATAA	GCCTTCTATA	TCTGATTTGC	TTGCTATTGG	GCGCGGTAAT	GATTCCTACG	3420
ATGAAAATAA	AAACGGCTTG	CTTGTTCTCG	ATGAGTGCGG	TACTTGGTTT	AATACCCGTT	3480
CTTGGAATGA	TAAGGAAAGA	CAGCCGATTA	TTGATTGGTT	TCTACATGCT	CGTAAATTAG	3540
GATGGGATAT	TATTTTTCTT	GTTCAGGACT	TATCTATTGT	TGATAAACAG	GCGCGTTCTG	3600
CATTAGCTGA	ACATGTTGTT	TATTGTCGTC	GTCTGGACAG	AATTACTTTA	CCTTTTGTCG	3660
GTACTTTATA	TTCTCTTATT	ACTGGCTCGA	AAATGCCTCT	GCCTAAATTA	CATGTTGGCG	3720
TTGTTAAATA	TGGCGATTCT	CAATTAAGCC	CTACTGTTGA	GCGTTGGCTT	TATACTGGTA	3780
AGAATTTGTA	TAACGCATAT	GATACTAAAC	AGGCTTTTTC	TAGTAATTAT	GATTCCGGTG	3840
TTTATTCTTA	TTTAACGCCT	TATTTATCAC	ACGGTCGGTA	TTTCAAACCA	TTAAATTTAG	3900
GTCAGAAGAT	GAAGCTTACT	AAAATATATT	TGAAAAAGTT	TTCACGCGTT	CTTTGTCTTG	3960
CGATTGGATT	TGCATCAGCA	TTTACATATA	GTTATATAAC	CCAACCTAAG	CCGGAGGTTA	4020
AAAAGGTAGT	CTCTCAGACC	TATGATTTTG	ATAAATTCAC	TATTGACTCT	TCTCAGCGTC	4080
TTAATCTAAG	CTATCGCTAT	GTTTTCAAGG	ATTCTAAGGG	AAAATTAATT	AATAGCGACG	4140
ATTTACAGAA	GCAAGGTTAT	TCACTCACAT	ATATTGATTT	ATGTACTGTT	TCCATTAAAA	4200
AAGGTAATTC	AAATGAAATT	GTTAAATGTA	ATTAATTTTG	TTTTCTTGAT	GTTTGTTTCA	4260
TCATCTTCTT	TTGCTCAGGT	AATTGAAATG	AATAATTCGC	CTCTGCGCGA	TTTTGTAACT	4320
TGGTATTCAA	AGCAATÇAGG	CGAATCCGTT	ATTGTTTCTC	CCGATGTAAA	AGGTACTGTT	4380
ACTGTATATT	CATCTGACGT	TAAACCTGAA	AATCTACGCA	ATTTCTTTAT	TTCTGTTTTA	4440
CGTGCTAATA	ATTTTGATAT	GGTTGGTTCA	ATTCCTTCCA	TAATTCAGAA	GTATAATCCA	4500
AACAATCAGG	ATTATATTGA	TGAATTGCCA	TCATCTGATA	ATCAGGAATA	TGATGATAAT	4560
TCCGCTCCTT	CTGGTGGTTT	CTTTGTTCCG	CAAAATGATA	ATGTTACTCA	AACTTTTAAA	4620
ATTAATAACG	TTCGGGCAAA	GGATTTAATA	CGAGTTGTCG	AATTGTTTGT	AAAGTCTAAT	4680
ACTTCTAAAT	CCTCAAATGT	ATTATCTATT	GACGGCTCTA	ATCTATTAGT	TGTTAGTGCA	4740
CCTAAAGATA	TTTTAGATAA	CCTTCCTCAA	TTCCTTTCTA	CTGTTGATTT	GCCAACTGAC	4800
CAGATATTGA	TTGAGGGTTT	GATATTTGAG	GTTCAGCAAG	GTGATGCTTT	AGATTTTTCA	4860
TTTGCTGCTG	GCTCTCAGCG	TGGCACTGTT	GCAGGCGGTG	TTAATACTGA	CCGCCTCACC	4920
TCTGTTTTAT	CTTCTGCTGG	TGGTTCGTTC	GGTATTTTTA	ATGGCGATGT	TTTAGGGCTA	4980
TCAGTTCGCG	CATTAAAGAC	TAATAGCCAT	TCAAAAATAT	TGTCTGTGCC	ACGTATTCTT	5040
ACGCTTTCAG	GTCAGAAGGG	TTCTATCTCT	GTTGGCCAGA	ATGTCCCTTT	TATTACTGGT	5100
CGTGTGACTG	GTGAATCTGC	CAATGTAAAT	AATCCATTTC	AGACGATTGA	GCGTCAAAAT	5160
GTAGGTATTT	CCATGAGCGT	TTTTCCTGTT	GCAATGGCTG	GCGGTAATAT	TGTTCTGGAT	5220
ATTACCAGCA	AGGCCGATAG	TTTGAGTTCT	TCTACTCAGG	CAAGTGATGT	TATTACTAAT	5280
CAAAGAAGTA	TTGCTACAAC	GGTTAATTTG	CGTGATGGAC	AGACTCTTTT	ACTCGGTGGC	5340

CTCACTGATT	ATAAAAACAC	TTCTCAAGA~	TCTGGCGTAC	CGTTCCTGTC	TAAAATCCCT	5400
TTAATCGGCC	TCCTGTTTAG	CTCCCGCTCT	GATTCCAACG	AGGAAAGCAC	GTTATACGTG	5460
CTCGTCAAAG	CAACCATAGT	ACGCGCCCTG	TAGCGGCGCA	TTAAGCGCGG	CGGGTGTGGT	5520
GGTTACGCGC	AGCGTGACCG	CTACACTTGC	CAGCGCCCTA	GCGCCCGCTC	CTTTCGCTTT	5580
CTTCCCTTCC	TTTCTCGCCA	CGTTCGCCGG	CTTTCCCCCGT	CAAGCTCTAA	ATCGGGGGCT	5640
CCCTTTAGGG	TTCCGATTTA	GTGCTTTACG	GCACCTCGAC	CCCAAAAAAC	TTGATTTGGG	5700
TGATGGTTCA	CGTAGTGGGC	CATCGCCCTG	ATAGACGGTT	TTTCGCCCTT	TGACGTTGGA	5760
GTCCACGTTC	TTTAATAGTG	GACTCTTGTT	CCAAACTGGA	ACAACACTCA	ACCCTATCTC	5820
GGGCTATTCT	TTTGATTTAT	AAGGGATTTT	GCCGATTTCG	GAACCACCAT	CAAACAGGAT	5880
TTTCGCCTGC	TGGGGCAAAC	CAGCGTGGAC	CGCTTGCTGC	AACTCTCTCA	GGGCCAGGCG	5940
GTGAAGGGCA	ATCAGCTGTT	GCCCGTCTCG	CTGGTGAAAA	GAAAAACCAC	CCTGGCGCCC	6000
AATACGCAAA	CCGCCTCTCC	CCGCGCGTTG	GCCGATTCAT	TAATGCAGCT	GGCACGACAG	6060
GTTTCCCGAC	TGGAAAGCGG	GCAGTGAGCG	CAACGCAATT	AATGTGAGTT	AGCTCE CA	6120
TTAGGCACCC	CAGGCTTTAC	ACTTTATGCT	TCCGGCTCGT	ATGTTGTGTG	GAATTG'LUAG	6180
CGGATAACAA	TTTCACACGC	CAAGGAGACA	GTCATAATGA	AATACCTATT	GCCTACGGCA	6240
GCCGCTGGAT	TGTTATTACT	CGCTGCCCAA	CCAGCCATGG	CCGAGCTCTT	CCCGCCATCT	6300
GATGAGCAGT	TGAAATCTGG	AACTGCCTCT	GTTGTGTGCC	TGCTGAATAA	CTTCTATCCC	6360
AGAGAGGCCA	AAGTACAGTG	GAAGGTGGAT	AACGCCCTCC	AATCGGGTAA	CTCCCAGGAG	6420
AGTGTCACAG	AGCAGGACAG	CAAGGACAGC	ACCTACAGCC	TCAGCAGCAC	CCTGACGCTG	6480
AGCAAAGCAG	ACTACGAGAA	ACACAAAGTC	TACGCCTGCG	AAGTCACCCA	TCAGGGCCTG	6540
AGCTCGCCCG	TCACAAAGAG	CTTCAACAGG	GGAGAGTGTT	CTAGAACGCG	TCACTTGGCA	6600
CTGGCCGTCG	TTTTACAACG	TCGTGACTGG	GAAAACCCTG	GCGTTACCCA	AGCTTAATCG	6660
CCTTGCAGAA	TTCCCTTTCG	CCAGCTGGCG	TAATAGCGAA	GAGGCCCGCA	CCGATCGCCC	6720
TTCCCAACAG	TTGCGCAGCC	TGAATGGCGA	ATGGCGCTTT	GCCTGGTTTC	CGGCACCAGA	6780
AGCGGTGCCG	GAAAGCTGGC	TGGAGTGCGA	TCTTCCTGAG	GCCGATACGG	TCGTCGTCCC	6840
CTCAAACTGG	CAGATGCACG	GTTACGATGC	GCCCATCTAC	ACCAACGTAA	CCTATCCCAT	6900
TACGGTCAAT	CCGCCGTTTG	TTCCCACGGA	GAATCCGACG	GGTTGTTACT	CGCTCACATT	6960
TAATGTTGAT	GAAAGCTGGC	TACAGGAAGG	CCAGACGCGA	ATTATTTTTG	ATGGCGTTCC	7020
TATTGGTTAA	AAAATGAGCT	GATTTAACAA	AAATTTAACG	CGAATTTTAA	CAAAATATTA	7080
ACGTTTACAA	TTAAAATATT	TGCTTATACA	ATCTTCCTGT	TTTTGGGGCT	TTTCTGATTA	7140
TCAACCGGGG	TACATATGAT	TGACATGCTA	GTTTTACGAT	TACCGTTCAT	CGATTCTCTT	7200
GTTTGCTCCA	GACTCTCAGG	CAATGACCTG	ATAGCCTTTG	TAGATCTCTC	AAAAATAGCT	7260
ACCCTCTCCG	GCATTAATTT	ATCAGCTAGA	ACGGTTGAAT	ATCATATTGA	TGGTGATTTG	7320
ACTGTCTCCG	GCCTTTCTCA	CCCTTTTGAA	TCTTTACCTA	CACATTACTC	AGGCATTGCA	7380

TTTAAAATAT ATGAGGGTTC TAAAAATTTT TATCCTTGCG TTGAAATAAA GGCTTCTCCC 7440 GCAAAAGTAT TACAGGGTCA TAATGTTTTT GGTACAACCG ATTTAGCTTT ATGCTCTGAG 7500 GCTTTATTGC TTAATTTTGC TAATTCTTTG CCTTGCCTGT ATGATTTATT GGATGTT 7557

58

(2) INFORMATION FOR SEQ ID NO:5:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8118 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: both
(D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

			•		•	• •
60	AAATGAAAAT	CTCGCGCCCC	ACCTTTTCAG	AATTGATGCC	CTATTAGTAG	AATGCTACTA
120	TAAATCTACT	ATGGTCAAAC	AATGTATCTA	CCATTTGCGA	AGGTTATTGA	ATAGCTAAAC
180	CCGTACTTTA	CTTCCAGACA	TGGAATGAAA	AACTGTTACA	ATTGGGAATC	CGTTCGCAGA
240	CTCTAAGCCA	AGCAATTAAG	CACCAGATTC	TGAGCTACAG	TAAAACATGT	GTTGCATATT
300	TCCTGACCTG	TACTCTCTAA	CAATTAAAGG	TCAAAAGGAG	TGACCTCTTA	TCTGCAAAAA
360	ATATTTGAAG	TTAAAACGCG	GAAGCTCGAA	GGTTCGCTTT	CTTCCGGTCT	TTGGAGTTTG
420	CTATAATAGT	TTGCTTCTGA	GCAATCCGCT	TCTTTTTGAT	TTCCTCTTAA	TCTTTCGGGC
480	GTTTAAAGCA	TTTCTGAACT	TCATTCTCGT	TGATTTATGG	ACCTGATTTT	CAGGGTAAAG
540	TATCCAGTCT	TATTGGACGC	GATTCCGCAG	TATTTATGAC	ATTCAATGAA	TTTGAGGGGG
600	TCGCTATTTT	CAAAAGCCTC	ACTTCTTTTG	CTCTGGCAAA	CTATTACCCC	AAACATTTTA
660	TATGCCTCGT	TTGCTCTTAC	TATGATAGTG	AAACGAGGGT	GTCGTCTGGT	GGTTTTTATC
720	ATCTCAACTG	GTATTCCTAA	GTTGAATGTG	ATCTGCATTA	GGCGTTATGT	AATTCCTTTT
780	CGTAGATTTT	GTTTTATTAA	CCGTTAGTTC	TAATGTTGTT	CTACCTGTAA	ATGAATCTTT
840	AGGTAATTCA	AAATCGCATA	CCAGTTCTTA	GTATAATGAG	GTCCTGACTG	TCTTCCCAAC
900	TCTGGTGTTT	TACTACTCGT	AAGCCCAATT	AAACCATCTC	AGTTGAAATT	CAATGATTAA
960	TTGGGTAATG	TTACGTTGAT	AGCAGCTTTG	TCACTGAATG	CAAGCCTTAT	CTCGTCAGGG
1020	GCGCCTGGTC	GCCAGCCTAT	ATGAAGGTCA	ATTACTCTTG	TCTTGTCAAG	AATATCCGGT
1080	ATGATTGACC	CGGTTCCCTT	TTGGTCAGTT	TCTTTCAAAG	TCATCTGTCC	TGTACACCGT
1140	CACAATTTAT	CGGATTTCGA	GAGCAGGTCG	AAGTAACATG	CGTTCCGGCT	GTCTGCGCCT
1200	CGCTGGGGGT	TTGGTATAAT	TGTTTCGCGC	CGTTGTACTT	TACAAATCTC	CAGGCGATGA
1260	TGCCTTCGTA	TTTAGGTTGG	CCTCTTTCGT	TATTCTTTCG	TGTTTTAGTG	CAAAGATGAG
1320	CTTTAGTCCT	ATGAAAAAGT	AAACTTCCTC	CGTTTAATGG	GTATTTTACC	GTGGCATTAC
1380	CTGAGGGTGA	TCTTTCGCTG	TCCGATGCTG	CTACCCTCGT	GTAGCCGTTG	CAAAGCCTCT
1440	ATATCGGTTA	GCGACCGAAT	GCAAGCCTCA	TTAACTCCCT	AAAGCGGCCT	CGATCCCGCA
1500	TGTTTAAGAA	GGTATCAAGC	CGCAACTATC	TCATTGTCGG	ATGGTTGTTG	TGCGTGGGCG

ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT	1560
TTTTTGGAGA	TTTTCAACGT	GAAAAAATTA	TTATTCGCAA	TTCCTTTAGT	TGTTCCTTTC	1620
TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTCA	1680
TTTACTAACG	TCTGGAAAGA	CGACAAAACT	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT	1740
CTGTGGAATG	CTACAGGCGT	TGTAGTTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA	1800
TGGGTTCCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	1860
TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
ATTCCGGGCT	ATACTTATAT	CAACCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA	1980
AACCCCCCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	2040
CAGAATAATA	GGTTCCGAAA	TAGGCAGGGG	GCATTAACTG	TTTATACGGG	CACTGTTACT	2100
CAAGGCACTG	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG	2160
TATGACGCTT	ACTGGAACGG	TAAATTCAGA	GACTGCGCTT	TCCATTCTGG	CTTTAATGAA	2220
GATCCATTCG	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCTCAACC	TCCTGTCAAT	2280
GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340
GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT	2400
GATTTTGATT	ATGAAAAGAT	GGCAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT	2460
GAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT	2520
GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	2580
GGTGATTTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTCACCT	2640
TTAATGAATA	ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	2700
TTTGTCTTTA	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	2760
TTCCGTGGTG	TCTTTGCGTT	TCTTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG	2820
TTTGCTAACA	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTTG	GGTATTCCGT	2880
TATTATTGCG	TTTCCTCGGT	TTCCTTCTGG	TAACTTTGTT	CGGCTATCTG	CTTACTTTTC	2940
TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CTATTTCATT	GTTTCTTGCT	CTTATTATTG	3000
GGCTTAACTC	AATTCTTGTG	GGTTATCTCT	CTGATATTAG	CGCTCAATTA	CCCTCTGACT	3060
TTGTTCAGGG	TGTTCAGTTA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTTT	TATGTTATTC	3120
TCTCTGTAAA	GGCTGCTATT	TTCATTTTTG	ACGTTAAACA	AAAAATCGTT	TCTTATTTGG	3180
ATTGGGATAA	ATAATATGGC	TGTTTATTTT	GTAACTGGCA	AATTAGGCTC	TGGAAAGACG	3240
CTCGTTAGCG	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT	3300
CTTGATTTAA	GGCTTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAAC	GCCTCGCGTT	3360
CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGGCG	CGGTAATGAT	3420
TCCTACGATG	AAAATAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCGGTAC	TTGGTTTAAT	3480
ACCCGTTCTT	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT	3540

AAATTAGGAT	GGGATATTAT	TTTTCTTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG	3600
CGTTCTGCAT	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT	3660
TTTGTCGGTA	CTTTATATTC	TCTTATTACT	GGCTCGAAAA	TGCCTCTGCC	TAAATTACAT	3720
GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT	3780
ACTGGTAAGA	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTTCTAG	TAATTATGAT	3840
TCCGGTGTTT	ATTCTTATTT	AACGCCTTAT	TTATCACACG	GTCGGTATTT	CAAACCATTA	3900
AATTTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTTGA	AAAAGTTTTC	ACGCGTTCTT	3960
TGTCTTGCGA	TTGGATTTGC	ATCAGCATTT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
GAGGTTAAAA	AGGTAGTCTC	TCAGACCTAT	GATTTTGATA	AATTCACTAT	TGACTCTTCT	4080
CAGCGTCTTA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
AGCGACGATT	TACAGAAGCA	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTTCC	4200
ATTAAAAAAG	GTAATTCAAA	TGAAATTGTT	AAATGTAATT	AATTTTGTTT	TCTTGATGTT	4260
TGTTTCATCA	TCTTCTTTTG	CTCAGGTAAT	TGAAATGAAT	AATTCGCCTC	TGCGCGATTT	4320
TGTAACTTGG	TATTCAAAGC	AATCAGGCGA	ATCCGTTATT	GTTTCTCCCG	ATGTAAAAGG	4380
			ΑССΤΩΔΔΔΑΤ	CTACGCAATT	ጥርጥጥጥል ጥጥጥር	4440
	GTATATTCAT	CTGACGTTAA	HOOTOMMINT		ICILIALITO	4440
TACTGTTACT	GTATATTCAT GCTAATAATT					4500
TACTGTTACT TGTTTTACGT		TTGATATGGT	TGGTTCAATT	CCTTCCATAA	TTCAGAAGTA	,,,,
TACTGTTACT TGTTTTACGT TAATCCAAAC	GCTAATAATT	TTGATATGGT ATATTGATGA	TGGTTCAATT ATTGCCATCA	CCTTCCATAA TCTGATAATC	TTCAGAAGTA AGGAATATGA	4500
TACTGTTACT TGTTTTACGT TAATCCAAAC TGATAATTCC	GCTAATAATT AATCAGGATT	TTGATATGGT ATATTGATGA GTGGTTTCTT	TGGTTCAATT ATTGCCATCA TGTTCCGCAA	CCTTCCATAA TCTGATAATC AATGATAATG	TTCAGAAGTA AGGAATATGA TTACTCAAAC	4500 4560
TACTGTTACT TGTTTTACGT TAATCCAAAC TGATAATTCC TTTTAAAATT	GCTAATAATT AATCAGGATT GCTCCTTCTG	TTGATATGGT ATATTGATGA GTGGTTTCTT GGGCAAAGGA	TGGTTCAATT ATTGCCATCA TGTTCCGCAA TTTAATACGA	CCTTCCATAA TCTGATAATC AATGATAATG GTTGTCGAAT	TTCAGAAGTA AGGAATATGA TTACTCAAAC TGTTTGTAAA	4500 4560 4620
TACTGTTACT TGTTTTACGT TAATCCAAAC TGATAATTCC TTTTAAAATT GTCTAATACT	GCTAATAATT AATCAGGATT GCTCCTTCTG AATAACGTTC	TTGATATGGT ATATTGATGA GTGGTTTCTT GGGCAAAGGA CAAATGTATT	TGGTTCAATT ATTGCCATCA TGTTCCGCAA TTTAATACGA ATCTATTGAC	CCTTCCATAA TCTGATAATC AATGATAATG GTTGTCGAAT GGCTCTAATC	TTCAGAAGTA AGGAATATGA TTACTCAAAC TGTTTGTAAA TATTAGTTGT	4500 4560 4620 4680
TACTGTTACT TGTTTTACGT TAATCCAAAC TGATAATTCC TTTTAAAATT GTCTAATACT TAGTGCACCT	GCTAATAATT AATCAGGATT GCTCCTTCTG AATAACGTTC TCTAAATCCT	TTGATATGGT ATATTGATGA GTGGTTTCTT GGGCAAAGGA CAAATGTATT TAGATAACCT	TGGTTCAATT ATTGCCATCA TGTTCCGCAA TTTAATACGA ATCTATTGAC TCCTCAATTC	CCTTCCATAA TCTGATAATC AATGATAATG GTTGTCGAAT GGCTCTAATC CTTTCTACTG	TTCAGAAGTA AGGAATATGA TTACTCAAAC TGTTTGTAAA TATTAGTTGT TTGATTTGCC	4500 4560 4620 4680 4740
TACTGTTACT TGTTTTACGT TAATCCAAAC TGATAATTCC TTTTAAAATT GTCTAATACT TAGTGCACCT AACTGACCAG	GCTAATAATT AATCAGGATT GCTCCTTCTG AATAACGTTC TCTAAATCCT AAAGATATTT	TTGATATGGT ATATTGATGA GTGGTTTCTT GGGCAAAGGA CAAATGTATT TAGATAACCT AGGGTTTGAT	TGGTTCAATT ATTGCCATCA TGTTCCGCAA TTTAATACGA ATCTATTGAC TCCTCAATTC ATTTGAGGTT	CCTTCCATAA TCTGATAATC AATGATAATG GTTGTCGAAT GGCTCTAATC CTTTCTACTG CAGCAAGGTG	TTCAGAAGTA AGGAATATGA TTACTCAAAC TGTTTGTAAA TATTAGTTGT TTGATTTGCC ATGCTTTAGA	4500 4560 4620 4680 4740 4800
TACTGTTACT TGTTTTACGT TAATCCAAAC TGATAATTCC TTTTAAAATT GTCTAATACT TAGTGCACCT AACTGACCAG TTTTTCATTT	GCTAATAATT AATCAGGATT GCTCCTTCTG AATAACGTTC TCTAAATCCT AAAGATATTT ATATTGATTG	TTGATATGGT ATATTGATGA GTGGTTTCTT GGGCAAAGGA CAAATGTATT TAGATAACCT AGGGTTTGAT CTCAGCGTGG	TGGTTCAATT ATTGCCATCA TGTTCCGCAA TTTAATACGA ATCTATTGAC TCCTCAATTC ATTTGAGGTT CACTGTTGCA	CCTTCCATAA TCTGATAATC AATGATAATG GTTGTCGAAT GGCTCTAATC CTTTCTACTG CAGCAAGGTG GGCGGTGTTA	TTCAGAAGTA AGGAATATGA TTACTCAAAC TGTTTGTAAA TATTAGTTGT TTGATTTGCC ATGCTTTAGA ATACTGACCG	4500 4560 4620 4680 4740 4800 4860
TACTGTTACT TGTTTTACGT TAATCCAAAC TGATAATTCC TTTTAAAATT GTCTAATACT TAGTGCACCT AACTGACCAG TTTTTCATTT CCTCACCTCT	GCTAATAATT AATCAGGATT GCTCCTTCTG AATAACGTTC TCTAAATCCT AAAGATATTT ATATTGATTG GCTGCTGGCT	TTGATATGGT ATATTGATGA GTGGTTTCTT GGGCAAAGGA CAAATGTATT TAGATAACCT AGGGTTTGAT CTCAGCGTGG CTGCTGGTGG	TGGTTCAATT ATTGCCATCA TGTTCCGCAA TTTAATACGA ATCTATTGAC TCCTCAATTC ATTTGAGGTT CACTGTTGCA TTCGTTCGGT	CCTTCCATAA TCTGATAATC AATGATAATG GTTGTCGAAT GGCTCTAATC CTTTCTACTG CAGCAAGGTG GGCGGTGTTA ATTTTTAATG	TTCAGAAGTA AGGAATATGA TTACTCAAAC TGTTTGTAAA TATTAGTTGT TTGATTTGCC ATGCTTTAGA ATACTGACCG GCGATGTTTT	4500 4560 4620 4680 4740 4800 4860 4920
TACTGTTACT TGTTTTACGT TAATCCAAAC TGATAATTCC TTTTAAAATT GTCTAATACT TAGTGCACCT AACTGACCAG TTTTTCATTT CCTCACCTCT AGGGCTATCA	GCTAATAATT AATCAGGATT GCTCCTTCTG AATAACGTTC TCTAAATCCT AAAGATATTT ATATTGATTG GCTGCTGGCT GTTTTATCTT GTTCGCGCAT	TTGATATGGT ATATTGATGA GTGGTTTCTT GGGCAAAGGA CAAATGTATT TAGATAACCT AGGGTTTGAT CTCAGCGTGG CTGCTGGTGG TAAAGACTAA	TGGTTCAATT ATTGCCATCA TGTTCCGCAA TTTAATACGA ATCTATTGAC TCCTCAATTC ATTTGAGGTT CACTGTTGCA TTCGTTCGGT TAGCCATTCA	CCTTCCATAA TCTGATAATC AATGATAATG GTTGTCGAAT GGCTCTAATC CTTTCTACTG CAGCAAGGTG GGCGGTGTTA ATTTTTAATG AAAATATTGT	TTCAGAAGTA AGGAATATGA TTACTCAAAC TGTTTGTAAA TATTAGTTGT TTGATTTGCC ATGCTTTAGA ATACTGACCG GCGATGTTTT	4500 4560 4620 4680 4740 4800 4860 4920 4980 5040
TACTGTTACT TGTTTTACGT TAATCCAAAC TGATAATTCC TTTTAAAATT GTCTAATACT TAGTGCACCT AACTGACCAG TTTTTCATTT CCTCACCTCT AGGGCTATCA TATTCTTACG	GCTAATAATT AATCAGGATT GCTCCTTCTG AATAACGTTC TCTAAATCCT AAAGATATTT ATATTGATTG GCTGCTGGCT GTTTTATCTT GTTCGCGCAT CTTTCAGGTC	TTGATATGGT ATATTGATGA GTGGTTTCTT GGGCAAAGGA CAAATGTATT TAGATAACCT AGGGTTTGAT CTCAGCGTGG CTGCTGGTGG TAAAGACTAA AGAAGGGTTC	TGGTTCAATT ATTGCCATCA TGTTCCGCAA TTTAATACGA ATCTATTGAC TCCTCAATTC ATTTGAGGTT CACTGTTGCA TTCGTTCGGT TAGCCATTCA TATCTCTGTT	CCTTCCATAA TCTGATAATC AATGATAATG GTTGTCGAAT GGCTCTAATC CTTTCTACTG CAGCAAGGTG GGCGGTGTTA ATTTTTAATG AAAATATTGT GGCCAGAATG	TTCAGAAGTA AGGAATATGA TTACTCAAAC TGTTTGTAAA TATTAGTTGT TTGATTTGCC ATGCTTTAGA ATACTGACCG GCGATGTTTT CTGTGCCACG	4500 4560 4620 4680 4740 4800 4860 4920 4980 5040 5100
TACTGTTACT TGTTTTACGT TAATCCAAAC TGATAATTCC TTTTAAAATT GTCTAATACT TAGTGCACCT AACTGACCAG TTTTTCATTT CCTCACCTCT AGGGCTATCA TATTCTTACG TACTGGTCGT	GCTAATAATT AATCAGGATT GCTCCTTCTG AATAACGTTC TCTAAATCCT AAAGATATTT ATATTGATTG GCTGCTGGCT GTTTTATCTT GTTCGCGCAT CTTTCAGGTC GTGACTGGTG	TTGATATGGT ATATTGATGA GTGGTTTCTT GGGCAAAGGA CAAATGTATT TAGATAACCT AGGGTTTGAT CTCAGCGTGG CTGCTGGTGG TAAAGACTAA AGAAGGGTTC AATCTGCCAA	TGGTTCAATT ATTGCCATCA TGTTCCGCAA TTTAATACGA ATCTATTGAC TCCTCAATTC ATTTGAGGTT CACTGTTGCA TTCGTTCGGT TAGCCATTCA TATCTCTGTT TGTAAATAAT	CCTTCCATAA TCTGATAATC AATGATAATG GTTGTCGAAT GGCTCTAATC CTTTCTACTG CAGCAAGGTG GGCGGTGTTA ATTTTTAATG AAAATATTGT GGCCAGAATG CCATTTCAGA	TTCAGAAGTA AGGAATATGA TTACTCAAAC TGTTTGTAAA TATTAGTTGT TTGATTTGCC ATGCTTTAGA ATACTGACCG GCGATGTTTT CTGTGCCACG TCCCTTTTAT	4500 4560 4620 4680 4740 4800 4860 4920 4980 5040 5100 5160
TACTGTTACT TGTTTTACGT TAATCCAAAC TGATAATTCC TTTTAAAATT GTCTAATACT TAGTGCACCT AACTGACCAG TTTTTCATTT CCTCACCTCT AGGGCTATCA TATTCTTACG TACTGGTCGT TCAAAATGTA	GCTAATAATT AATCAGGATT GCTCCTTCTG AATAACGTTC TCTAAATCCT AAAGATATTT ATATTGATTG GCTGCTGGCT GTTTTATCTT GTTCGCGCAT CTTTCAGGTC GTGACTGGTG GGTATTTCCA	TTGATATGGT ATATTGATGA GTGGTTTCTT GGGCAAAGGA CAAATGTATT TAGATAACCT AGGGTTTGAT CTCAGCGTGG CTGCTGGTGG TAAAGACTAA AGAAGGGTTC AATCTGCCAA TGAGCGTTTT	TGGTTCAATT ATTGCCATCA TGTTCCGCAA TTTAATACGA ATCTATTGAC TCCTCAATTC ATTTGAGGTT CACTGTTGCA TTCGTTCGGT TAGCCATTCA TATCTCTGTT TGTAAATAAT TCCTGTTGCA	CCTTCCATAA TCTGATAATC AATGATAATG GTTGTCGAAT GGCTCTAATC CTTTCTACTG CAGCAAGGTG GGCGGTGTTA ATTTTAATG AAAATATTGT GGCCAGAATG CCATTTCAGA ATGGCTGGCG	TTCAGAAGTA AGGAATATGA TTACTCAAAC TGTTTGTAAA TATTAGTTGT TTGATTTGCC ATGCTTTAGA ATACTGACCG GCGATGTTTT CTGTGCCACG TCCCTTTTAT CGATTGAGCG	4500 4560 4620 4680 4740 4860 4920 4980 5040 5100 5160 5220
TACTGTTACT TGTTTTACGT TAATCCAAAC TGATAATTCC TTTTAAAATT GTCTAATACT TAGTGCACCT AACTGACCAG TTTTTCATTT CCTCACCTCT AGGGCTATCA TATTCTTACG TACTGGTCGT TCAAAATGTA TCTGGATATT	GCTAATAATT AATCAGGATT GCTCCTTCTG AATAACGTTC TCTAAATCCT AAAGATATTT ATATTGATTG GCTGCTGGCT GTTTCAGGTC GTTCAGGTC GTGACTGGTG GGTATTTCCA ACCAGCAAGG	TTGATATGGT ATATTGATGA GTGGTTTCTT GGGCAAAGGA CAAATGTATT TAGATAACCT AGGGTTTGAT CTCAGCGTGG CTGCTGGTGG TAAAGACTAA AGAAGGGTTC AATCTGCCAA TGAGCGTTTT CCGATAGTTT	TGGTTCAATT ATTGCCATCA TGTTCCGCAA TTTAATACGA ATCTATTGAC TCCTCAATTC ATTTGAGGTT CACTGTTGCA TTCGTTCGGT TAGCCATTCA TATCTCTGTT TGTAAATAAT TCCTGTTGCA GAGTTCTTCT	CCTTCCATAA TCTGATAATC AATGATAATG GTTGTCGAAT GGCTCTAATC CTTTCTACTG CAGCAAGGTG GGCGGTGTTA ATTTTTAATG AAAATATTGT GGCCAGAATG CCATTTCAGA ATGGCTGGCG ACTCAGGCAA	TTCAGAAGTA AGGAATATGA TTACTCAAAC TGTTTGTAAA TATTAGTTGT TTGATTTGCC ATGCTTTAGA ATACTGACCG GCGATGTTTT CTGTGCCACG TCCCTTTTAT CGATTGAGCG GTAATATTGT	4500 4560 4620 4680 4740 4800 4860 4920 4980 5040 5100 5160 5220 5280
TACTGTTACT TGTTTTACGT TAATCCAAAC TGATAATTCC TTTTAAAATT GTCTAATACT TAGTGCACCT AACTGACCAG TTTTTCATTT CCTCACCTCT AGGGCTATCA TATTCTTACG TACTGGTCGT TCAAAATGTA TCTGGATATT TACTAATCAA	GCTAATAATT AATCAGGATT GCTCCTTCTG AATAACGTTC TCTAAATCCT AAAGATATTT ATATTGATTG GCTGCTGGCT GTTTTATCTT GTTCGCGCAT CTTTCAGGTC GTGACTGGTG GGTATTTCCA ACCAGCAAGG AGAAGTATTG	TTGATATGGT ATATTGATGA GTGGTTTCTT GGGCAAAGGA CAAATGTATT TAGATAACCT AGGGTTTGAT CTCAGCGTGG CTGCTGGTGG TAAAGACTAA AGAAGGGTTC AATCTGCCAA TGAGCGTTTT CCGATAGTTT CTACAACGGT	TGGTTCAATT ATTGCCATCA TGTTCCGCAA TTTAATACGA ATCTATTGAC TCCTCAATTC ATTTGAGGTT CACTGTTGCA TTCGTTCGGT TAGCCATTCA TATCTCTGTT TGTAAATAAT TCCTGTTGCA GAGTTCTTCT TAATTTGCGT	CCTTCCATAA TCTGATAATC AATGATAATG GTTGTCGAAT GGCTCTAATC CTTTCTACTG CAGCAAGGTG GGCGGTGTTA ATTTTTAATG AAAATATTGT GGCCAGAATG CCATTTCAGA ATGGCTGGCG ACTCAGGCAA GATGGACAGA	TTCAGAAGTA AGGAATATGA TTACTCAAAC TGTTTGTAAA TATTAGTTGT TTGATTTGCC ATGCTTTAGA ATACTGACCG GCGATGTTTT CTGTGCCACG TCCCTTTTAT CGATTGAGCG GTAATATTGT GTGATGTTT	4500 4560 4620 4680 4740 4800 4860 4920 4980 5040 5100 5160 5220 5280 5340
TACTGTTACT TGTTTTACGT TAATCCAAAC TGATAATTCC TTTTAAAATT GTCTAATACT TAGTGCACCT AACTGACCAG TTTTTCATTT CCTCACCTCT AGGGCTATCA TATTCTTACG TACTGGTCGT TCAAAATGTA TCTGGATATT TACTAATCAA CGGTGGCCTC	GCTAATAATT AATCAGGATT GCTCCTTCTG AATAACGTTC TCTAAATCCT AAAGATATTT ATATTGATTG GCTGCTGGCT GTTTTATCTT GTTCAGGTC GTGACTGGTG GGTATTTCA ACCAGCAAGG AGAAGTATTG ACTGATTATA	TTGATATGGT ATATTGATGA GTGGTTTCTT GGGCAAAGGA CAAATGTATT TAGATAACCT AGGGTTTGAT CTCAGCGTGG CTGCTGGTGG TAAAGACTAA AGAAGGGTTC AATCTGCCAA TGAGCGTTTT CCGATAGTTT CTACAACGGT AAAACACTTC	TGGTTCAATT ATTGCCATCA TGTTCCGCAA TTTAATACGA ATCTATTGAC TCCTCAATTC ATTTGAGGTT CACTGTTGCA TTCGTTCGGT TAGCCATTCA TATCTCTGTT TGTAAATAAT TCCTGTTGCA GAGTTCTTCT TAATTTGCGT TCAAGATTCT	CCTTCCATAA TCTGATAATC AATGATAATG GTTGTCGAAT GGCTCTAATC CTTTCTACTG CAGCAAGGTG GGCGGTGTTA ATTTTTAATG AAAATATTGT GGCCAGAATG CCATTTCAGA ATGGCTGGCG ACTCAGGCAA GATGGACAGA GGCGTACCGT	TTCAGAAGTA AGGAATATGA TTACTCAAAC TGTTTGTAAA TATTAGTTGT TTGATTTGCC ATGCTTTAGA ATACTGACCG GCGATGTTTT CTGTGCCACG TCCCTTTTAT CGATTGACG GTAATATTGT GTGATGTTAT CTCTTTTAT	4500 4560 4620 4680 4740 4800 4860 4920 4980 5040 5100 5160 5220 5280 5340 5400
TACTGTTACT TGTTTTACGT TAATCCAAAC TGATAATTCC TTTTAAAATT GTCTAATACT TAGTGCACCT AACTGACCAG TTTTTCATTT CCTCACCTCT AGGGCTATCA TATTCTTACG TACTGGTCGT TCAAAATGTA TCTGGATATT TACTAATCAA CGGTGGCCTC AATCCCTTTA	GCTAATAATT AATCAGGATT GCTCCTTCTG AATAACGTTC TCTAAATCCT AAAGATATTT ATATTGATTG GCTGCTGGCT GTTTTATCTT GTTCAGGTC GTGACTGGTG GGTATTTCCA ACCAGCAAGG AGAAGTATTG ACTGATTATA ATCGGCCTCC	TTGATATGGT ATATTGATGA GTGGTTTCTT GGGCAAAGGA CAAATGTATT TAGATAACCT AGGGTTTGAT CTCAGCGTGG CTGCTGGTGG TAAAGACTAA AGAAGGGTTC AATCTGCCAA TGAGCGTTTT CCGATAGTTT CTACAACGGT AAAACACTTC TGTTTAGCTC	TGGTTCAATT ATTGCCATCA TGTTCCGCAA TTTAATACGA ATCTATTGAC TCCTCAATTC ATTTGAGGTT CACTGTTGCA TTCGTTCGGT TAGCCATTCA TATCTCTGTT TGTAAATAAT TCCTGTTGCA GAGTTCTTCT TAATTTGCGT TCAAGATTCT CCGCTCTGAT	GCTTCCATAA TCTGATAATC AATGATAATG GTTGTCGAAT GGCTCTAATC CTTTCTACTG CAGCAAGGTG GGCGGTGTTA ATTTTTAATG AAAATATTGT GGCCAGAATG CCATTTCAGA ATGGCTGGCG ACTCAGGCAA GATGGACAGA GGCGTACCGT TCCAACGAGG	TTCAGAAGTA AGGAATATGA TTACTCAAAC TGTTTGTAAA TATTAGTTGT TTGATTTGCC ATGCTTTAGA ATACTGACCG GCGATGTTTT CTGTGCCACG TCCCTTTTAT CGATTGAGCG GTAATATTGT GTGATGTTAT CTCTTTTACT TCCTGTCTAA	4500 4560 4620 4680 4740 4800 4860 4920 4980 5040 5100 5160 5220 5280 5340 5400 5460

TCGCTTTCTT	CCCTTCCTTT	CTCGCCACGT	TCGCCGGCTT	TCCCCGTCAA	GCTCTAAATC	5640
GGGGGCTCCC	TTTAGGGTTC	CGATTTAGTG	CTTTAUGGCA	CCTCGACCCC	AAAAAACTTG	5700
ATTTGGGTGA	TGGTTCACGT	AGTGGGCCAT	CGCCCTGATA	GACGGTTTTT	CGCCCTTTGA	5760
CGTTGGAGTC	CACGTTCTTT	AATAGTGGAC	TCTTGTTCCA	AACTGGAACA	ACACTCAACC	5820
CTATCTCGGG	CTATTCTTTT	GATTTATAAG	GGATTTTGCC	GATTTCGGAA	CCACCATCAA	5880
ACAGGATTTT	CGCCTGCTGG	GGCAAACCAG	CGTGGACCGC	TTGCTGCAAC	TCTCTCAGGG	5940
CCAGGCGGTG	AAGGGCAATC	AGCTGTTGCC	CGTCTCGCTG	GTGAAAAGAA	AAACCACCCT	6000
GGCGCCCAAT	ACGCAAACCG	CCTCTCCCCG	CGCGTTGGCC	GATTCATTAA	TGCAGCTGGC	6060
ACGACAGGTT	TCCCGACTGG	AAAGCGGGCA	GTGAGCGCAA	CGCAATTAAT	GTGAGTTAGC	6120
TCACTCATTA	GGCACCCCAG	GCTTTACACT	TTATGCTTCC	GGCTCGTATG	TTGTGTGGAA	6180
TTGTGAGCGG	ATAACAATTT	CACACGCCAA	GGAGACAGTC	ATAATGAAAT	ACCTATTGCC	6240
TACGGCAGCC	GCTGGATTGT	TATTACTCGC	TGCCCAACCA	GCCATGGCCG	AGCTCTTCCC	6300
GCCATCTGAT	GAGCAGTTGA	AATCTGGAAC	TGCCTCTGTT	GTGTGCCTGC	TGAATAACTT	6360
CTATCCCAGA	GAGGCCAAAG	TACAGTGGAA	GGTGGATAAC	GCCCTCCAAT	CGGGTAACTC	6420
CCAGGAGAGT	GTCACAGAGC	AGGACAGCAA	GGACAGCACC	TACAGCCTCA	GCAGCACCCT	6480
GACGCTGAGC	AAAGCAGACT	ACGAGAAACA	CAAAGTCTAC	GCCTGCGAAG	TCACCCATCA	6540
GGGCCTGAGC	TCGCCCGTCA	CAAAGAGCTT	CAACAGGGGA	GAGTGTTCTA	GAACGCGTCA	6600
CTTGGCACTG	GCCGTCGTTT	TACAACGTCG	TGACTGGGAA	AACCCTGGCG	TTACCCAAGC	6660
TTTGTACATG	GAGAAAATAA	AGTGAAACAA	AGCACTATTG	CACTGGCACT	CTTACCGTTA	6720
CTGTTTACCC	CTGTGGCAAA	AGCCGCCTCC	ACCAAGGGCC	CATCGGTCTT	CCCCTGGCA	6780
CCCTCCTCCA	AGAGCACCTC	TGGGGGCACA	GCGGCCCTGG	GCTGCCTGGT	CAAGACTAAT	6840
TCCCCGAACC	GGTGACGGTG	TCGTGGAACT	CAGGCGCCCT	GACCAGCGGC	GTGCACACCT	6900
TCCCGGCTGT	CCTACAGTCC	TCAGGACTCT	ACTCCCTCAG	CAGCGTGGTG	ACCGTGCCCT	6960
CCAGCAGCTT	GGGCACCCAG	ACCTACATCT	GCAACGTGAA	TCACAAGCCC	AGCAACACCA	7020
AGGTGGACAA	GAAAGCAGAG	CCCAAATCTT	GTACTAGTGG	ATCCTACCCG	TACGACGTTC	7080
CGGACTACGC	TTCTTAGGCT	GAAGGCGATG	ACCCTGCTAA	GGCTGCATTC	AATAGTTTAC	7140
AGGCAAGTGC	TACTGAGTAC	ATTGGCTACG	CTTGGGCTAT	GGTAGTAGTT	ATAGTTGGTG	7200
CTACCATAGG	GATTAAATTA	TTCAAAAAGT	TTACGAGCAA	GGCTTCTTAA	GCAATAGCGA	7260
AGAGGCCCGC	ACCGATCGCC	CTTCCCAACA	GTTGCGCAGC	CTGAATGGCG	AATGGCGCTT	7320
TGCCTGGTTT	CCGGCACCAG	AAGCGGTGCC	GGAAAGCTGG	CTGGAGTGCG	ATCTTCCTGA	7380
GGCCGATACG	GTCGTCGTCC	CCTCAAACTG	GCAGATGCAC	GGTTACGATG	CGCCCATCTA	7440
CACCAACGTA	ACCTATCCCA	TTACGGTCAA	TCCGCCGTTT	GTTCCCACGG	AGAATCCGAC	7500
GGGTTGTTAC	TCGCTCACAT	TTAATGTTGA	TGAAAGCTGG	CTACAGGAAG	GCCAGACGCG	7560
AATTATTTT	GATGGCGTTC	CTATTGGTTA	AAAAATGAGC	TGATTTAACA	AAAATTTAAC	7620

WO 92/06204 PCT/US91/07149

62

GCGAATTTTA	ACAAAATATT	AACGTTTACA	ATTTAAATAT	TTGCTTATAC	AATCTTCCTG	7680
TTTTTGGGGC	TTTTCTGATT	ATCAACCGGG	GTACATATGA	TTGACATGCT	AGTTTTACGA	7740
TTACCGTTCA	TCGATTCTCT	TGTTTGCTCC	AGACTCTCAG	GCAATGACCT	GATAGCCTTT	7800
GTAGATCTCT	CAAAAATAGC	TACCCTCTCC	GGCATTAATT	TATCAGCTAG	AACGGTTGAA	7860
TATCATATTG	ATGGTGATTT	GACTGTCTCC	GGCCTTTCTC	ACCCTTTTGA	ATCTTTACCT	7920
ACACATTACT	CAGGCATTGC	ATTTAAAATA	TATGAGGGTT	CTAAAAATTT	TTATCCTTGC	7980
GTTGAAATAA	AGGCTTCTCC	CGCAAAAGTA	TTACAGGGTC	ATAATGTTTT	TGGTACAACC	8040
GATTTAGCTT	TATGCTCTGA	GGCTTTATTG	CTTAATTTTG	CTAATTCTTT	GCCTTGCCTG	8100
TATGATTTAT	TGGACGTT					8118

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:

 (A) LENGTH: 22 base pairs

 (B) TYPE: nucleic acid

 (C) STRANDEDNESS: single

 (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: misc_difference
 (B) LOCATION: replace(5, "")
 (D) OTHER INFORMATION: /note- "S REPRESENTS EQUAL MIXTURE OF G AND C"

(ix) FEATURE:

- (A) NAME/KEY: misc_difference
 (B) LOCATION: replace(6, "")
 (D) OTHER INFORMATION: /note= "M REPRESENTS EQUAL MIXTURE OF A AND C"

(ix) FEATURE:

- (A) NAME/KEY: misc_difference
 (B) LOCATION: replace(8, "")
 (D) OTHER INFORMATION: /note- "R REPRESENTS EQUAL MIXTURE OF A AND G"

(ix) FEATURE:

- (A) NAME/KEY: misc_difference
 (B) LOCATION: replace(11, "")
 (D) OTHER INFORMATION: /note= "K REPRESENTS EQUAL MIXTURE OF G AND T"

(ix) FEATURE:

- (A) NAME/KEY: misc_difference
 (B) LOCATION: replace(20, "")
 (D) OTHER INFORMATION: /note= "W REPRESENTS EQUAL MIXTURE" OF A AND T"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AGGTSMARCT KCTCGAGTCW GG

(2) INFORMATION FOR	SEQ ID NO:7:		
(A) LENGT (B) TYPE: (C) STRAN	HARACTERISTICS: H: 22 base pairs nucleic acid DEDNESS: single OGY: linear		
•	ESCRIPTION: SEQ ID	NO:7:	22
AGGTCCAGCT GCTCGAGT			22
(2) INFORMATION FOR	SEQ ID NO:8:		
(A) LENGT (B) TYPE: (C) STRAN	HARACTERISTICS: H: 22 base pairs nucleic acid DEDNESS: single OGY: linear	-	
(xi) SEQUENCE D	ESCRIPTION: SEQ ID	NO:8:	
AGGTCCAGCT GCTCGAGT	CA GG		22
(2) INFORMATION FOR	SEQ ID NO:9:		
(A) LENGT (B) TYPE: (C) STRAN	HARACTERISTICS: H: 22 base pairs nucleic acid DEDNESS: single OGY: linear		
(xi) SEQUENCE D	ESCRIPTION: SEQ ID	NO:9:	
AGGTCCAGCT TCTCGAGT	CT GG		22
(2) INFORMATION FOR	SEQ ID NO:10:		
(A) LENGT (B) TYPE: (C) STRAN	HARACTERISTICS: H: 22 base pairs nucleic acid DEDNESS: single OGY: linear		
(xi) SEQUENCE D	ESCRIPTION: SEQ ID	NO:10:	
AGGTCCAGCT TCTCGAGT	CA GG		22
(2) INFORMATION FOR	SEQ ID NO:11:		
(A) LENGT (B) TYPE: (C) STRAN	HARACTERISTICS: H: 22 base pairs nucleic acid DEDNESS: single OGY: linear		

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:	
AGGTCCAACT GCTCGAGTCT GG	22
(2) INFORMATION FOR SEQ ID NO:12:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:	
AGGTCCAACT GCTCGAGTCA GG	22
(2) INFORMATION FOR SEQ ID NO:13:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:	
AGGTCCAACT TCTCGAGTCT GG	22
(2) INFORMATION FOR SEQ ID NO:14:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:	
AGGTCCAACT TCTCGAGTCA GG	22
(2) INFORMATION FOR SEQ ID NO:15:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
<pre>(ix) FEATURE: (A) NAME/KEY: misc_difference (B) LOCATION: replace(56, "") (D) OTHER INFORMATION: /note= "N-INOSINE"</pre>	
<pre>(ix) FEATURE: (A) NAME/KEY: misc_difference (B) LOCATION: replace(8, "") (D) OTHER INFORMATION: /note= "N=INOSINE"</pre>	

	(ix)	FEATURE: (A) NAME/KEY: misc_difference (B) LOCATION: replace(11, "") (D) OTHER INFORMATION: /note= "N-INOSINE"	
	(ix)	FEATURE: (A) NAME/KEY: misc_difference (B) LOCATION: replace(20, "") (D) OTHER INFORMATION: /note= "W REPRESENTS EQUAL MIXTURE OF A AND T"	
	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:15:	
AGG	TNNAN	CT NCTCGAGTCW GG	22
(2)	INFO	RMATION FOR SEQ ID NO:16:	
	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:16:	
CTA'	TTAAC'	TA GTAACGGTAA CAGTGGTGCC TTGCCCCA	38
(2)	INFO	RMATION FOR SEQ ID NO:17:	
	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:17:	
AGG	CTTAC	TA GTACAATCCC TGGGCACAAT	30
(2)	INFO	RMATION FOR SEQ ID NO:18:	
	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:18:	
CCA	STTCC	GA GCTCGTTGTG ACTCAGGAAT CT	32
(2)	INFO	RMATION FOR SEQ ID NO:19:	
	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:	
CCAGTTCCGA GCTCGTGTTG ACGCAGCCGC CC	32
(2) INFORMATION FOR SEQ ID NO:20:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(x1) SEQUENCE DESCRIPTION: SEQ ID NO:20:	
CCAGTTCCGA GCTCGTGCTC ACCCAGTCTC CA	32
(2) INFORMATION FOR SEQ ID NO:21:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:	
CCAGTTCCGA GCTCCAGATG ACCCAGTCTC CA	32
(2) INFORMATION FOR SEQ ID NO:22:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:	
CCAGATGTGA GCTCGTGATG ACCCAGACTC CA	32
(2) INFORMATION FOR SEQ ID NO:23:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(x1) SEQUENCE DESCRIPTION: SEQ ID NO:23:	
CCAGATGTGA GCTCGTCATG ACCCAGTCTC CA	32
(2) INFORMATION FOR SEQ ID NO:24:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:	
CCAGTTCCGA GCTCGTGATG ACACAGTCTC CA	32
(2) INFORMATION FOR SEQ ID NO:25:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:	
GCAGCATTCT AGAGTTTCAG CTCCAGCTTG CC	32
(2) INFORMATION FOR SEQ ID NO:26:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:	34
GCGCCGTCTA GAATTAACAC TCATTCCTGT TGAA	34
(2) INFORMATION FOR SEQ ID NO:27:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:	
GATCCTAGGC TGAAGGCGAT GACCCTGCTA AGGCTGC	37
(2) INFORMATION FOR SEQ ID NO:28:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:	
ATTCAATACT TTACACCCAA GTGCTACTGA GTACA	35

(2) INFORMATION FOR SEQ ID NO:29:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:	
TTGGCTACGC TTGGGCTATG GTAGTTA TAGTT	35
(2) INFORMATION FOR SEQ ID NO:30:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:	
GGTGCTACCA TAGGGATTAA ATTATTCAAA AAGTT	35
(2) INFORMATION FOR SEQ ID NO:31:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:	
TACGAGCAAG GCTTCTTA	18
(2) INFORMATION FOR SEQ ID NO:32:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:	
AGCTTAAGAA GCCTTGCTCG TAAACTTTTT GAATAATTT	39
(2) INFORMATION FOR SEQ ID NO:33:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:33:	
AATCCCTATG GTAGCACCAA CTATAACTAC TACCAT	36
(2) INFORMATION FOR SEQ ID NO:34:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:	
AGCCCAAGCG TAGCCAATGT ACTCAGTAGC ACTTG	35
(2) INFORMATION FOR SEQ ID NO:35:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(x1) SEQUENCE DESCRIPTION: SEQ ID NO:35:	
CCTGTAAACT ATTGAATGCA GCCTTAGCAG GGTC	34
(2) INFORMATION FOR SEQ ID NO:36:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:	
ATCGCCTTCA GCCTAG	16
(2) INFORMATION FOR SEQ ID NO:37:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:	
CATTTTTGCA GATGGCTTAG A	21
(2) INFORMATION FOR SEQ ID NO:38:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:	
TAGCATTAAC GTCCAATA	18
(2) INFORMATION FOR SEQ ID NO:39:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(x1) SEQUENCE DESCRIPTION: SEQ ID NO:39:	
ATATATTTA GTAAGCTTCA TCTTCT	26
(2) INFORMATION FOR SEQ ID NO:40:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	·
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:	
GACAAAGAAC GCGTGAAAAC TTT	23
(2) INFORMATION FOR SEQ ID NO:41:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:	
GCGGGCCTCT TCGCTATTGC TTAAGAAGCC TTGCT	35
(2) INFORMATION FOR SEQ ID NO:42:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:	
AAACGACGGC CAGTGCCAAG TGACGCGTGT GAAATTGTTA TCC	43

(2) INFORMATION FOR SEQ ID NO:43:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:	
GGCGAAAGGG AATTCTGCAA GGCGATTAAG CTTGGGTAAC GCC	43
(2) INFORMATION FOR SEQ ID NO:44:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:	
GGCGTTACCC AAGCTTTGTA CATGGAGAAA ATAAAG	36
(2) INFORMATION FOR SEQ ID NO:45:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi SEQUENCE DESCRIPTION: SEQ ID NO:45:	
TGAAACAAAG CACTATTGCA CTGGCACTCT TACCGTTACC GT	42
(2) INFORMATION FOR SEQ ID NO:46:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:	
TACTGTTTAC CCCTGTGACA AAAGCCGCCC AGGTCCAGCT GC	42
(2) INFORMATION FOR SEQ ID NO:47:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 44 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:	
TCGAGTCAGG CCTATTGTGC CCAGGGATTG TACTAGTGGA TCCG	44
(2) INFORMATION FOR SEQ ID NO:48:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:	
TGGCGAAAGG GAATTCGGAT CCACTAGTAC AATCCCTG	38
(2) INFORMATION FOR SEQ ID NO:49:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:	
GGCACAATAG GCCTGACTCG AGCAGCTGGA CCAGGGCGGC TT	42
(2) INFORMATION FOR SEQ ID NO:50:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:	
TTGTCACAGG GGTAAACAGT AACGGTAACG GTAAGTGTGC CA	42
(2) INFORMATION FOR SEQ ID NO:51:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(x1) SEQUENCE DESCRIPTION: SEQ ID NO:51:	
GTGCAATAGT GCTTTGTTTC ACTTTATTTT CTCCATGTAC AA	42
(2) INFORMATION FOR SEQ ID NO:52:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	

PCT/US91/07149

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:	
TAACGGTAAG AGTGCCAGTG C	21
(2) INFORMATION FOR SEQ ID NO:53:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:	
CACCTTCATG AATTCGGCAA GGAGACAGTC AT	32
(2) INFORMATION FOR SEQ ID NO:54:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:	22
(2) INFORMATION FOR SEQ ID NO:55:	
(1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acii (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:	
AATGAAATAC CTATTGCCTA CGGCAGCCGC TGGATTGTT	39
(2) INFORMATION FOR SEQ ID NO:56:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(x1) SEQUENCE DESCRIPTION: SEQ ID NO:56:	
ATTACTCGCT GCCCAACCAG CCATGGCCGA GCTCGTGAT	39

(2) INFORMATION FOR SEQ ID NO:57:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:	
GACCCAGACT CCAGATATCC AACAGGAATG AGTGTTAAT	39
(2) INFORMATION FOR SEQ ID NO:58:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(x1) SEQUENCE DESCRIPTION: SEQ ID NO:58:	
TCTAGAACGC GTC	13
(2) INFORMATION FOR SEQ ID NO:59:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 45 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:	
TTCAGGTTGA AGCTTACGCG TTCTAGAATT AACACTCATT CCTGT	45
(2) INFORMATION FOR SEQ ID NO:60:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:	
TGGATATCTG GAGTCTGGGT CATCACGAGC TCGGCCATG	39
(2) INFORMATION FOR SEQ ID NO:61:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	

PCT/US91/07149

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:	
GCTGGTTGGG CAGCGAGTAA TAACAATCCA GCGGCTGCC	39
(2) INFORMATION FOR SEQ ID NO:62:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:	
GTAGGCAATA GGTATTTCAT TATGACTGTC CTTGGCG	37
(2) INFORMATION FOR SEQ ID NO:63:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:	
TGACTGTCTC CTTGGCGTGT GAAATTGTTA	30
(2) INFORMATION FOR SEQ ID NO:64:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:	
TAACACTCAT TCCGGATGGA ATTCTGGAGT CTGGGT	36
(2) INFORMATION FOR SEQ ID NO:65:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:	
GCCAGTGCCA AGTGACGCGT TCTA	24
(2) INFORMATION FOR SEQ ID NO:66:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:	
ATATATTTTA GTAAGCTTCA TCTTCT	26
(2) INFORMATION FOR SEQ ID NO:67:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:	
GACAAAGAAC GCGTGAAAAC TTT	23
(2) INFORMATION FOR SEQ ID NO:68:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 76 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(x1) SEQUENCE DESCRIPTION: SEQ ID NO:68:	
CTGAACCTGT CTGGGACCAC AGTTGATGCT ATAGGATCAG ATCTAGAATT CATTTAGAGA	60
CTGGCCTGGC TTCTGC .	76
(2) INFORMATION FOR SEQ ID NO:69:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 80 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(x1) SEQUENCE DESCRIPTION: SEQ ID NO:69:	
TCGACCGTTG GTAGGAATAA TGCAATTAAT GGAGTAGCTC TAAATTCAGA ATTCATCTAC	60
ACCCAGTGCA TCCAGTAGCT	80
(2) INFORMATION FOR SEQ ID NO:70:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:	

GGTAAACAGT AACGGTAAGA GTGCCAG

PCT/US91/07149

(2) INFORMATION FOR SEQ ID NO:71:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 54 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:	
CGCCTTCAGC CTAAGAAGCG TAGTCCGGAA CGTCGTACGG GTAGGATCCA CTAG	54
(2) INFORMATION FOR SEQ ID NO:72:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 41 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:	
CACCGGTTCG GGGAATTAGT CTTGACCAGG CAGCCCAGGG C	41
(2) INFORMATION FOR SEQ ID NO:73:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:	
ATTCCACACA TTATACGAGC CGGAAGCATA AAGTGTCAAG CCTGGGGTGC C	51
(2) INFORMATION FOR SEQ ID NO:74:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:	
CTGCTCATCA GATGGCGGGA AGAGCTCGGC CATGGCTGGT TG	42
(2) INFORMATION FOR SEQ ID NO:75:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	

78

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:75:
GAACAGAGTG ACCGAGGGGG CGAGCTCGGC CATGGCTGGT TG

I Claim:

- 1. A composition of matter comprising a plurality of cells containing diverse combinations of first and second DNA sequences encoding first and second polypeptides which form heteromeric receptors, one or both of said polypeptides being expressed as fusion proteins on the surface of a cell.
 - 2. The composition of claim 1, wherein said plurality of cells are $\underline{E.\ coli}$.
 - 3. The composition of claim 1, wherein said heteromeric receptors selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.
 - 4. The composition of claim 1, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.
 - 5. The composition of claim 4, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.
 - 6. The composition of claim 1, wherein said cell produces filamentous bacteriophage.
 - 7. The composition of claim 6, wherein said filamentous bacteriophage are selected from the group consisting of M13, fd and fl.
 - 8. The composition of claim 6, wherein at least one of the encoded first or second polypeptides is expressed as a fusion protein with gene VIII.

80

9. A kit for the preparation of vectors useful for the coexpression of two or more DNA sequences encoding polypeptides which form heteromeric receptors comprising two vectors, a first vector having two pairs of restriction sites symmetrically oriented about a cloning site which can be combined with a second vector, having two pairs of restriction sites symmetrically oriented about a cloning site and in an identical orientation to that of the first vector, wherein one or both vectors contains sequences necessary for expression of polypeptides encoded by DNA sequences inserted in said cloning sites.

- 10. The kit of claim 9, wherein said first and second vectors are circular.
- 11. The kit of claim 9, wherein said expression peptides is as fusion proteins on the surface of a cell.
- 12. The kit of claim 9, wherein said cell produces filamentous bacteriophage.
- 13. The kit of claim 9, wherein said filamentous bacteriophage is selected from the group consisting of M13, fd and fl.
- 14. The kit of claim 13, wherein at least one of the DNA sequences is expressed as a fusion protein with gene VIII.
- 15. The kit of claim 9, wherein said two pairs of restriction sites are Hind III-Mlu I and Hind III-Mlu I.

- or more DNA sequences encoding polypeptides which form a heteromeric receptor, comprising a set of first vectors having a diverse population of first DNA sequences and a set of second vectors having a diverse population second DNA sequences, said first and second vectors having two pairs of restriction sites symmetrically oriented about a cloning site for containing said first and second populations of DNA sequences so as to allow only the operational combination of vector sequences containing said first and second first and second DNA sequences.
 - 17. The cloning system of claim 16, wherein said first and second vectors are circular.
 - 18. The cloning system of claim 16, wherein said heteromeric receptors selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.
 - 19. The cloning system of claim 16, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.
 - 20. The cloning system of claim 19, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.
 - 21. The cloning system of claim 16, wherein said coexpression of two or more DNA sequences encoding polypeptides which form a heteromeric receptor is on the surface of cell.
 - 22. The cloning system of claim 16, wherein said cell produces a filamentous bacteriophage.

82

23. The cloning system of claim 22 wherein said filamentous bacteriophage selected from the group consisting of M13, fd and fl.

- 24. The cloning system of claim 23, wherein at least one of the DNA sequences is expressed as a fusion protein with the protein product of gene VIII.
- 25. The cloning system of claim 16, wherein said two pairs of restriction sites are Hind III-Mlu I and Hind III-Mlu I.
- 26. A plurality of expression vectors containing a plurality of possible first and second DNA sequences encoding polypeptides which form a heteromeric receptor exhibiting binding activity toward a preselected molecule, said DNA sequence encoding heteromeric receptors being operatively linked to genes encoding surface proteins of a cell.
 - 27. The expression vectors of claim 26, wherein said expression vectors are circular.
 - 28. The expression vectors of claim 23, wherein said heteromeric receptors are selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.
 - 29. The expression vectors of claim 26, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.
 - 30. The expression vectors of claim 29, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.

83

31. The expression vectors of claim 26, wherein said cells produce filamentous bacteriophage.

- 32. The expression vectors of claim 26, wherein said filamentous bacteriophage are selected from the group consisting of M13, fd and fl.
- 33. The expression vectors of claim 32, wherein at least one of the encoded first or second polypeptides is expressed as a fusion protein with gene VIII.
- 34. A method of constructing a diverse population of vectors capable of expressing a diverse population of heteromeric receptors, comprising:
 - (a) operationally linking to a first vector a first population of diverse DNA sequences encoding a diverse population of first polypeptides, said first vector having two pairs of restriction sites symmetrically oriented about a cloning site;
 - (b) operationally linking to a second vector a second population of diverse DNA sequences encoding a diverse population of second polypeptides, said second vector having two pairs of restriction sites symmetrically oriented about a cloning site in an identical orientation to that of the first vector; and
 - (c) combining the vector products of step (a) and (b) under conditions which allow only the operational combination of vector sequences containing said first and second DNA sequences.

15

5

10

84

35. The method of claim 34, wherein said first and second vectors are circular.

36. The method of claim 34, wherein said heteromeric receptors are selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.

*

- 37. The method of claim 34, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.
- 38. The method of claim 34, wherein said expression of a diverse population of heteromeric receptors is on the surface of a cell.
- 39. The method of claim 37, wherein said cell produces a bacteriophage.
- 40. The method of claim 39, wherein said filamentous bacteriophage is selected from the group consisting of M13, fd and fl.
- 41. The method of claim 34, wherein at least one of said first or second DNA sequences is expressed as a gene VIII fusion protein.
- 42. The method of claim 34, wherein said two pairs of restriction sites are Hind III-Mlu I and Hind III-Mlu I.

5

10

15

85

43. The method of claim 34, wherein said combining step further comprises:

- (C1) restricting said first vector with a restriction enzyme recognizing one of the restriction sites encoded in said two pairs of restriction sites;
- (C2) restricting said second vector with a different restriction enzyme recognizing the second restriction site encoded in said two pairs of restriction sites;
- (C3) digesting the 3' ends of said restricted first and second vectors with an exonuclease; and
- (C4) annealing said first and second vectors.

86

method for selecting a heteromeric receptor exhibiting binding activity toward a preselected molecule from a population of diverse heteromeric receptors, comprising: (a) operationally linking to a first vector 5 a first population of diverse DNA sequences encoding a diverse population first polypeptides, said first vector having two pairs of restriction sites symmetrically oriented about a 10 cloning site; operationally linking to a second (b) vector a second population of diverse sequences encoding a diverse population of second polypeptides, said 15 second vector having two pairs of restriction sites symmetrically oriented about a cloning site in an identical orientation to that of the first vector; 20 combining the vector products of step (C) (a) and (b) under conditions which allow only the operational combination of vector sequences containing said 25 first and second DNA sequences. introducing said population of combined (d) vectors into a compatible host under conditions sufficient for expressing said population of first and second DNA sequences; and 30

(e) determining the heteromeric receptors which bind to said preselected molecule. WO 92/06204

- 45. The method of claim 44, wherein said first and second vectors are circular.
- 46. The method of claim 44, wherein said heteromeric receptors are selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.
- 47. The method of claim 44, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.
- 48. The method of claim 47, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.
- 49. The method of claim 44, wherein said expression of a diverse population of heteromeric receptors is on the surface of a cell.
- 50. The method of claim 49, wherein said cell produces a filamentous bacteriophage.
- 51. The method of claim 50, wherein said filamentous bacteriophage is selected from the group consisting of M13, fd and fl.
- 52. The method of claim 51, wherein at least one of said first or second DNA sequences is expressed as a gene VIII fusion protein.
- 53. The method of claim 44, wherein said two pairs of restriction sites are Hind III-Mlu I and Hind III-Mlu I.

5

10

88

54. The method of claim 44, wherein said combining step further comprises:

(C1) restricting said first vector with a restriction enzyme recognizing one of the restriction sites encoded in said two pairs of restriction sites;

*

- (C2) restricting said second vector with a different restriction enzyme recognizing the second restriction site encoded in said two pairs of restriction sites;
- (C3) digesting the 3' ends of said
 restricted first and second vectors
 with an exonuclease; and
- 15 (C4) annealing said first and second vectors.

PCT/US91/07149

89

55. A method for determining the nucleic acid sequences encoding a heteromeric receptor exhibiting binding activity toward a preselected molecule from a diverse population of heteromeric receptors, comprising:

(a) operationally linking to a first vector a first population of diverse DNA sequences encoding a diverse population of first polypeptides, said first vector having two pairs of restriction sites symmetrically oriented about a cloning site;

(b) operationally linking to a second vector a second population of diverse DNA sequences encoding a diverse population of second polypeptides, said second vector having two pairs of restriction sites symmetrically oriented about a cloning site in an identical orientation to that of the first vector;

- (c) combining the vector products of step (a) and (b) under conditions which allow only the operational combination of vector sequences containing said first and second DNA sequences.
- (d) introducing said population of combined vectors into a compatible host under conditions sufficient for expressing said population of first and second DNA sequences;

10

5

15

20

25

5

90

(e) determining the heteromeric receptors
 which bind to said preselected
 molecule;

(f) isolating the nucleic acid sequences encoding said first and second polypeptides; and

- (g) sequencing said nucleic acid sequences.
- 56. The method of claim 55, wherein said first and second vectors are circular.
- 57. The method of claim 55, wherein said first heteromeric receptors selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.
- 58. The method of claim 55, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.
- 59. The method of claim 58, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.
- 60. The method of claim 55, wherein said expression of a diverse population of heteromeric receptors is on the surface of a cell filamentous bacteriophage selected from the group consisting of M13, fd and fl and at least one of said first or second DNA sequences is expressed as a gene VIII fusion protein.
- 61. The method of claim 55, wherein said cell produces filamentous bacteriophage.

91

62. The method of claim 61, wherein said filamentous bacteriophage is selected from the group consisting of M13, fd and fl.

- 63. The method of claim 62, wherein at least one of said frist or second DNA sequences is expressed as a gene VIII fusion protein.
- 64. The method of claim 50, wherein said two pairs of restriction sites are Hind III-Mlu I and Hind III-Mlu I.
- 65. The method of claim 50, wherein said combining step further comprises:
 - (C1) restricting said first vector with a restriction enzyme recognizing one of the restriction sites encoded in said two pairs of restriction sites;
 - (C2) restricting said second vector with a different restriction enzyme recognizing the second restriction site encoded in said two pairs of restriction sites;
 - (C3) digesting the 3' ends of said restricted first and second vectors with an exonuclease; and
 - (C4) annealing said first and second vectors.

10


5

92

66. A vector comprising two copies of a gene encoding a filamentous bacteriophage coat protein, one copy of said gene capable of being operationally linked to a DNA sequence encoding a polypeptide of a heteromeric receptor wherein said DNA sequence can be expressed as a fusion protein on the surface of said filamentous bacteriophage or as a soluble polypeptide.

- 67. The vector of claim 66, wherein said two copies of said gene encode substantially the same amino acid sequence but have different nucleotide sequences.
- 68. The vector of claim 66, wherein said one copy of said gene is expressed on the surface of said filamentous bacteriophage.
- 69. The vector of claim 66, wherein said bacteriophage coat protein is M13 gene VIII.
- 70. The vector of claim 66, wherein said vector has substantially the same sequence as that shown in Figure 2 (SEQ ID NO: 1).
- 71. A vector comprising sequences necessary for the coexpression of two or more inserted DNA sequences encoding polypeptides which form heteromeric receptors and two copies of a gene encoding a filamentous bacteriophage coat protein, one copy of said gene capable of being operationally linked to one of said two or more inserted DNA sequences wherein said DNA sequence can be expressed as a fusion protein on the surface of said filamentous bacteriophage or as a soluble polypeptide.
 - 72. The vector of claim 71, wherein said two copies of said gene encode substantially the same amino acid sequence but have different nucleotide sequences.

- 73. The vector of claim 71, wherein said one copy of said gene is expressed on the surface of said filamentous bacteriophage.
- 74. The vector of claim 71, wherein said bacteriophage coat protein is M13 gene VIII.
- 75. The vector of claim 71, wherein said vector has substantially the same sequence as that shown in Figure 6 (SEQ ID NO: 5).



SUBSTITUTE SHEET

11233445667784911111111111111111111111111111111111	GGCTTAACTC TTGTTCAGGG	CTATTAGACTTCTAGATTCTAGATTCTAGATTCTAGATTCTTCTAGATTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTC	CCATTGAGATTTTAGGATTTTATAGGTTGAATTTTAGGAATTTTAGGAATTTTATAGGTTTTTT	40 CAGA AACTCGAGATTGGCAATTGCAATTGGCAATTGGCTTTTCATGATATGTGCTTTCATGGTTTCATGGTTTCATGGTTTCATGTTTTCATGCAATTGCAATTGCAATTGCAATTGCAATTCCTTGAATTGCAATTCCTTGAATTTCATGTTTTCATGCCAATTCCTTGAATTTCATGTTTTCATGTTTTCATGCCAATTCCTAATTTCATGCCAAATTCCTAATTTCATGCCAAATTCCAAAATTCCAAAATTCCAAAAATTCCAAAAATTCCAAAAATTCCAAAAAA	CTCGGTCAAAA TTTCGCTCAAAAATTTCGGGTCATTGAATTTCGGTTAAAATTTCGCAATTTCGCTCAAAAATTTCGCGAATTTTCGCTCAAAAATTTCGCGAATTTCAAAATTTCGCGAATTTCAAAATTTCGCGAATTTCGCTTAAAATTTCGCGGAATTTCGCGAATTTCGCGAATTTCGCGGAATTTCGCGGAATTTCGCGGAATTTCGCGGAATTTCGCGGAATTTCGCGGAATTTCGCGGAATTTCGCGGAATTTCGCGGAATTTCGCGGAATTTCGCGGAATTTCGCGGAATTTCGCGGAATTCCTTCAAACGGGCCAATCCTTAAACGGGCCAATTCGCGGAATTCCTCAAACGGGCCCTCAAACGGGCCCCTCAAACGGGCCCCCTAAACGGCCCCCTAAACGGCCCCCCTAAACGGCCCCCCTAAACGGCCCCCCCC	GGTATTCCGT 2880 CTTACTTTTC 2940 CTTATTATTG 3000 CCCTCTGACT 3060 TATGTTATTC 3120
2701 2761 2821 2881 2941 3001	GGTGATTTTG TTAATGAATA TTTGTTTTTA TTCCGTGGTG TTTGCTAACA TTATAAAAAGGG GGCTTAACTC TTGTTCAGGG TCTCTGTAAA ATTGGGATAA CTCGTTAGCG CTTGATTTAA CTTAGAATAC TCCTACGTTTG TCCTACGTTTAA CTTAGCATTG AAATTAGGAT ACTTCTGCAT TCGTTCTGCAT	ATTTCCGTCA GCGCTGGTAA TCTTTGCGTT TACTGCGTAA TTTCCTCGGT CTTCGGTAAG AATTCTTGTG	ATATTTACCT ACCATATGAA TCTTTTATAT TAAGGAGTCT TTCCTTCTGG ATAGCTATTG GGTTATCTCT TCATTTTTG TGTTTATTTT TCAGGATAAA CCTCCCGCAA TTCTATATCT CGGCTTGCTT GGAAAGACAG TTTTATTATT TGTTGTTTATT TGTTGTTTATT	TCCCTCCCTC TTTTCTATTG GTTGCCACCT TAATCATGCC TAACTTTCATT CTGATATTAGT CTAATGCGCT ACGTTAAACCA GTAACTGGCCA ATTGTAGCTG GTTCGGGAGGT GATTTGCTTG GTTCTCGATG CCGATTATTG CCGATG CCGATCT CCGATC CCCC CCC	AATCGGTTGA ATTGTGACAA TTATGTATGT AGTTCTTTTG CGGCTATCTG CGCTCAATTA TCCCTGTTTT AAAAATCGTT AATTAGGCTC GGTGCAAAAC CTATTGGGCG AGTGCGGTAC AGTGCGGTTCC AGTGCGGTTCC AGTGCGGTTCC AGTGCGGTTCC AGTGCGGTTCC AGTGCCTCTGCC	AATAAACTTA 2760 ATTTTCTACG 2820 GGTATTCCGT 2880 CTTACTTTTC 2940 CTTATTATTG 3000 CCCTCTGACT 3060

FIG. 2-1
SUBSTITUTE SHEET

11111111111111111111111111111111111111	ACTGGTAAGA TCCGGTGTTT AATTTAGGTC TGTCTTGCGA GAGGGTTAAAA AGCGACGATT ATTTACTTAC TGTTAACTTAC TGTTTACTTAC TGTTTAAATACT TGTTTAAATACT TGTTTAAATACT TGTCTAAATACT TAATCAATACT TAATCAATACT TAATCAATACT AACTGACCAG TTTTTACATTCA ACTGGCTATCA ACTGGCTATCA TACTGGTCGT TACTGGTCGT TACTGGTCGT TCAAAATGT	ATTTGTATAA ATTCTTATTT AGAAGATGAA TTGGATTTGC AGGTAGCTA AGCTAAGCTA	CGCATATGAT AACGCCTTAT GCTTACTAAA ATCAGCATTT TCAGCTATTTTA TCAGCTATTTAT TCGCTATTGAT AGGTTATTGAT CTCAGGGTGAA TTGATAGGTAAT ATATTGATAGT GGGCAAAAGGA CTAGATATGAT TAGATATGAT GGGCAAAAGGA CTCAGCGTGG CTCAGCGTGG CTGCTGGCTGG TAGAAGACTAA AATCTGCTAA TGAGCGTTTT	ACTAAACAGG TTATCACACACACACACACACACACACACACACACACAC	CTTTTTCTAG GTCGGTATTT AAAAGTTTTC ATATAACCCA AATTCACTAT CTAAGGGAAA TTGATTTATG AATTTCGCCTC GTTTCTCCATTA AATTCGCCATT CCTTCCCATAATC CTTCCCATAATC CTTCCAATC CTTCTAATC GGCTGTTAATG GGCCAGGTG AAAAATGTAATG AACATATTTAATG AACATATGT GGCCAGTGAATG ACCATTTCAGA ATGGCTGGCG	TAATTATGAT 3840 CAAACCATTA 3900 ACGCGTTCTT 3960 ACCCTAAGCCG 4020 TGACTCTTCT 4080 ATTAATTAAT 4140 TACTGTTTCC 4200 TCCTGAGATT 4320 ATGTAAAAAGG 4560 TTCTTAATTC 4440 TTCAGAAAGTA 4560 TTACTCAAAAC 4680 TATTAGTTGC 4800 ATGATTAGTTGT 4740 TTGATTTGCC 4800 ATGCTTTAATTGT 4980 CTGTTGCCACG 5160 ATGCTTTAATTGT 5220 CCGATTGACCG 5160 GCGATTGACCG 5160 GCGATTGACGG 5160 GTAATATTGT 5220
566612111111111111111111111111111111111	CCAGGCGATT GGCGCCCAAT TCACTCATTA TTGTGAGCGGA TCACTCAGTAT TTGTGACCGGAT CCTAGGTACATT CCTAGGTACATT TAAATTATTC GCACCCACTTA GCACCCACTTA GCACCCACTTA GCACCCATTA TATCACCATTTA GCACTCCATTA TATCACCATTA AAAATTATTAAC TCTCACATTTA AAAATTATTAAC TCTCACATTTA AAAATTATTAAC TCTCACATTCA AAAATTATTCAC ACGTT CTTCTCAG GCATTCCCAGGC ACGTT ACGCTCCACATTC AAAATTATTCACCATC ACGTTCCCACATC ACGTT ACGCTTCCACATC ACGTTCCCACACATC ACGTT ACGCCACACACACACACACACACACACACACACACACAC	AAGGGCAATC ACGCAAACCG TCCCGACCCAG TCCCGACCCAG ATAACAATTC GCACCTGCAC GCACTGCAC GCACTGCAC GGCACCGGCA CAAACAGTTTA CCACAACAGTTT CCACAACAGTT CCACAACTGCA CCGACTCCCAGC ATGTTAAAATT AACCCTCCCGGC TAAAATTA TTTCCTCTCCGGC TAAAATTA TTTACTTCT AAAAGTATTA TTTACTTCT AAAAATTATT TTTACTTCT TAAAAATTATT TTTACTTCT TAAAATTATT TTTACTTCT TTTACTTCT TTTACTTCT TAAAATTATT TTTACTTCT TTTACTCT TTTACTTCT TTTACTCT TTTACT TTTACTCT TTTACTCT TTTACT TT	AGCTGTTGCC CCTCTCCCG AAAGCCGGGCA GCTTTACCCGTC GTTACCCCGTT TCTTACCCCGTT AGTCAGGCGC GCGCTATGGC GCGCAAGGCTG GCGCAGCCTG GCGCAGCCTG GCGCAGCCTG GAGCTGCTA AATGAGCTGCTA AATGAGCTGCA CATTACTTCACC CATTACTCACC CATTACTTCACC ATTACTTCACC CAGGGTTCATA AATTTTGCTA AATTTTGCTA	CGTCTCGCTG CGCTCTCGCTG CGCGTTCGCCCA GTGAGCCGCAC ACTTGGCACTC ACTTGGCACTCAC ACCGTTACCGA ATCGTTACCGA ATCGTTACCAAT ACCACTGAGCAC ACCGCGAGCC CAGCGAAGGCC CAGCACGGAGCC CAGCACGGAAC CAGCTGCACAC CAGCTAGAAC CAGCTAGAAC CAGCTAGAAC CAGCTAGAAC CAGCTTTTACCAAT ATGTTTTTTGC AAAATTTTTTA ATTCTTTTGCC	GTGAAAAGAA GATTCATTAAT GGCCAATTAAT GGCCAATTAAT GGCCGTCGTTA GGCCGTCGTA TTTACACTGTA AGTTTACACAC GTTGGTGCGAAGC GTTGCCTGACAC GTTCCTCACACAC ATACCCTTACACAC TTCCTTACACACT TTTACCTACACT TTTACCTTACA GGTTGAATAT TTTACCTTACA TTTCCTTCGATT TTTACCTTACA TTTCCTTCGATT TTTACCTTACA TTTCCTTCGATT TTTCCTTCCTTAT TTTCCTTCCTTAT	AAACCACCT 6000 TGCAGCTGGC 6060 GTGAGTTAGC 6120 TTGTGTGGAAA 6180 TTACAACGTC 6240 AAGTGAAAAGC 6360 CTAGTGGATC 6420 CTAGTGGATC 6420 CCAAGTGCTAC 66600 CCAAGTGCTAC 66600 CCAACGTAACCC 6780 TTGTTACTCG 6840 TTGTTACTCG 6840 TTGTTACTCG 6840 TTGTTACTCG 7200 CAACGTAACGA 7140 CAACGTCATCA 7200 CAACATCATCA 7200 CAACATCA 7200 CAACATCATCA 7200 CAACATCA 7

FIG. 2-2

11111111111111111111111111111111111111	TTTGCTAACA TATTATTGCG TTAAAAAGGG GGCTTAACTC TTGTTCAGGG TCTCTGTAAA	20 GATAGA 21 AGATAGA 2	30 CGAAGA GAAGA GAAGAA	ACTAMACCTC GACGGCACTT GAGTCTCAGC GCATTAACTC GCATTAACTC GACTGCGCTT TCGCGCTTCCG GCCGCTTCCG GACTAAGGGGG AAACTTGATT TCCGGCCTTC GCTCAAGTCC TTTTCTATTG GTTGCCACCT TAATCATGCC TAATCATGCC TCAATTTCATT CAATTTCATT CAATTCATT CAATTTCATT CAATTTCATT CAATTTCATT CAATTTCATT CAATTTCATT CAATTCATT CAATTTCATT CAATTTCATT CAATTTCATT CAATTTCATT CAATTTCATT CAATTCATT CAATTTCATT CAATTCATT CAATTTCATT CAATTCATT CAATTTCATT CAATTTCATT CAATTTCATT CAATTTCATT CAATTTCATT CAATTCATT CAATTTCATT CAATTCATT CAATTTCATT CAATTTCATT CAATTTCATT CAATTTCATT CAATTTCATT CAAT	TTTCCCCTAACTTCCCTAACTTCCCTAACTTCCCCTAACTTCCCCTAACTTCCCCTAACTTCCCCTAACTTCCCCTAACTTCCCCTAACTTCCCCTAACTTCCCCCTAACTTCCCCCTAACTTCCCCCC	100 00 00 00 00 00 00 00 00 00 00 00 00
22222233353333333333333333333333333333	TTTGTCTTTA TTCCGTGGTG TTTGCTAACA TATTATTGCG TTAAAAAGGG GGCTTAACTC TTGTTCAGGA ATTGGTAAAA CTCGTTAGCA CTCGTTAAC CTCAACAATTAAC CTCAACAATTAAC CTCAACAATTAAC TCCTAACAATTAAC TCCTAACAATTAAC TCCTACGATATTAAC TCCTACGATTCTAAC TCCTACGAT	GCGCTGGTAA TCTTTGCGTAA TTTCCTCGGT CTTCGGTAAG AATTTCAGTA AATTTCAGTAT ATAATATGGC TGGCTAAAA ACCTTCAAAA CGGATAAGAC AAAATAAAAA GGAATGATAA GGGATGATAA TACGGTTGATAA TACGGTTGATAA TACGGTTGATAT TTAAATATC	TCTTTTATAT TAAGGAGTCT TTCCTTCTGG ATAGCTATTG GGTTATCTCT ATTCTCCCGT TTCATTTTTG TGTTTATTTT TCAGGATATAT TCTCCCGCAA CCTCCCGCAA CCTCCCGCAA TTCTATATCT GGAAAGACAG TTTTCTTGTT TGTTGTTTAT TCTTATTACT CGATTCTCAA	GTTGCCACCT TAATCATGCC TAATCTTGTT CTATTTCATT CTGATATTAG CTAATGCCA GTAACTGGCA ATTGTAGCTG GTCGGGAGGT GATTTGCTTG CCGGTTATTG CCAGGACTTATTG CAGGACTTATT TGTCGCTCGATA TTAAGCCCTA	TTATGTATGT AGTTCTTTTG CGGCTATCTG GTTTCTTGCT CGCTCAATTA TCCCTGTTTT	ATTITCTACG 2820 GGTATTCCGT 2880 CTTACTTTTC 2940 CTTATTATTG 3000 CCCTCTGACT 3060 TATGTTATTC 3120

FIG. 3-1
SUBSTITUTE SHEET

ATGAGGCTTTTCGCTCCATCGATACGTTAAAGCAGCCAGC	TCGCGACTTCGTTTAGTTACACTTCGTCGTGGGCCTGAGGGTTAAAGAGGGGTTTAGCCTCAAAAATTGAGCTTCAAAAAAATTGAAGTTTCAGTTAAAAAAAA	ATTAGAGETTATCAGETTATCAGETTATCAGETTATCAGETTATCAGETTATCAGETTATCAGETTAGETT	ACTTAGATTTTTTCCCGAACCGAACACACACACACACACA	TCTTTACCTA	GTCAGAATTACAACAACAACAACTTCAAATTCCAAAACAAAC	ATTOTA AT TOTA AT GOLD TO A COLOR AT TOTA A COLOR A COLOR AT TOTA A COLOR A CO	00000000000000000000000000000000000000
7081 ACT 7141 TTT 7201 GCA	GTCTCCG AAAATAT AAAGTAT	GCCTTTCTCA	CCCTTTTGAA	TCTTTACCTA	CACATTACTC	AGGCATTGCA GGCTTCTCCC ATGCTCTGAG	7140 7200

FIG. 3-2

11121111111111111111111111111111111111	TTGTTCAGGG TCTCTGTAAA ATTGGGATAA	CTATTAGTAGA CTAGTAGA ATTAGTAGA ATTAGTAGA ATTAGTAGA ATTAGACATGT TGACCTCTT TGACCTCT TTCTCTAATTAGC TTCTCTAATTAGC TTCTCTAATTAGC TCTCTCTAATTAGC TCTCTCTAATTAGC TCTCTCTGAATTAT ACTTCTGAATTAT ACTTCTCTGAATTAT TCTTCTGAATTAGC TCTTCTGAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCCAATTTCAATTTCCAATTTCAATTTCAATTTCAATTTCAATTTCAATTTCAATTTCAATTTCAATTTCAATTTCAATTTCAAT	CACAGAGTTTTAGGAAATTTTTTAGGAATTTTTAGGAATTTTTT	40 40 40 40 40 40 40 40 40 40	CTCGCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	TGAGGGTTGT TTACGGTACA GGGTGGCGGT TGATACACCT TACTGAGCAA TTTCATTGATCAT CACTGTTACT AAAAGCCATG CTTTAATGAA TCCTGAGGGT TGGTTCCGGT AAATGCCGAT TGATTACCGGT TGATTCACCT AATAAACTTA ATTTTCTACG GGTATTCCGT CTTACTTTTTC CCTTATTATTG CCCTCTGACT TATTTTTTTTTT	61284000000000000000000000000000000000000
2230061 2230061 2230061 2401 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23332 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 2332 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 2332 23322 23322 23322 23322 23322 23322 23322 23322 23322 23322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 232 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 232 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 2322 232 2322 2322 2322 232 2322 2322 2322 232 232 232 232 232 232 232 22	TATTATTGCG TTAAAAAGGG GGCTTAACTC TTGTTCAGGG TCTCTGTAAA ATTGGGATAAC CTTGATTTAA CTTAGAATAC TCCTACGATG ACCCGTTCTT ACCCGTTCTT ACCCGTTCTT ACCTGCAT TTTGTCGGTA GTTGGCGTTG	TTTCCTCGGT CTTCGGTAAG AATTCTTGTG TGTTCAGTTA GGCTGCTATT ATAATATGGC TTGGTAAGAT GGCTTCAAAA CGGATAAGCC AAAATAAAAA GGGATATAT TAGCTGAACA CTTTATATTC TTAAATATGG	ATAGCTATTG GGTTATCTCT ATTCTCCCGT TTCATTTTTTG TGTTTATTTT TCAGGATAAA CCTCCCGCAA TTCTATTCT CGGAAAGACAG GGAAAGACAG TTTTCTTGTT TGTTGTTTTTT TCTTATTAT TCTTATTACT CGATTCTCAA	CTATTTCATT CTGATATTAG CTAATGCGCT ACGTTAAACA GTAACTGGCA ATTGTAGCTG GTCGGGAGGT GATTTGCTTG GTTCTCATTG CCGATCTTATTG CCGATCTTATTG TGTCGCTCGAAAA TTAAGCCCTA	GTTTCTTGCT CGCTCAATTA TCCCTGTTTT AAAAATCGTT AATTAGGCTC GGTGCAAAAT TCGCTAAAAC CTATTGGGCG AGTGGGTTTCT ATTGGTTTCT CTATTGTTGA TGGACAGAAT TGCCTCTGCC CTGTTGAGCG	CCCTCTGACT TATGTTATTC TCTTATTTTGG TGGAAAGACG AGCAACTAAT GCCTCGCGTT CGGTAATGAT TTGGTTTAAT ACATGAT ACATGACT TAAACAGGCG TACTTTACCT TAAATTACAT TTGGCTTTACT TTGGCTTTACT TTGGCTTTACT TTGGCTTTAT	3060 3120

FIG. 4-1
SUBSTITUTE SHEET

4021 GAGGTTAAAA AGGTA 4081 CAGCGTCTTA ATCTAG 4141 AGCGACGATT TACAG 4201 ATTAAAAAAG GTAAT 4261 TGTTTACTTGC TATTCC 4321 TGTTAACTTGCT GCTAAA 4381 TACTGTTACGT GCTAAA 4561 TGATAAATTT AATAAA 4561 TGATAAATTT AATAAA 4561 TGATAAATTT GCTGC 4581 TACTGACCTG AATATT 4681 GTCTAAATACT GCTGC 4881 ACTGACCAG ATATT 4981 AGGGGCTATCA GTTCG 5041 TATTTCATTC GTTTCC 5161 TCAAAATTCA ACCAG 5521 TCTGGATATT ACCAGG 5521 TCTGGATTCC TTCCC 5161 TCAAAATCT ACCAGG 5521 TCTGGATTCC GTCAAA 5521 TCTGGATTCT CCCCTTA 5521 TCTGGATTTCC 55641 AATACGTGCT TACCGC 55761 CGTGTGGTGT CACGCT 55821 CTATCTCGGATT CCCCTT 56641 ATACGTGCGTT AAGGGG 6061 ACGACACGTTTA GCACC 6121 TCACTCATTA GCA	TTTGC ATCAGCATTA GTCTC TCAGACCTAT AAGCTA TCGCTATGTA AAGCTA TCGCTATGTA AAGCTA TCGCTATGTA AAGCTA AGGTTATTCAA TCAAA TGAAAATGAT TAAAT TTGATTGATGAT TAAAT TTGATTGATGAT TAAAT ATAGTTGATGAT TAAAT ATAGTTGATGAT TAATT ATAGTTGATGAT TCGTTC CAAAATGATAGTTGAT TCGTTCT TAGAAATGACCTAA TCGTTCT TAGAAATGACTTC AATTGATTT TAAAACTTCCAAACTTC AATTGATCT TAAAACTTCCAACCTTC CAATTGATTT AATTGATCTC AATTGATTT CAAAACCTTCCAACCTTC CAATTGATTT CAAAACCTTCCAACCTTC CAATTGATTT CAAAACCTTCCAACCTTCCAACCTCAACCTCCAACCTCCAACCTCCAACCTCCAACCTCCAACCTCCAACCTCCAACCTCCAACCTCCAACCTCCAACCTCCAACCTCCAACCTCCAACCTCCAACCTCCAACCTCCAACCTCCAACCCCAACCCCAACCCCAACCCCAACCCCAACCCCAACCCC	ACATTA TA	AAATTCCATAA AATTCCATAA AATTCCCCTA AATTCCCCCCCC	GCGATGTTT CTGTGCCACG TCCCTTTTAT CGATTGAGG GTAATATTGT GTGATGTTACA ACAGCACGCGT ACAGCACGCGT GCTCTAAATC ACACCCTCACA ACACCTTTGA ACACCCTCACCA CCCCCCTCACA ACACCCTCACCA TCCCCACCCC TCCCCACCCC TCCCCACCCC TCCCCACCCC TTGTGTGGAAACA TTACAAACCA TTACAAACCA TTACAACCACCC TTACAACCCC TTCCCAGGAACA CCTCCAGGACAC CCTCCAGGACAC CCTCCAGGACCC CCTCCAGGACCC CCTCCAGGACCC CCTCCAGGACCC CCTCCAGGACCC CCTCCAGGACCC CCTCCAGGACCC CCTCCACCACCCC CCTCCACCACCCCC CCTCCACCACCCCCCCC	\$\frac{1}{3}444444444444444444444445555555555555
5221 TCTGGATATT ACCAG 5281 TACTAATCAA AGAAG 5341 CGGTGGCCTC ACTGA 5401 AATCCCTTTA ATCGG 5461 ATACGTGCTC GTCAA 5521 GTGTGGTGTT CCCTT 5581 TCGCTTTCTT CCCTT 5641 GGGGGCTCCC TTTAG 5701 ATTTGGAGTG TGGTT 5761 CGTTGGAGTC CACGT 5821 CTATCTCGGG CTATT 5881 ACAGGATTTT CGCCT 5881 ACAGGAGTT TCCCGA 6061 ACGACAGGTT ACGCAA 6061 ACGACAGGTT ACGCAA 6061 TTGTGAGTGGA AAACC 6121 TCACTCATTA GGCAAC 6241 GTGACTGGGA AAACC 6361 CCAGCTGCTC GAGTC 6361 CCAGCTGCTC GAGTC 6421 AGCGGCCCTG GGCTG	TATTG CTACACCGGT TTATA ACCACTTC TTATA ACCACTTC ACCACCTCC ACCACCTCC ACCACC ACCACC ACCACC ACCACC ACCACC ACCACC	TAAAGCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	GATGGACAGA GGCGCACATA CGCCCCTAGCA CGCCCCTAGCA CCCCCGACCCT CCCCGACCCT CACTGGAAACA GACTTCGAAACA GATTTCGGAAA GATTCGTAAT GGCCAATTAAT GGCCAATTAAT GGCCAATTAAT GGCCAATTAAT GGCCAATTAAT GGCCAATTAAT CGCTGTGGCACAT CCTGTGCACAT CCTGTGCACAT CCTACAGTC	CTCTTTACA TCCTGTCTACA ACCGCGGGGGG CCCCGCTCCTACACA AGCGCGCTCCTACACACT GCTCTACACTTGA ACCCCCTCACACGC TCCTCACACGCT CACCCCCACGCT GCACCTCACACGC TCCTCACACGCT TGCACGCTGGC TTGCACACACC TTGCACGCTCACACC TTGCACGCTCACACC TTGCACGCTCACACC TTCCCCACACCCT GCCCCACACCC GCCCCACACCC TTACTCACCCTC TCCTCCCCCCC TTACTCCCCCCCC	55555555555555566666666666666666666666

FIG. 4-2 SUBSTITUTE SHEET

			. 70	1 40	, ,,	1 60	
_	10	20	30	1 40	CTCGCGCCCC	AAATGAAAAT	60
_1	AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTTCAG	ATGGTCAAAC	TAAATCTACT	120
51	ATAGCTAAAC	AGGTTATTGA	CCATTTGCGA	AATGTATCTA	CTTCCAGACA	CCGTACTTTA	180
121	CGTTCGCAGA	ATTGGGAATC	AACTGTTACA	TGGAATGAAA	CTTCCAGACA	CTCTAAGCCA	240
181	GTTGCATATT	TAAAACATGT	TGAGCTACAG	CACCAGATTC	AGCAATTAAG	TOCTOACCTO	300
241	TCCGCAAAAA	TGACCTCTTA	TCAAAAGGAG	CAATTAAAGG	TACTCTCTAA	TCCTGACCTG	360
241 301	TTGGAGTTTG	CTTCCGGTCT	GGTTCGCTTT	GAAGCTCGAA	TTAAAACGCG	ATATTTGAAG	700
361	TCTTTCGGGC	TTCCTCTTAA	TCTTTTTGAT	GCAATCCGCT	TTGCTTCTGA	CTATAATAGT	420
421	CAGGGTAAAG	ACCTGATTTT	TGATTTATGG	TCATTCTCGT	TTTCTGAACT	GTTTAAAGCA	480 540
481	TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCCGCAG	TATTGGACGC	TATCCAGTCT	
541	AAACATTTTA	CTATTACCCC	CTCTGGCAAA	ACTICITITE	CAAAAGCCTC	TCGCTATTTT	600
601	GGTTTTTATC	GTCGTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCTCGT	<u>660</u>
661	AATTCCTTTT	GGCGTTATGT	ATCTGCATTA	GTTGAATGTG	GTATTCCTAA	ATCTCAACTG	720 780
721	ATGAATCTTT	CTACCTGTAA	TAATGTTGTT	CCGTTAGTTC	GTTTTATTAA	CGTAGATTTT	840
781	TCTTCCCAAC	GTCCTGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA		900
841	CAATGATTAA	AGTTGAAATT	AAACCATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGTTT	960
901	CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTTG	TTACGTTGAT	GCGCCTGGTC	1020
961	AATATCCGGT	TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	ATGATTGACC	1080
1021	TGTACACCGT	TCATCTGTCC	TCTTTCAAAG	TTGGTCAGTT	CGGTTCCCTT	CACAATTTAT	1140
1081	GTCTGCGCCT	CETTCCEGCT	AAGTAACATG	GAGCAGGTCG	CGGATTTCGA	CGCTGGGGGT	1200
1141	CAGGCGATGA	TACAAATCTC	CGTTGTACTT	TGTTTCGCGC		TGCCTTCGTA	1260
1201	CAAAGATGAG		TATTCTTTCG	CCTCTTTCGT	TTTAGGTTGG ATGAAAAAGT	CTTTAGTCCT	1320
1261	GTGGCATTAC	GTATTTTACC	CGTTTAATGG	AAACTTCCTC	TCTTTCGCTG	CTGAGGGTGA	1380
1321	CAAAGCCTCT	GTAGCCGTTG	CTACCCTCGT	TCCGATGCTG	GCGACCGAAT	ATATCGGTTA	1440
1381	CGATCCCGCA	AAAGCGGCCT	TTAACTCCCT	GCAAGCCTCA CGCAACTATC	GGTATCAAGC	TGTTTAAGAA	1500
1441	ŢĠĊĠŢĠĠĠĊĠ	ATGGTTGTTG	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT	1560
1501	ATTCACCTCG	AAAGCAAGCT	GAAAAAATTA	TTATTCGCAA	TTCCTTTAGT	TGTTCCTTTC	1620
1561	TTTTTGGAGA	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	ÁĞAAAATTCA	1680
1621 1681	TATTCTCACT	TCTGGAAAGA	CGACAAAACT	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT	1740
1741	CTGTGGAATG	CTACAGGCGT	TGTÄGTTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA	1800
1801	TGGGTTCCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	1860
1861	TCTGAGGGTG	ĠĊĞĞTŤĊŤĞĂ	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
1921	ATTCCGGGCT	ATACTTATAT	CAACCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA	1980
1981	AACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	2040
2041	CAGAATAATA	GGTTCCGAAA	TAGGCAGGGG	GCATTAACTG	TTTATACGGG	CACTGTTACT	2100
วับกี	CAAGGCACTG	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG	2160
2161	TATGACGCTT	ACTGGAACGG	TAAATTCAGA		TCCATTCTGG	CTTTAATGAA	2220
2101 2161 2221 2281 2341	GATCCATTCG	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCTCAACC	TCCTGTCAAT	2280
2281	GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340 2400
2341	GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT	2400
2401	GATTTTGATT	ATGAAAAGAT	GGCAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT TGATTACGGT	2460 2520
2461	GAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGGTGCTACT	2500
2521	GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA GTGACGGTGA	TAATTCACCT	2580 2640
2581	GGTGATTTTG	CTGGCTCTAA	TTCCCAAATG	ĠČŤČĂĀĠŤĊĠ ŤĊĊĊŤĊĊĊŤĊ	AATCGGTTGA	ATGTCGCCCT	2700
2641	TTAATGAATA	ATTTCCGTCA	ATATTTACCT ACCATATGAA	TTTTCTATTG	ATTGTGACAA	ÄATÄÄÄČTTÄ	2760
2701	TTTGTCTTTA	GCGCTGGTAA	TCTTTTATAT	ĠŤŤĠČĊÃĊĊŤ	TTATGTATGT	ATTTTCTACG	2820
2761	TTCCGTGGTG	TACTGCGTAA	TÄÄGGÄGTCT	TAATCATGCC	AGTTCTTTTG	GGTATTCCGT	2880
2821	TTTGCTAACA		TTCCTTCTGG	TAACTTTGTT	CGGCTATCTG	CTTACTTTTC	2940
2881 2941 3001	TATTATTGCG	TTTCCTCGGT	ATAGCTATTG	ĊĊŦĞŦŦĬĊŢŢ	GCTCTTATTA	TTGGGCTTAA	3000
2001	CTCAATTCTT	ĞTĠĞĞTTÂŢÇ	TCTCTGATAT	TĂĠČĠĊŤČÁÁ	TTACCCTCTG	ACTTTGTTCA	3060
3061	GGGTGTTCAG	TTAATTCTCC	CGTCTAATGC	GCTTCCCTGT	TTTTATGTTA	TTCTCTCTGT	3120
3121	AAAGGCTGCT	ATTTTCATTT	TTGACGTTAA	ACAAAAAATC	GTTTCTTATT	TGGATTGGGA	3180
4161	TAAATAATAT	GĠĊŢĠŢŢŢĀŢ	TTTGTAACTG	GCAAATTAGG	CTCTGGAAAG	ACGCTCGTTA	3240
3181 3241 3301 3361	GCGTTGGTAA	GATTCAGGAT	AAAATTGTAG	CTGGGTGCAA	AATAGCAACT	AATCTTGATT	3300
ร์รักวี	TÄÄGĠČŤŤĊÄ	AAACCTCCCG	CAAGTCGGGA	GGTTCGCTAA	AACGCCTCGC	GTTCTTAGAA	3360
3361	TACCGGATAA	GCCTTCTATA	TCTGATTTGC	TTGCTATTGG	GCGCGGTAAT	GATTCCTACG	3420
3421	ATGAAAATAA	AAACGGCTTG	CTTGTTCTCG	ATGAGTGCGG	TACTTGGTTT	AATACCCGTT	3480
3481	CTTGGAATGA	TAAGGAAAGA	CAGCCGATTA	TTGATTGGTT	TCTACATGCT	CGTAAATTAG	3540 3600
3541	GATGGGATAT	TATTTTTCTT	GTTCAGGACT	TATCTATTGT	TGATAAACAG	GCGCGTTCTG	3660 3660
3541 3601	CATTAGCTGA	ACATGTTGTT	TATTGTCGTC	GTCTGGACAG	AATTACTTTA	CATETTECCE	3720
3661	GTACTTTATA	TTCTCTTATT	ACTGGCTCGA	AAATGCCTCT	GCCTAAATTA	CATGTTGGCG	3780
3721	TTGTTAAATA	TGGCGATTCT	CAATTAAGCC	CTACTGTTGA	GCGTTGGCTT	TATACTGGTA	3840
3781	AGAATTTGTA	TAACGCATAT	GATACTAAAC	AGGCTTTTTC	TÄĞTÄÄTTAT	GATTCCGGTG	JU4U

FIG. 5-1 SUBSTITUTE SHEET

7201 GTTTGCTCCA GACTCTCAGG CAATGACTO ATGGCTGAAT ATCATATTGA TGGTGATTTG 7320 7261 ACCCTCTCG GCATTAATTT ATCAGCTAGA ACGGTTGAAT ATCATATTGA TGGTGATTTG 7320 7321 ACTGTCTCG GCCTTTCTCA CCCTTTTGAA TCTTTACCTA CACATTACTC AGGCATTGCA 7380 7381 TTTAAAATAT ATGAGGGTCA TAAAGATTTT TATCCTTGCG TTGAAATAAA GGCTTCTCCC 7440 7441 GCAAAAGTAT TACAGGGTCA TAATGTTTTT GGTACAACCG ATTTAGCTTT ATGCTCTGAG 7500 7501 GCTTTATTGC TTAATTTTGC TAATTCTTTG CCTTGCCTGT ATGATTTATT GGATGTT 7557

FIG. 5-2

10/11 | 10 | 11 | 10 | 11 | 10 | 11 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 10/11 Ī8Ī 1021 $\bar{1}141$ 1261 Ī381 1741 1981 2221 2281 2341 2701 3181

FIG. 6-1 SUBSTITUTE SHEET




FIG. 6-2 SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/07149

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) 6					
According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): C12N 15/64, 15/70					
U.S.C1.: 435/252.3, 320.1					
II. FIELD	S SEARC				
<u>.</u>		Minimum Docume	entation Searched 7		
Classificati	on System		Classification Symbols		
U.	s.C1.	435/69.7, 172.3, 252.3,	, 320.1		
	Documentation Searched othe than Minimum Documentation to the Extent that such Documents are included in the Fields Searched 6				
APS, STN/MEDLINE, TERMS USED: SURFACE EXPRESSION VECTOR#, DIRECTED EVOLUTION, SINGLE CHAIN ANTIBOD?.					
III. DOCL	JMENTS C	ONSIDERED TO BE RELEVANT			
Calegory *	Citat	ion of Document, 11 with indication, where ap	propriate, of the relevant passages 12	Relevant to Claim No. 13	
Y .		WC, A, 28/26530 (FON E see entire document.	T AL) 07 September 1988	1-75	
Y		Muclaic Acido Research		5-75	
	recased SEFTEMBER 1984, BCSS ET AL, "Assembly of functional antibodies from immunoglobulin heavy and light chains synthesized in E. coli", pages 3731-3806, see the abstract.				
Y	Proceedings of the National Academy of Sciences. Yol. 85, issued AUGUST 1989, SASTRY ET AL. 'Cloning of the immunological repertoire in Escherichia seli for generation of monoclonal setalytic antibodies: Construction of a heavy chain variable-region specific cDNA library", pages 5728-5702, see the abstract.				
Y		Science, Vol 246, issued 08 "Generation of a Large Combinat Immunoglobulin Repertoire in Ph 1281, see entire document.		1–75	
*Special categories of cited documents: 10 "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filling date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the international Search O6 January 1992					
	a: Searching	Authority	Signature of Authorized Officer		
ISA/US			John D. Ulm	1	

International	Application	No.

· PCT/US91/07149

FURTHE	R INFORMATION CONTINUED FROM THE SECOND SHEET	101/0391/0/149
Y	Gene, Vol. 73, issued 1988, PARMLEY ET AL, "Antibody-selectable filamentous fd phage vectors: affinity purification of target genes", pages 305-218, see entire document.	6-75
•		
_ V.	SERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE 1	
This inter	ational search report has not been established in respect of certain claims under Article 17(2)	(a) for the following reasons:
	n numbers . because they relate to subject matter 12 not required to be searched by th	
2. Clair	n numbers because they relate to parts of the international application that do not cor	note with the prescribed service
men	s to such an extent that no meaningful international search can be carried out 13, specifically:	uply with the prescribes require-
	•	
_		•
3. Clain	numbers, because they are dependent claims not drafted in accordance with the secondance. Rule 6.4(a).	and and third sentences of
		·····
VI. OB	SERVATIONS WHERE UNITY OF INVENTION IS LACKING?	
This Intern	ational Searching Authority found multiple inventions in this international application as follow	/6:
	•	
1. As a	t required additional search fees were timely paid by the applicant, this international search repo International application.	ort covers all searchable claims
_	international application. Ny some of the required additional search fees were timely paid by the applicant, this internati	
those	claims of the international application for which fees were paid, specifically claims:	unal search report covers only
• 🗆		
3. No re	quired additional search fees were timely paid by the applicant. Consequently, this internations vention first mentioned in the claims; it is covered by claim numbers:	il search report is restricted to
	·	
4. As al invite	searchable claims could be searched without effort justifying an additional fee, the internation payment of any additional fee.	nal Searching Authority did not
Remark on		
☐ The a	dditional search fees were accompanied by applicant's protest.	
☐ No p	otest accompanied the payment of additional search fees.	